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K
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Global Outcomes
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L
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M
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S
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The present work focuses on the epide-
miology and outcome of acute kidney 
injury (AKI) in critically ill patients treated 
with renal replacement therapy (RRT). 
All presented studies describe the epi-
demiology and (long-term) outcome of 
critically ill patients with AKI treated with 
RRT (AKI-RRT). Special attention was 
paid to timing of initiation of RRT in crit-
ically ill patients suffering from AKI. As 
an epidemiological research project we 
reported different types of endpoints. 
Chapter 1 gives an introduction in the field 
of AKI starting with a short overview of 
the history of intensive care medicine with 
special focus on the historical milestones 
of AKI. It describes the epidemiological 
aspects, clinical consequences and man-
agement of AKI. It further briefly addresses 
the principles of dialysis. Controversial 
issues regarding RRT in critically ill patients 
with AKI are highlighted. Finally an over-
view of the different outcome measures 
used in epidemiological research is given.
Chapter 2 formulates the objectives and 
describes the methodology of the thesis. 
Chapter 3 shows the results of a retrospec-
tive study evaluating whether conventional 
serum urea cut-off values as described in 
the literature were associated with out-
come at time of initiation of RRT for AKI. It 
explores the impact of timing of initiation 
of RRT in the light of patient outcome. 
Chapter 4 presents the results of an ob-
servational cohort analysis describing the 
epidemiology of severe lactic acidosis in 
critically ill patients with AKI treated with 
RRT. In addition factors that may influence 
outcome in these patients were evaluated.
Chapter 5 presents the results of a pro-
spective cohort analysis evaluating the 
long-term patient and kidney outcomes in 
critically ill patients with AKI-RRT. It further 
assesses possible modifying factors of out-
come such as chronic kidney disease (CKD), 
timing of initiation of RRT and RRT modality.
Chapter 6 presents the results of an 
observational matched cohort study as-
sessing the long-term outcomes and 
quality-of-life of critically ill AKI-RRT 
patients at baseline, and at 3 months, 1 
year and 4 years after ICU discharge and 
comparing quality of life with a cohort 
of matched non-AKI-RRT patients.
Chapter 7 discusses the results of 
the above mentioned studies.
Chapter 8 addresses some limitations 
of the present work and formulates 
some future perspectives.
Chapter 9 briefly summarizes the thesis.
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1. Critically ill patients 
Modern day intensive care medicine was 
born in the early 1950s. The polio epidemic 
forced the anesthesiologist Dr. Ibsen from 
Copenhagen to set up the first intensive 
care unit (ICU) to take care of patients with 
respiratory insufficiency [1]. Over the past 
decades, intensive care has kept pace with 
the medical and surgical advances. ICUs 
evolved from small and restricted units to 
larger and technically high-end areas [2]. 
Modern ICU structures can be classified in 
several different models. In open-model 
ICUs patients are cared for by multiple 
specialists with or without the expertise 
as an intensivist. In a closed-model ICU a 
team of dedicated intensivists take care 
of critically ill patients. External specialists 
may be consulted. Apart from the open and 
closed-model classification, intermediate 
models of ICU structure also exist [3]. 
Modern day ICUs accommodate a very 
heterogeneous group of severely ill patients. 
Patients may be admitted because of 
severe trauma or demanding surgery. In 
addition, problems can be very complex. 
For example in sepsis patients suffer 
from multi-organ dysfunction, rather than 
a single physiological impairment [4]. A 
major limitation in treatment is the fact 
that many therapeutic options in critical 
care are supportive rather than curative 
in nature. In the case of severe AKI, RRT 
only supports the electrolyte, acid-base 
and volume balance, thus it cannot restore 
all renal functions. Furthermore, if organ 
failure is sustained, complex interactions 
with other organ systems and changes in 
the inflammatory response of the host 
will lead to subsequent deterioration. So 
even after a successful initial resuscitation 
episode, this host iflammatory process may 
lead to progressive multi-organ failure and 
eventually death [5]. In addition, a growing 
population of aging people has led to a 
change in case mix in ICU admissions. 
Nowadays, elderly patients of 65 years and 
older account for 42-52% of ICU admis-
sions and for almost 60% of all ICU days 
[6]. Along with this geriatric population, 
the concept of frailty entered the ICU. 
Frailty is defined as a syndrome of loss of 
physical and psychological reserves that 
gives rise to increased vulnerability [7, 8]. 
Frail patients, with their higher prevalence 
of comorbidities and age-related loss 
of physical and cognitive reserves, form 
a new challenge for modern ICU care. 
Not surprisingly, actual determinants for 
long-term mortality in ICU patients are age, 
reason for ICU admission and preexisting 
comorbidities [9]. Until very recently, a 
historic emphasis on ICU mortality diverted 
attention from the post-ICU experience with 
its risk of long-term physical and psycho-
logical dysfunctioning and ongoing health 
care utilization threatened by increased 
rationing of limited health resources [10].
2. Critically ill patients  
 with acute kidney  
 injury
2.1.  FROM “ISCHURIA RENALIS”  
 TO “ACUTE KIDNEY INJURY”
In 1802 suppression of urine flow, depicted 
by Heberden as “ischuria renalis”, was rec-
ognized as a fundamental manifestation 
of renal disease. In the nineteenth century 
this disease was described in more detail 
and was named “Bright’s disease” after dr. 
Bright who studied patients presenting with 
decreased diuresis, followed by coma and 
1
CHAPTER 1    Introduction
In
tr
o
d
u
ct
io
n
1312
finally death [11, 12]. During World War I, “war 
nephritis” referred to renal granular and hy-
aline casts seen on histological specimens 
from critically ill soldiers suffering from a 
new renal disease characterized by symp-
toms of dyspnea and decreased urine flow 
[13]. During World War II, Bywaters and Beall 
were the first to describe in detail deterio-
ration of renal function due to crush injury 
and rhabdomyolysis. Based on the histolog-
ical findings in these kidneys the condition 
was called “acute tubular necrosis” (ATN) 
[14]. In 1946 the concept of “acute renal 
failure” (ARF) was introduced in literature 
by Frank. In 1951 Homer W. Smith described 
the concept of ARF in his textbook “The 
kidney – Structure and Function in Health 
and Disease”. That same year a whole issue 
of the Journal of Clinical Investigation was 
dedicated to ARF [15]. ARF is defined as “the 
abrupt loss of kidney function, resulting 
in the retention of urea and other waste 
products and in the dysregulation of ex-
tracellular volume and electrolytes” [16]. 
Over the last decades this clinical picture 
has shifted from a single-organ disease to 
acute renal failure as part of multi-organ 
systemic illness predominantly occurring 
in ICU patients. In parallel more than 35 
different definitions on ARF emerged in 
literature resulting in a wide variation in 
reported incidence from 1% to 25% in criti-
cally ill patients and mortality rates from 15 
to 60% [17]. As a consequence comparative 
research on epidemiology and outcome 
of AKI was hampered and highlighted the 
need for a uniform definition of ARF. 
The Acute Dialysis Quality Initiative (ADQI), a 
group of experts in the field of nephrology 
and intensive care, advocated this need in 
2004 and proposed a new definition [18]. 
This resulted in the RIFLE classification, 
an acronym for Risk, Injury, Failure, Loss 
and End stage renal failure (RIFLE). This 
condition covers a spectrum of injuries 
this condition covers a spectrum of inju-
ries comprising the whole range from mild 
impairment of renal function to the need 
of RRT. Definitions are based on changes 
in serum creatinine or urine output. The 
Table 1.
Comparison between RIFLE, 
AKIN and KDIGO criteria.
SCR AND GFR CRITERIA URINE OUTPUT CRITERIA
RIFLE category
Risk sCr x1.5-1.9 OR 25% decrease 
in GFR from baseline
<0.5 ml/kg/h for ≥6 hours
Injury sCr x2-2.9 OR 50% decrease 
in GFR rom baseline
<0.5 ml/kg/h for ≥12 hours
Failure sCr x3 OR 75% decrease in GFR from 
baseline OR sCr>4mg/dl with an acute 
increase of at least 0.5 mg/dl
<0.3ml/kg/h for ≥24 hours OR 
anuria for ≥12 hours
Loss Complete loss of renal function 
(RRT) for > 4 weeks
End stage kidney disease RRT > 3 months
AKIN criteria
Risk sCr increase ≥ 0.3 mg/dl increase OR 
sCR x1.5-2-fold from baseline
<0.5ml/kg/h for ≥6 hours
Injury sCr increase > 2-3-fold from baseline <0.5ml/kg/h ≥12 hours
Failure sCr increase > 3-fold from baseline OR 
sCr ≥4 mg/dL with an acute increase 
of at least 0.5 mg/dl or RRT
<0.3ml/kg/h for ≥24 hours OR 
anuria for ≥12 hours
KDIGO criteria
Stage 1 sCr increase ≥ 0.3 mg/dl increase OR 
sCR x1.5-1.9-times from baseline
<0.5ml/kg/h for 6-12 hours
Stage 2 sCr increase > 2-2.9-times from baseline <0.5ml/kg/h ≥12 hours
Stage 3 sCr increase > 3.0-fold from baseline OR 
sCr ≥4 mg/dL OR RRT OR eGFR<35mL/
min/1.73m² in patients < 18 years
<0.3 ml/kg/h for ≥24 hours OR 
anuria for ≥12 hours
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RIFLE classification was later modified by 
the Acute Kidney Injury Network (AKIN) 
group, stressing the importance of small 
declines in kidney function [19]. This group 
also introduced the present day term 
“Acute Kidney Injury”. Later, the Kidney 
Disease: Improving Global Outcomes 
(KDIGO) Clinical Practice Guidelines for AKI 
harmonized the previous definitions and 
staging systems proposed by ADQI and 
AKIN [20]. The differences between the AKI 
staging systems are presented in Table 1.
2.2. Incidence of AKI in critically ill  
patients   To obtain an overall concept on 
the incidence of AKI in critically ill patients, 
two landmark studies can be put forward. 
In 2005 Uchino and colleagues presented 
the Beginning and Ending Supportive 
Therapy (BEST) for the Kidney study, a 
multinational, multicenter, prospective 
epidemiological study of ARF on 29,269 
patients [16]. They found an incidence of 
ARF in the ICU of approximately 6%. ARF 
was defined as a urine output of < 200 mL 
in 12 hours and/or a blood urea nitrogen 
(BUN) level > 84 mg/dL (> 30 mmol/L). More 
recently Hoste and colleagues demon-
strated in The Acute Injury-Epidemiologic 
Prospective Investigation (AKI-EPI) study 
an incidence of AKI in 1,032 out of 1,802 ICU 
patients (57.3%) [21]. AKI was diagnosed and 
classified on the basis of the worst serum 
creatinine or urine output criteria accord-
ing to the KDIGO classification. This wide 
variation in the rates of AKI in critically ill 
patients can be explained in several ways. 
First, the applied definitions of AKI in the 
above mentioned studies were not uniform. 
Based on the applied definition, the BEST 
Kidney trial mainly focused on patients with 
severe AKI [16]. On the contrary, the KDIGO 
classification based definition of AKI used in 
the AKI-EPI trial encompasses less severe 
forms of AKI [21]. Nevertheless, AKI can be 
considered a common complication in crit-
ically ill patients. Secondly, aside from the 
definition used, an increase of AKI has been 
reported over time. This observation may be 
related to an increasing awareness of AKI 
but also because of the above mentioned 
change in case-mix of patients as geriatric 
patients with notable comorbidities [6, 22].
2.3. Causes and risk factors of AKI in 
critically ill patients   AKI is a syndrome that 
encompasses the entire spectrum rang-
ing from purely functional to completely 
structural dysfunction with the requirement 
of RRT. Classically, AKI is categorized into 
three types of etiology: prerenal, renal or 
intrinsic and post-renal AKI. Prerenal and 
postrenal failures describe conditions 
“outside” the kidney and are otherwise 
called “functional” renal failure. Intrinsic 
renal failure is due to conditions “inside” 
the kidney, so-called “structural” renal 
failure or ATN [23]. To date this somewhat 
artificial classification is still widely used in 
the clinical identification and treatment of 
AKI. For example, patients suffering from 
intrinsic renal pathologies such as acute 
glomerulonephritis, vasculitis or interstitial 
nephritis need an immediate diagnosis and 
a decidedly different treatment than that 
of patients with prerenal or postrenal AKI. 
Despite its widely use, this classification 
is being  questioned as it is not supported 
by hard data. Assigning the diagnosis of 
prerenal or intrinsic AKI is difficult as the 
underlying pathophysiological mechanisms 
are not fully understood. There is also 
an unclear differentiation and nebulous 
overlap between functional and structural 
AKI. So prerenal and intrinsic AKI may co-
exist in the same patient [24]. The rise in 
concentration of novel urinary biomark-
ers in patients with “solely prerenal AKI” 
suggests that cellular damage is already 
present in this prerenal phase of AKI [25]. 
Novel biomarkers such as urinary NGAL 
may shed a new light on the discussion 
but their diagnostic discriminatory value 
should not be overemphasized [26]. 
Risk factors for AKI can be classified into 
baseline or preadmission risks, acute 
clinical conditions and agents associated 
with the development of AKI [27]. Older 
age, diabetes and heart failure typically 
predispose to AKI. However, the most im-
portant risk factor for AKI is preexisting 
CKD. Patients with underlying CKD have a 
ten-fold increased risk of the development 
of AKI. The underlying mechanisms of this 
acute-on-chronic kidney failure include 
impairment of autoregulation, abnormal va-
sodilatation and side effects of medication 
(antihypertensive agents, diuretic agents).
CHAPTER 1    Introduction
1514
Further, a number of acute clinical condi-
tions have been identified as risk factors 
for AKI. Sepsis accounts for most cases 
of AKI (21.0 to 47.5%) in  critically ill pa-
tients [16, 21]. The etiology of AKI in critically 
ill patients with sepsis is usually multi-
factorial and frequently develops from a 
combination of hypovolemia, nephrotoxic 
effects by medications and hemodynamic 
perturbations [28]. Other frequent clinical 
conditions that may increase the risk of AKI 
in critically ill patients are major surgery 
and trauma, intra-abdominal hypertension 
and intra-abdominal compartment syn-
drome, cardiogenic shock, hypovolemia 
and hepatorenal syndrome. Finally, nephro-
toxic agents such as NSAIDs or contrast 
media are associated with the develop-
ment of AKI in critically ill patients [16, 29].
2.4. Novel biomarkers of AKI   Currently, 
the standard diagnostic tools for AKI 
detection are sCr concentration and 
urine output. Both are markers of renal 
function but not kidney injury [30]. In the 
recent past, several potential biomark-
ers for AKI have been introduced. 
Ideally these novel biomarkers have the 
ability to identify the injury to the tubu-
lar system and to facilitate the diagnosis 
and the differential diagnosis of AKI. As a 
consequence they may identify patients 
who are going to develop AKI. Furthermore 
they could assist in the evaluation of the 
intensity of injury. Finally they should 
be prognostic relevant by predicting the 
need for RRT, AKI-related complications 
and short- and long-term prognosis [31].
This section describes the basic pathophys-
iology and the ability to predict outcome of 
the most important currently proposed bio-
markers of AKI. The novel biomarkers can be 
classified into three groups. The first group 
encompasses inflammatory biomarkers 
including Neutrophil Gelatinase-Associated 
Lipocalin (NGAL) and pro-inflammatory 
cytokines such as IL-18. The second group 
includes cell injury biomarkers such as 
Kidney Injury Molecule 1 (KIM-1) and Liver-
type Fatty Acid-Binding Protein (L-LFABP). 
The third recently identified group con-
sists of cell cycle markers such as Tissue 
Inhibitor of MetalloProteinase-2 (TIMP-2) 
and IGF-Binding Protein-7 (IGFBP-7) [32, 33].
Inflammatory biomarkers   NGAL is a 
25-kDA protein of the lipocalin family. The 
known functions of NGAL are related to its 
ability to bind iron-siderophore complexes. 
It binds to free iron and exerts a bacterio-
static function by preventing iron uptake by 
bacteria [32]. NGAL is expressed at very low 
constant levels in different cell types. After 
ischemic, septic or toxic AKI it is highly up-
regulated in the thick ascending limb and 
the intercalated cells of the collecting duct 
[33]. NGAL is filtered by the glomerulus and 
is reabsorbed by the proximal tubules [34]. 
A decrease in tubular reabsorption after 
AKI may lead to a further increase in uri-
nary NGAL concentration. Elevated NGAL 
protein is detectable in the urine as early 
as three hours after injury and peaks ap-
proximately 6 hours after injury.  In severe 
injury the elevation can persist up to 5 days 
after the initial harmful event [35,36]. NGAL 
expression in AKI follows a dose-dependent 
curve with respect to the severity of kidney 
injury. Urine and plasma NGAL concentra-
tions rise rapidly and proportionally to the 
severity and duration of the insult [25].
It is the most widely investigated new 
biomarker for AKI. The performance of 
NGAL was determined in different settings 
and populations. A recent meta-analysis 
including almost 3,000 cardiac surgery pa-
tients evaluated the performance of urinary 
NGAL and reported an AUC of 0.72 [37].
Interestingly, NGAL levels increase in the 
setting of stimuli damaging the kidney but 
not in the setting of rapidly reversible and 
fluid-sensitive volume depletion [38,39]. As 
such NGAL is able to separate volume de-
pletion and intrinsic damage, two clinical 
separate entities making up the differential 
diagnosis in AKI. Further, in sepsis NGAL 
can rise days before sCr increases [33].
NGAL predicted death or RRT at the time of 
admission to the emergency room. Patients 
with NGAL > 104 ng/mL and sCr>1.4mg/
dL demonstrated a 15% incidence of 
death or RRT during hospitalization [40]. 
Further Singer et al demonstrated an as-
sociation between elevated urinary NGAL 
levels at AKI diagnosis and long-term 
adverse outcomes of ESRD or death [41].
IL-18, also known as interferon-gamma in-
ducing factor is a 22-kDa proinflammatory 
cytokine [42]. It is synthesized by multiple 
15
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tissues, including monocytes, macrophages 
and the intercalated cells of the collecting 
ducts in healthy kidney [43]. Ischemia-
reperfusion injury leads to an increase in IL 
18 levels [44]. IL-18 is an attractive target for 
biomarker-directed therapy of AKI, because 
this cytokine seems to play a prominent 
role in the inflammatory processes that 
exacerbate renal injury during the exten-
sion phase of AKI. Urinary IL-18 is elevated 
within the first 6 h after renal injury and 
peaks after 12-18 hours.  Only few clinical 
studies have analyzed the utility of IL-18 as 
a biomarker for AKI [45]. Although promising 
for the prediction of delayed graft function 
urinary IL-18 failed to show reliable pre-
diction in the general ICU population [46].
Cell injury biomarkers   KIM-1 is a 38-kDa 
transmembrane protein. Basal expression 
of KIM-1 is low in the normal kidney but is 
rapidly upregulated after ischemia-reperfu-
sion injury. KIM-1 protein can be localized to 
proliferating dedifferentiated epithelial cells 
of the proximal tubule 48 hours after injury 
[47]. The late timing of peak changes (2-3 
days after AKI) in urine KIM-1 concentrations 
suggests a functional role in the molecular 
and cellular biology of AKI associated with 
renal recovery and tubular regeneration 
after AKI. Unfortunately, studies evaluating 
the prognostic use of KIM-1A are rather 
disappointing [48]. Because increased KIM-1 
can indicate either injury or repair, the 
concentration of KIM-1 by itself may not 
be able to discriminate between worsening 
AKI and injury which will recovery. Kim-1 
has been approved by the US Food and 
Drug Administration as an AKI biomarker 
for preclinical drug development [49].
L-FABP is a 14k-Da protein expressed pre-
dominantly in the proximal tubule. L-FABP 
concentration elevates immediately after 
AKI and peaks within 6 hours [50]. It is a 
renoprotectif protein and has antioxidant 
properties by mitigating H2O2-induced ox-
idative stress. The L-FABP gene expression 
is induced by hypoxia and reduces the se-
verity of renal ischemia-reperfusion injury 
[51]. L-FABP has already been approved as 
a diagnostic test for use in Japan. A study 
in ICU patients found that urinary L-FABP 
at the time of ICU admission predicted the 
development of AKI within 1 week (AUC=0.7), 
suggesting that patients with elevated base-
line L-FABP values are at greater risk for the 
development of AKI [52]. Therefore L-FABP 
measurement may be used to identify high-
risk patients and minimize their exposure 
to renal insults. In summary, urinary L-FABP 
appears to be a promising biomarker for 
both diagnosis and prediction of AKI and its 
outcomes among critically ill patients [53].
Cell cycle markers   Each phase of the 
cell cycle has a specific function that is 
required for appropriate cell proliferation. 
Cells can use the cell cycle arrest as a 
protective mechanism to avoid cell divi-
sion during stress and injury. Failure to 
achieve G1 cell cycle arrest can lead to an 
increased proportion of renal tubular cells 
in the G2/M phase, producing profibrotic 
growth factors that are capable of stimu-
lating fibroblast proliferation and collagen 
production leading to kidney damage [54].
The cell cycle biomarkers TIMP-2 and 
IGFBP-7 are expressed in the tubular 
cells and involved in several biological 
processes, including cell cycle arrest [55]. 
Additionally, TIMP-2, a 21-kDa protein, 
is involved in the pathophysiology of is-
chemia-reperfusion injury. It promotes 
disease progression through the activa-
tion of metalloproteinase and triggering 
of tubulointerstitial fibrosis and injury. 
IGFBP-7 is a 29-kDa secreted protein that 
is a member of the IGFBP-related pro-
teins. They exhibit pleiotropic effects in 
development and disease, and IGFBP-7 
regulates the bioavailability of IGFs 
through direct low-affinity bindings [56]. 
By detecting cell cycle arrest markers in 
the urine, one may actually be detecting 
cell stress before injury has occurred. 
The Sapphire study tested the ability of 340 
proteins involved in biological pathways 
presumably linked to the pathogenesis 
of AKI, to predict development of AKI in 
ICU patients [57]. The product of [TIMP-2] 
[IGFBP-7] provided an AUC of 0.80 (95% CI 
0.74-0.84) for severe AKI in the validation 
cohort. Urinary [TIMP-2] [IGFBP-7] was signif-
icantly superior to all previously described 
markers of AKI (p<0.002), including NGAL 
and KIM-1 in forecasting AKI stage 2 or 3.
The Topaz study validated [TIMP-2] [IGFBP-7] 
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in a multicenter study using clinical adjudi-
cation to determine the primary endpoint  
of moderate-severe AKI [58]. ICU patients 
with urinary [TIMP-2] [IGFBP-7] levels  
> 0.3 ng/ml2/1000 had 7 times the risk 
for AKI compared with ICU patients with 
a negative test result. On the contrary, a 
recent study from Bell et al found that 
in ICU patients  the biomarker panel did 
not predict AKI within 24-48 hours [59].
In long-term follow-up of the original 
validation study (i.e. Sapphire study) 
Koyner et al explored the association of 
the combined biomarker and long-term 
outcome (9 months). A composite end-
point of mortality or the need for RRT 
was evaluated. Univariate analysis showed 
that [TIMP-2] [IGFBP-7] value of 2.0 was 
associated with increased risk of the 
composite endpoint (HR 2.11 (95% CI 1.37-
3.23), P<0.001). In a multivariate analysis 
levels >0.3 were associated with death or 
RRT only in subjects who developed AKI. 
They concluded that the combined bio-
marker measured early in the setting of 
critical illness may identify patients with 
AKI at increased risk for mortality or re-
ceipt of RRT over the next 9 months [60]. 
At present 3 kidney damage biomarkers 
are available for clinical use: neutrophil 
gelatinase-associated lipocalin (NGAL), 
and the combination of insulin-like 
growth factor-binding protein IGFBP-7 
and TIMP-2 or urinary [TIMP-2] [IGFBP-7].
Unfortunately there is no perfect bio-
marker of AKI. Each of the described 
biomarkers is not entirely specific for AKI 
and demonstrates imperfect test charac-
teristics. However, the novel biomarkers 
will likely develop a deeper understanding 
of kidney injury, giving clinicians more 
powerful tools in the decision-making. 
 
2.5. Evolution from AKI to CKD: patho-
physiological insights   AKI, regardless of 
its etiology, is associated with a greater 
risk of CKD and with progression to ESRD. 
The pathophysiological mechanisms of 
renal injury and repair include vascular, 
tubular and inflammatory factors [61].
Vascular factors   The kidney has a high 
oxygen demand with a relatively low O2 
extraction. In addition, the oxygenation of 
the outer medulla is quite marginal making 
this region very susceptible to reduced 
vascular perfusion and oxygenation [62,63].
Injury to the microvascular endothelium 
leads to oxidative stress and the expres-
sion of cell surface markers that promote 
recruitment and adhesion of leukocytes 
and platelets. Subsequently, increasing 
vascular permeability induces interstitial 
edema and further reduces blood flow and 
oxygen delivery. These processes result in 
additional cell injury and inflammation [64].
The long-term consequence is a reduc-
tion in the number of microvessels in the 
kidney, potentially facilitated by the down-
regulation of VEGF (vascular endothelial 
growth factor) and TGF-beta (transforming 
growth factor beta) and upregulation of 
angiogenesis inhibitors [65].This so-called 
“vascular dropout” may trigger a positive 
feedback process by which the loss of 
vessels results in hypoxia to areas of the 
nephron which than generate hypoxia-in-
ducible factors. This chronic hypoxia may 
induce proinflammatory responses and 
cellular infiltrate leading to increased tubu-
lointerstitial fibrosis and nephron loss [66].
Tubular factors   AKI leads to an alteration 
of tissue architecture and cell structure. 
Injury induces a disruption of normal cell-
cell interactions, a rapid loss of proximal 
tubular cell and cytoskeletal integrity and 
cell polarity. There is shedding of the prox-
imal tubule brush border into the lumen 
and a desquamation of viable and nonviable 
cells leaving regions where the basement 
membrane remains the only barrier be-
tween the filtrate and the peritubular 
interstitium [67,68]. Severe injury may result 
into apoptosis and necrosis of tubular cells, 
but also impairs the epitelial proliferative 
response with cell cycle arrest at the G2/M 
phase of the cell. This process activates 
a signaling cascade that acts to upregu-
late profibrotic cytokines production [69].
Inflammatory factors   AKI is an inflam-
matory disease characterized by the 
recruitment of various immune cells such 
as macrophages and T cells to the injured 
kidney tissue [70].Together with dendritic 
cells, this cellular infiltrate contributes to 
both parenchymal damage and fibrosis 
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by releasing inflammatory mediators. 
On the contrary, the cellular infiltrate also 
directly activates naive T cells providing a 
protective response and beneficial effects 
on repair [71,72].Further, the recruitment of 
monocytes may determine the ultimate 
fate of the tissue after injury: complete 
repair with little sequelae versus fibrosis 
with a tendency to progress to CKD. 
Although renal recovery from injury is 
possible through regeneration by sur-
viving tubular epithelial cells, AKI may 
result in incomplete repair with persis-
tent tubulointerstitial inflammation and 
the transformation of epithelial cells 
into fibroblasts contributing to fibrosis 
[73,74]. The vascular dropout and tubuloin-
terstitial fibrosis are hallmarks of CKD. 
Especially in the setting of underlying 
kidney disease, this maladaptive repair 
may enhance the worsening of CKD 
and the progression to ESKD [75].
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The recent paradigm shift that patients 
die of AKI rather than with AKI is based 
on epidemiological data demonstrat-
ing the association between AKI and 
mortality. In the following article the 
clinical consequences of AKI are sum-
marized, this may help explain the as-
sociation between AKI and mortality.
3. Clinical  
 consequences  
 of acute  
 kidney injury 
ABSTRACT
AKI can no longer be considered a surrogate 
marker for severity of illness. Recent 
epidemiologic data demonstrate the as-
sociation of AKI and mortality. Even small 
decreases of kidney function are associated 
with increased mortality. Several clinical 
consequences of AKI may explain the as-
sociation of AKI and mortality. Decreased 
free water clearance leading to volume 
overload contributes to morbidity and 
mortality but also to deterioration of kidney 
function. Acid base disorders and electro-
lyte abnormalities interfere with normal 
functioning of many processes in the body. 
Critically ill patients have an increased 
prevalence of infection. Infection and anti-
microbial therapy can be the cause of AKI, 
but infection can also be a consequence 
of AKI. Finally, inadequate antimicrobial 
dosing probably plays an important role 
in morbidity and mortality of AKI. These 
findings lead to a paradigm shift: Patients 
die because of AKI, rather than with AKI. 
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3.1 INTRODUCTION
In the past, AKI was considered a surrogate 
marker for severity of illness, and patient 
mortality was considered a consequence of 
the underlying disease [1]. Especially in ICU 
patients, AKI develops as a consequence 
of other disease, e.g. sepsis, cardiogenic 
shock or trauma, that in a certain number 
of patients will lead to mortality. However, 
there is an abundance of epidemiologic 
data that demonstrates that AKI itself 
also contributes to higher mortality. This 
is so for the most severe form of AKI, 
where patients are treated with RRT [2-6]. 
Small decreases of kidney function are 
also associated with increased short-term 
mortality (hospital and 28-day). This has 
been demonstrated in various settings 
such as in contrast induced-AKI (CI-AKI), in 
patients who underwent cardiac surgery, 
in hospitalized patients and in ICU patients 
[7-12]. When AKI is classified according to 
the newly developed sensitive RIFLE or AKI 
classification, all studies demonstrated an 
association with hospital mortality [5, 13-15]. 
Other outcomes, such as length of 
hospital stay, readmission rate, devel-
opment of end stage kidney disease, 
and long term (1-10 year) mortality are 
also affected by severe and less severe 
episodes of AKI during ICU stay [16-21].
In this overview we will discuss clinical 
consequences of AKI that may explain the 
association of AKI and mortality (Fig. 1).
3.2 MORBIDITY CAUSED BY AKI
3.2.1 Fluid overload   Fluid resuscitation is 
one of the cornerstones for treatment of 
ICU patients with an episode of oliguria or 
developing AKI. The majority of AKI patients, 
especially those with severe AKI, will have 
decreased (free) water clearance. This will 
lead to accumulation of water, and several 
observational studies found that this is 
associated with worse outcome [22-24]. It 
is difficult to delineate whether fluid over-
load is only a surrogate marker of severity 
of illness or if it is in itself the cause of 
increased morbidity and mortality. Some 
arguments are in favour for the latter. 
Underlying 
cause of AKI
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- Multiple organ 
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Consequences 
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Fig. 1.
Patients are dying of AKI 
and not with AKI.
The interaction between the aetiology 
of AKI and the consequences of AKI and 
the impact on morbidity and mortality.
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Fluid overload may lead to a series of 
minor and major complications that may 
influence outcome. It may result in a broad 
range of complication such as development 
of tissue oedema, ascites and eventually 
intra-abdominal hypertension and ab-
dominal compartment syndrome, pleural 
effusion and pulmonary oedema [25]. An 
elegant demonstration of the untoward 
effects of increased total body water was 
in a prospective study on patients who un-
derwent colorectal surgery, and who were 
randomized to a restrictive and a normal 
peri-operative fluid regimen [26]. Patients 
who were randomized to the restrictive 
fluid regimen had significantly less com-
plications, in particular cardiopulmonary 
complications, and better tissue healing.
Despite many AKI patients are already fluid 
overloaded, the majority of these patients 
will receive fluid boluses in order to restore 
effective arterial blood volume and restore 
pre-renal AKI. However, fluid overload may 
not only contribute to extra morbidity, but 
may also contribute to deterioration of 
kidney function. Especially, in cardiac pa-
tients, increased central venous pressure 
and right ventricular failure, is associated 
with development of AKI [27-29].  Also, in 
Acute Respiratory Distress Syndrome 
(ARDS), randomisation to a restrictive fluid 
therapy regimen resulted in less need for 
renal replacement therapy (10% versus 
14%, p = 0.06) [30]. Another mechanism by 
which fluid overload may lead to AKI is 
through development of intra-abdominal 
hypertension, abdominal compartment 
syndrome (ACS), by decreased thoracic 
and abdominal wall compliance, retrop-
eritoneal oedema and ascites [25, 31, 32]. 
3.2.2 Inflammation and “organ cross talk”   
AKI is characterised by a profound inflam-
matory reaction in the kidneys and in the 
systemic circulation. This systemic inflam-
matory response leads to dysfunction of 
other organs. Animal experiments demon-
strated that AKI leads to gene activation of 
pro-inflammatory and anti-inflammatory 
mediators in the lung, which results in 
ARDS, with exudation of albumin in the 
alveoli, changes of aquaporins and sodium 
channels and infiltration of neutrophils 
[33-40]. Acid base disorders, which are com-
monly seen in AKI, also play a role in this 
inflammatory reaction. Hyperchloremic 
acidosis is associated with an increased 
interleukin (IL)-6/IL-10 ratio with a result-
ant pro-inflammatory effect, while lactic 
acidosis will decrease both IL-6 and IL-10 
resulting in an anti-inflammatory status 
[41-43]. A more extensive discussion on this 
topic can be found in other chapters in this 
issue of “Contributions to Nephrology”.
3.2.3 Acidosis   The kidneys play an im-
portant role in acid-base homeostasis. 
Metabolic acidosis is the resultant of 
accumulation of anions such as chloride, 
phosphate, and other anions that are not 
routinely measured [44,45]. Acidosis occurs in 
up to one-third of patients who are initiated 
on RRT [46]. Acidosis interferes with normal 
functioning of many processes in the body. 
It will lead to hemodynamic instability by 
decreased cardiac output and vasodilata-
tion. Decreased density of β-receptors at 
the cell surface of the myocardium, inter-
ference with intracellular calcium handling, 
increased nitric oxide production and in-
terference with the inflammatory response 
are the mechanisms that most likely play 
a role in this [41,42,47-49]. Further, different 
aetiology of acidosis is associated with 
different systemic effects [41-43]. Moderate 
hyperchloremic acidosis is associated with 
an increased NO production, leading to 
vasodilatation, while in lactic acidosis there 
is a gradual decline in NO production.
3.2.4 Electrolyte abnormalities   Also the 
kidney regulates electrolyte homeostasis. 
Up to one third of patients with severe 
AKI will develop dilution hyponatremia 
by decreased free water clearance [50, 
51]. Hyponatremia is associated with 
severe complications such as cerebral 
oedema, and with worse outcomes [52, 53]. 
Furthermore, between 6,1% and one third 
of the patients who are initiated on RRT 
develop hyperkalemia, a condition that is 
associated with arrhytmias and death [46,50].
3.2.5 Infection   Infection and antimicro-
bial therapy for infection play a central 
role in the course of AKI [54]. ICU patients 
with AKI have an increased prevalence of 
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infection [54-58]. Infection and antimicrobial 
therapy may be the cause of AKI, but in-
fection may also be a resultant of AKI. In a 
series in our centre we found that 80.2% of 
ICU patients who had AKI and were treated 
with RRT, were also treated for infection 
[55]. 37,5% of the patients even had two 
ore more episodes of infection. Almost 
half of these infections started just before 
initiation of RRT, 40% during RRT and ap-
proximately 10% in the period immediately 
after discontinuation of RRT. Several factors 
may play a role in this interplay between 
infection, antimicrobial therapy and AKI. 
3.2.6 Inadequate antimicrobial therapy   
Adequate prescription of antimicrobial 
therapy is a challenge in ICU patients. The 
volume of distribution, metabolization and 
clearance can have important variations 
among patients and also within the same 
patient in different time periods of ICU 
stay. This may result in underdosing and 
overdosing of antimicrobials when standard 
antimicrobial dosing schedules are used. 
Correct dosing is even more difficult in AKI 
patients. A first issue is correct evaluation 
of kidney function. Formulas that are used 
for assessment of kidney function in pa-
tients with chronic kidney disease, such 
as the Cockcroft-Gault and Modification 
of Diet in Renal Disease (MDRD) equations 
were validated in non-ICU patients with 
moderate chronic kidney disease and are 
based on serum creatinine, and variables 
such as age, body eight and gender. These 
equations are not adequate for assessment 
of kidney function in ICU patients [59, 60]. 
Kidney function is best assessed by meas-
urement of urinary creatinine clearance, 
i.e. (= (urine volume) x (urine creatinine 
concentration) / (time in minutes) x 
(serum creatinine concentration)). This 
calculation requires exact timing and meas-
urement of urine volume, and a stable 
kidney function during the measurement 
period. As this condition is seldom met 
in patients with AKI, one can shorten the 
measurement period to, for example, 2 
or 4 h, or use the mean of serum creati-
nine concentration measured just before 
and after the measurement period [60]. 
Another issue that precludes correct dosing 
of antimicrobial therapy in ICU patients 
who have AKI, is that dosing schedules 
for antimicrobial therapy are most based 
on data from patients with chronic kidney 
disease. These are not necessarily useful 
in ICU patients with AKI and comparable 
degree of GFR. Serum concentration can be 
lower in ICU patients by increased volume 
of distribution, decreased gastro intestinal 
absorption, increased GFR during treatment, 
or RRT. Examples of factors that may in-
crease serum concentrations are decreased 
albumin concentration, decreased kidney 
function and periods without RRT. 
In patients treated with RRT, dosing 
schedules are available. But variables as 
dialysis blood flow, dialysate flow, ultra-
filtration rate, administration of pre- or 
postdilution, filter characteristics, may vary 
from centre to center, and have impact 
on dialysis dose and so on clearance. 
3.2.7 Inadequate metabolic and nutritional 
support   ICU patients with AKI are usually 
in a catabolic state, and treatment with RRT 
leads to additional losses of amino acids 
and proteins. Loss of phosphorus in CRRT 
can lead to prolonged time on mechanical 
ventilation [61]. Further, the concentration of 
trace elements can be lower as a resultant 
of acute phase reaction, losses of fluids, 
and removal by RRT. Finally, water-solu-
ble vitamins such as vitamins C, thiamine 
and folic acid are removed by RRT [62].
At present, the data on the effects of nu-
tritional interventions and different RRT 
modalities on nutritional status and blood 
concentration of trace elements and 
vitamins in ICU patients with AKI are insuf-
ficient. Given the data that we do know, 
and given the vast evidence on the impor-
tance of nutritional status and nutritional 
interventions in chronic haemodialysis 
patients and in ICU patients in general, this 
aspect of care needs further exploration.
3.3 CONCLUSION
Current epidemiologic findings demonstrate 
the strong association between AKI and 
short-term and long-term mortality. 
A whole range of clinical complications 
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of AKI help to explain this. Factors that 
may help explain increased morbidity and 
mortality in AKI patients are a consequence 
of decreased kidney function such as 
volume overload, acidosis and electrolyte 
abnormalities. AKI may also impact 
on other organs, as in organ crosstalk 
between kidneys and lungs. AKI patients 
have an increased incidence of infection. 
Infection may impact on mortality, but 
also, inadequate antimicrobial therapy 
may play an important role. Current dosing 
recommendations for antimicrobials 
are most inadequate for ICU patients 
who have AKI, and adequate dosing is 
therefore a topic that needs further 
study. Finally, nutritional support is an 
underemphasized aspect of care for 
AKI patients in the ICU. Especially in AKI 
patients treated with RRT, we need more 
data on nutrition and supplementation 
of trace elements and vitamins.
The paradigm shift that patients die 
of, rather than with AKI, emphasizes 
the need for early recognition of AKI or 
clinical circumstances that eventually can 
lead to the development of AKI. RIFLE 
and AKIN criteria can be useful tools for 
intensivists in the early identification 
and management of AKI. The prevention 
of AKI in critically ill patients cannot be 
overemphasized. Adequate fluid therapy, 
the correction of acid base disorders and 
electrolyte imbalances, the early recognition 
of infections and adequate dosing of 
antimicrobial therapy are key issues in the 
management of AKI and in reducing its 
additional mortality in critically ill patients.
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ABSTRACT
Purpose of review   AKI is a frequent com-
plication in ICU patients, and is associated 
with adverse outcomes. With the purpose 
of improving outcome of AKI, the Kidney 
Disease: Improving Global Outcomes (KDIGO) 
group, a group of experts in critical care 
nephrology, has presented a set of guide-
lines in 2012, based on the evidence gathered 
until mid 2011. This review will update 
these guidelines with recent evidence. 
Recent findings   Early application of a set 
of therapeutic measures – a bundle – is 
advised for the prevention and therapy of 
AKI. Hemodynamic optimization remains 
the cornerstone of prevention and treat-
ment of AKI. Fluid resuscitation should be 
with isotonic crystalloids. Recent evidence 
demonstrated a higher risk for RRT an 
mortality in hydroxyethyl starch-exposed 
patients. Further, blood pressure should 
be maintained by the use of vasopressors 
in vasomotor shock. Nephrotoxic drugs 
should be avoided or stopped when pos-
sible. Contrast-associated AKI should be 
prevented by prehydration with either NaCl 
0.9% or a bicarbonate solution. Other thera-
pies, including intravenous N-acetylcysteine 
and hemofiltration are not recommended. 
Optimal timing of RRT remains controversial. 
Fluid overload remains an important deter-
minant for the initiation of RRT. Continuous 
therapies are preferred in hemodynamically 
unstable patients; otherwise choice of 
modality does not impact on outcomes. 
Summary   The KDIGO guidelines as pre-
sented in 2012 provide guidelines on the 
domain of definition of AKI, prevention and 
treatment, contrast-induced AKI and dialysis 
interventions for AKI. Especially, early appli-
cation of a set of measures, the AKI bundle 
may prevent AKI and improve outcome.
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4. Management of 
 acute kidney injury
4.1  PREVENTION OF 
  ACUTE KIDNEY INJURY
AKI can no longer be considered a  
surrogate marker for severity of illness.  
The association between AKI and mortality 
emphasizes the need for early recognition 
and prevention of AKI. In the following arti-
cle we summarized the KDIGO guidelines on 
AKI in critically ill patients. Special attention 
was paid to the KDIGO AKI bundle propos-
ing measures for the prevention of AKI. 
IMPLEMENTING THE KIDNEY DISEASE: 
IMPROVING GLOBAL OUTCOMES 
ACUTE KIDNEY INJURY GUIDELINES 
IN ICU PATIENTS.
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4.1.1 Introduction   Acute kidney injury (AKI) 
is a frequent complication in ICU patients, 
and is associated with worse outcomes. 
When it is defined by the sensitive RIFLE 
definition for AKI or its modifications, 
the Acute Kidney Injury Network (AKIN) 
or Kidney Disease: Improving Global 
Outcomes (KDIGO) definitions for AKI, it 
occurs in one-third to two-thirds of ICU 
patients [1-8]. Approximately 5 to 10 % of 
ICU patients are treated with renal re-
placement therapy (RRT) for AKI [9-11].
AKI is associated with worse outcomes 
such as, longer length of ICU and hospital 
stay, short-term survival (e.g. 28 d, ICU or 
hospital survival), also long-term survival 
(up to 10 years follow-up), development 
of chronic kidney disease (CKD) and end 
stage renal disease (ESRD), and therefore 
increased use of resources and costs.  
Despite decades of research, and dozens 
of compounds evaluated, there are 
at present still very little therapeutic 
options for treatment or prevention of 
AKI. Explanations for this may be the 
heterogenous and multifactorial cause.
Despite the absence of specific therapies 
for AKI, outcome has improved over years 
[12, 13]. This may be explained by improve-
ment of therapy for associated disease, and 
increased awareness of specific nephrology 
issues. Several studies showed that simple 
“kidney-friendly” interventions (e.g. stopping 
of nephrotoxic drugs such as non-steroidal 
anti-inflammatory drugs (NSAIDs), and early 
correction of volume status), resulted in 
less (severe) AKI, and better outcomes [14-19]. 
Therefore, the guidelines that were issued 
by the KDIGO group are of great importance 
for advances in the treatment of AKI. This 
process was conducted by a group of 
experts, using an evidence-based method-
ology and the Grading of Recommendations 
Assessment, Development and Evaluation 
system. As the amount of guidelines 
is too large to cover them all in this 
article, we will highlight those that are 
most pertinent for everyday practice.
4.1.2 Definition of AKI   An important ac-
complishment of the last decade was the 
introduction by the Acute Dialysis Quality 
Initiative (ADQI) of the RIFLE consensus 
definition for AKI [1]. It allows compari-
sons between studies, interventions in 
AKI patient cohort with similar severity 
stage, and as it also defines very early AKI 
with low severity, it allows early interven-
tion. This definition was later modified, 
first by the Acute Kidney Injury Network 
(AKIN) [2], and recently by KDIGO [3]. 
AKI is defined by either an increase of 
serum creatinine (sCr) or an episode 
of decreased urine output (UO) (Table 
1). Importantly, a patient needs to fulfill 
only one of the criteria for the definition 
of AKI. Subsequently, the severity of 
AKI can be graded into one of 3 severity 
grades. There are some issues in this 
definition that needs extra discussion. 
4.1.3 Timing   As the emphasis is on acute 
deterioration of kidney function, the 
Table 1.
Definition and classification of AKI
SCR URINE  
OUTPUT
STAGE 1 ≥ 1.5 to 1.9 times 
baseline 
OR
≥ 0.3 mg/dL increase
<0.5 mL/kg/h 
for 6-12 h
STAGE 2 ≥ 2.0 to 2.9 times 
baseline
<0.5 mL/kg/h 
for ≥12 h
STAGE 3 ≥ 3.0 times baseline
OR
Increase of sCr 
to ≥ 4.0 mg/dL
OR
RRT
OR 
In patients <18y, 
decrease 
<0.3 mL/kg/h 
for ≥ 24 h
OR 
Anuria for ≥12 h
A. AKI is defined by either an increase of sCr  
    or an episode of oliguria 
Increase of sCr >0.3 mg/dL within 48-hours, or
Increase of sCr by >1.5-fold above baseline,  
know or assumed to have occurred within 7days, or
Urine volume < 0.5 mL/kg/h for 6 hours.
B. AKI severity is staged by the worst  
    of either sCr changes or oliguria
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patients should fulfill the criteria within a 
limited time frame. Therefore, one should 
compare a new sCr measurement to all 
sCr measurements in the preceding 7-day 
period for the 50% of increase of sCr, 
or 48 h for the 0.3 mg/dl sCr increase. 
If the increase of sCr takes place over a 
longer period the patient may be clas-
sified as having acute kidney disease. 
Of note, this time frame is only for the 
definition of AKI, and is not applicable for 
the staging of the AKI severity grade.
4.1.4 Baseline and reference serum 
creatinine   When a patient has no sCr 
measurements available during the 
preceding 7-day period, one may use 
the baseline sCr concentration as a 
reference sCr for the 50% or greater 
increase of sCr, if this is presumed to 
have occurred within the prior 7 days. 
For the 0.3 mg/dL or greater increase 
of sCr, one needs a documented 
increase; therefore, the presumed 
baseline sCr may not be used for this. 
In patients who are in stable condition, 
ADQI recommended baseline sCr concen-
tration may be obtained within a 3-month 
period preceding the current event [20]. 
Clinical judgment is essential for the correct 
estimation of this baseline sCr. For instance, 
if a baseline sCr is obtained at the end of a 
preceding ICU admission, it is very unlikely 
that this value represents true baseline 
kidney function. Also, assessment on 
whether the acute condition of AKI occurred 
within a 7-day period may be challenging. 
When there is no baseline sCr measure-
ment available, the ADQI group advocated 
the use of the MDRD equation when there 
is an assumed baseline glomerular filtra-
tion rate (GFR) of 75 mL/min or greater 
[1]. The MDRD equation estimates GFR on 
gender, age, race, and sCr. This method 
has obviously limitations. The equation 
was validated in a cohort of US patients, 
and is therefore not applicable in patients 
with different body composition such as in 
Asia, or as in patients with lower muscle 
mass, e.g. as in critical illness, cirrhosis 
or paraplegia. Also, it is less precise in 
patients who have GFR>60 mL/min. Despite 
its shortcomings, this MDRD-based esti-
mation of baseline sCr proved reasonably 
well in a cohort of ICU patients recruited 
in 3 centers in the USA [21]. Alternatively, 
baseline sCr may be estimated by use of 
multiple imputation method [22]. These 
single center data need to be confirmed 
in other settings, and although more 
precise, the complexity of this method 
may limits its use in daily practice.
4.1.5 Urine output criteria   The definition 
requires that urine output is less than 
0.5 ml/kg every hour for a 6 period. This 
limits its use to ICU patients with a urinary 
catheter. Studies have used variants of 
the original urine output criteria, e.g. urine 
output less than 3 ml/kg in a period of 6 
hours, use of fixed blocks of 6 or 8 hours 
similar to the nurses’ shift, back calculation 
of 24-h urine output and so on [23].
There is no indication what patient weight 
one should use for the oliguria criterion. 
It seems reasonable to use the “baseline” 
patients’ weight, as actual patient weight in 
critically ill patients is seldom measured, 
and varies according to fluid overload, 
muscle wasting and weight loss secondary 
to critically illness. In morbidly obese, an-
tibiotic dosing is recommended according 
to adjusted body weight. Although, this 
may also be reasonable for the definition 
of AKI, there are no data to support this. 
4.1.6 Prevention and treatment of acute 
kidney injury   This section describes a 
set of measures that are often described 
as the “AKI bundle” (Fig. 1). Summary of the 
KDIGO recommendations for the prevention 
and treatment of AKI are as follows:
1. Hemodynamic management 
a. Isotonic crystalloids  
 rather than colloids
 b. Vasopressors in conjunction with fluids
 c. Protocol-based management  
of hemodialysis and oxygenation in  
perioperative setting or septic shock
2. Metabolism
 a. Target blood glucose 
at 110-149 mg/dl
 b. Energy intake of 20-30 
kcal/kg per day
 c. Preferable enteral route
 d. Avoid protein restriction
  i.  0.8-1.0 g/kg per day of protein 
 in non-catabolic AKI without RRT
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  ii.  1.0-1.5 g/kg per day of 
 protein in AKI on RRT, up to 1.7 g 
 kg per day in patients on continuous 
 renal replacement therapy 
 (CRRT) and hypercatabolic patients. 
3. Pharmacological management
 a. No diuretics for the prevention  
or treatment of AKI 
 b. No dopamine for the prevention  
or treatment of AKI
 c. No fenoldopam for the prevention  
or treatment of AKI
 d. No N-acetylcysteine (NAC)  
for prevention of AKI in hypotension  
and postsurgery
 e. No atrial natriuretic peptide for 
the prevention or treatment of AKI
 f. No recombinant human insulin 
growth factor-1 for the  
prevention or treatment of AKI
 g. No aminoglycosides  
unless no suitable, less nephrotoxic 
alternatives are availbale
  i.  Aminoglycosides: once daily 
 ii.  Monitor drug level in multiple 
 dosing after 24 h, and in once daily 
 dosing when more than 48h 
 iii.  Use topical or local  
 instead of intravenous
 h. Amphotericine B: 
 i.  Lipid formulations 
 ii.  Prefer azoles/echinocandins
4. Nonpharmacological management
 a. Off-pump coronary artery 
bypass surgery not for AKI reasons
5. Contrast-induced AKI (CI-AKI)
 a. Define CI-AKI according 
to the KDIGO definition
 b. Assess risk for CI-Aki
 c. Consider not using contrast
 d. Use low-osmolar  
or iso-osmolar contrast
 e. Prehydrate and posthydrate 
with saline or bicarbonate solution
 f. Oral NAC, no intravenous 
N-acetylcysteine (IV NAC)
 g. Insufficient data on  
fenoldopam and theophylline
 h. No RRT
Bundles such as these are attractive and 
successful as these guarantee that all 
patients receive care according to the best 
evidence available. These allow healthcare 
workers, physicians and nurses to simply 
tick the measures that need to be done 
in patients at risk. Implementation of 
these care bundles has proven to improve 
the outcomes for instance sepsis [24,25]. 
Also, several studies in AKI patients have 
demonstrated that early implemen-
tation of simple measures by content 
experts improved outcomes [14-19].
Fig. 1.
The KDIGO AKI bundle: AKI-stage based management (after [3]).
High risk 1 2 3
Discontinue all nephrotoxic agents when possible
Ensure volume status and perfusion pressure
Consider functional hemodynamic monitoring
Monitor Serum creatinine and urine output
Avoid hyperglycemia
Consider alternatives to radiocontrast procedures
Non-invasive diagnostic workup
Consider invasive diagnostic workup
Check for changes in drug dosing
Consider Renal 
Replacement Therapy
Consider ICU admission
Avoid subclavian 
catheters if possible
AKI stage
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4.1.7 Hemodynamic support
Guideline 3.1.1 “In the absence of hemor-
rhagic shock, we suggest using isotonic 
crystalloids rather than colloids (albumin 
or starches) as initial management for 
expansion of intravascular volume in 
patients at risk for AKI or with AKI (2B).”
As colloids remain in the intravascular 
compartment for a longer period of time 
compared to crystalloids, they may seem at-
tractive. However, older hydroxyethyl starch 
(HES) solutions showed nephrotoxicity, and 
observational data on gelatin containing 
solutions, suggest that these solutions 
have similar risk for nephrotoxicity [26,27]. 
Two well-designed studies on modern HES 
solutions with presumably less nephro-
toxicity, further addressed this topic. The 
6S trial included 798 critically ill patients 
with severe sepsis or septic shock. They 
compared a potato based 6% HES formu-
lation with 130 kD molecular weight (6% 
HES 130) to Ringer’s acetate [28]. At 90 days 
patients treated with HES had an increased 
mortality and a higher prevalence of RRT. 
The Crystalloid versus HydroxyEthyl Starch 
Trial included 7,000 general ICU patients 
and compared a corn-based 6% HES 130 
formulation with 0.9% saline [29]. At 90 days 
the investigators found a lower incidence 
of AKI in HES treated patients compared 
with saline; however, there was a greater 
use of RRT in the HES group. There was no 
difference in mortality between both groups. 
Several meta-analyses have been published 
since. In a meta-analysis, including older 
and newer types of HES solutions, HES 
treatment was associated with increased 
mortality and AKI [30]. Two other meta-anal-
yses on the new HES 130 solutions only, 
in all type of critically ill patients and in 
severe sepsis, found higher risk for RRT and 
mortality in HES exposed patients [31, 32]. 
On the basis of currently available evidence 
the US Food and Drug Administration (FDA), 
issued a boxed warning on the drug’s label 
that HES solutions should not be used in 
critically ill patients. Also, the European 
Medicine Agency (EMA) suspended the 
marketing authorization for HES formulations, 
and started a new review on its use (www.
bit.ly/2gC8lLE, accessed July 22nd, 2013). 
The guideline also advises against the use 
of albumin, this was because the greater 
cost of this fluid is not associated with 
greater need for RRT. Unfortunately, this 
study did not report on AKI defined by more 
sensitive criteria. Albumin treated patients 
had a less positive fluid balance compared 
to saline treated patients. As a positive fluid 
balance may impact occurrence of AKI and 
outcome, this may in fact be an argument 
in favor of the use of albumin [34-38].
It is important to notice that the guideline 
specifically mentions that isotonic crys-
talloid solutions should be used for 
volume resuscitation. Two large studies 
found that non-isotonic crystalloid 
solutions containing high concentra-
tions of chloride, such as in NaCl 0.9%, 
are associated with worse outcomes, 
including AKI, when compared to crystal-
loid solutions with lower chloride content 
such as Plasma-Lyte® (Baxter Healthcare 
Inc., Deerfield, Illinois, USA) [39,40]. 
These data illustrate that fluids should 
be seen as drugs with benefit, but 
also potential toxicity [41] (Fig. 2).
Fig. 2.
Relationship between fluid volume administered 
and beneficial and adverse effects.
mL of fluid
B
en
efi
t
H
ar
m
33
Guideline 3.1.2 “We recommend the 
use of vasopressors in conjunction 
with fluids in patients with vasomotor 
shock with, or at risk for, AKI (1C).”
In critically ill patients, systemic hypo-
tension may instigate a decreased renal 
perfusion eventually leading to AKI. To 
counter for this hypotensive state and 
to secure renal perfusion, vasopressor 
therapy is often used in these patients. 
In a state of vasomotor paralysis, the 
use of norepinephrine, an alpha-adr-
energic agonist, has beneficial effects 
on renal blood flow and GFR [42-45].
Guideline 3.1.3 Protocol-based manage-
ment of hemodynamic and oxygenation 
parameters to prevent development or 
worsening of AKI in high-risk patients 
in the perioperative setting (2C) or 
in patients with septic shock. 
Goal directed therapy has been studied 
extensively in the perioperative setting, 
and in meta-analysis, it was shown that 
this resulted in less postoperative AKI 
[46]. Although the beneficial effect of 
early goal-directed therapy (EGDT) in ICU 
patients on prevention of AKI is plausible, 
the evidence is still limited. The landmark 
study by Rivers et al. on EGDT for severe 
sepsis unfortunately reported no data on 
AKI [47]. In another study on EGDT in septic 
ICU patients by Lin et al., EGDT patients 
had a lower incidence of AKI compared 
to controls (38.9% vs. 55.2%, p = 0.015) 
[48]. At present several large multicenter 
studies on EGDT are under way that will 
provide additional evidence for its use.
4.1.8 Glycemic control and nutritional 
support   AKI patients are severely catabolic 
and nutritional support is therefore an 
important aspect in the therapeutic plan 
for these patients. KDIGO summarized the 
available evidence on this topic and could 
only formulate recommendations with 2C 
or 2D grade of evidence, i.e. suggestions, 
with low or very low quality of evidence, 
mostly based upon expert opinion. 
The landmark study of Van de Berghe 
and colleagues introduced the concept 
of intensive insulin therapy (IIT) in the 
ICU [49]. In surgical -, and a subgroup of 
medical ICU patients IIT protocol improved 
outcome and lowered the incidence of AKI 
[50,51]. These beneficial results could not be 
reproduced in subsequent studies on IIT 
[26,52]. One of the great concerns about IIT 
is the occurrence of hypoglycemia and its 
impact on outcome [53]. The KDIGO group 
suggests the use of a less stringent insulin 
therapy protocol targeting plasma glucose 
110-149 mg/dL in critically ill patients. 
On the basis of guidelines by expert panels, 
a total energy intake of 20-30 kcal/kg/d 
is suggested, preferably via enteral route. 
Proteins should not be restricted with the 
aim for preventing or delaying RRT. It is 
suggested to administer 0.8-1.0 g/kg/d in AKI 
patients not treated with RRT, and 1.0-1.5 
g/kg/d in patients treated with RRT, up to 
1.7 g/kg/d in patients treated with CRRT. 
Guideline 3.4 We recommend not using 
diuretics to prevent or treat AKI, except 
in the management of fluid overload.
The available evidence from small 
studies cannot demonstrate that AKI is 
prevented with use of diuretics, or that 
AKI patients have faster recovery [54,55]. 
So far, diuretics only have a role in the 
management of volume overload.
Guideline 3.5 and 3.7: It is not recommend 
to use low-dose dopamine to prevent 
or treat AKI, similar it is suggested not 
to use fenoldopam or atrial natriuret-
ic peptide to prevent or treat AKI.
Although vasodilation and increasing 
renal blood flow may seem a logic 
therapy for prevention and therapy of 
AKI, this has not been proven in studies. 
The evidence for being not beneficial is 
strongest for low-dose dopamine [56-58]. 
Guideline 3.6: Growth factor intervention.
Three observational studies in cardiac 
surgery found that erythropoietin 
(EPO) -treated patients prevented 
AKI [63-65]. However, these results 
could not be confirmed in an early 
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intervention study in ICU patients and 
in cardiac surgery patients [62,63]. 
KDIGO recommends therefore evalu-
ating the usefulness of EPO in RCTs.
Guideline 3.8 Prevention of aminoglycoside- 
and amphotericin-related AKI
Given the nephrotoxicity of aminoglyco-
sides and amphotericin, it is suggested 
to limit their use to infections where 
no alternative antimicrobial drug is 
available. Aminoglycosides should be 
administered preferably once daily, and 
drug levels should be monitored daily.
Amphotericin should be given 
as a lipid formulation in order to 
reduce the nephrotoxicity.
4.1.9 Contrast-induced AKI   Contrast 
media cause nephrotoxicity, but other 
risk factors for the development of AKI 
are often present in critically ill patients. 
For that reason, the term contrast 
associated AKI (CA-AKI) may seem more 
appropriate [64]. CA-AKI occurs in 10% to 
22.5% of ICU patients, seldom requires 
RRT, and is associated with mortality, 
even on long-term follow up [64-68].
ICU patients should be assessed for risk 
for CA-AKI (pre-existing renal impairment, 
diabetes, nephrotoxic agents, advanced age, 
hemodynamic instability or hypertension). 
One should always consider not admin-
istering iodinated contrast. The lowest 
possible dose of modern low or iso-os-
molar contrast agents should be used. 
Ideally NSAIDs, metformin, and diuretics 
are stopped one day on beforehand. In 
patients who are at risk for CA-AKI, intrave-
nous volume expansion is recommended, 
either by administering saline (NaCl 0.9%) 
or a bicarbonate solution (846 mL Glucose 
5% + 154 mL of 1000 mEg/L NaHCO3) at 
a rate of 3 m/kg, for 1 h before and 1 mL/
kg per hour for 6 h after contrast admin-
istration [69-72]. Although meta-analyses 
suggest benefit for the bicarbonate solution 
over saline, bias and heterogeneity limit 
this recommendation. In case the bicar-
bonate solution needs to be prepared, 
this may be associated with errors.
As the data on prevention of CA-AKI by 
N-acetycysteine (NAC) are conflicting, 
intravenous (IV) NAC is not recommended. 
But, given its beneficial potential and low 
toxicity, oral NAC should be administered 
in patients at risk for developing AKI. 
For most ICU patients, this seems less 
applicable, as most studies on oral NAC 
were performed in patients undergoing 
elective coronary angiography, with ad-
ministration the night before contrast. 
Evidence for the administration of fenoldo-
pam or theophylline in patients at risk for 
AKI is lacking. Similarly, data supporting 
the prophylactic use of RRT in patients at 
increased risk for CA-AKI are insufficient.
4.1.10 Dialysis Interventions for treatment 
of AKI   Although RRT has been in use for 
more than half a century, many aspects 
of this therapy remain controversial. 
1. Timing and initiation of  
renal replacement therapy
It seems plausible that early initiation of 
RRT may positively impact on outcomes in 
ICU patients with AKI. But because of the 
possible side effects of this invasive therapy 
(hypotension, arrhythmia, hemorrhage, 
and complications of vascular access), 
there is a tendency to avoid RRT as long as 
possible. Also, RRT-induced hypoperfusion 
of the kidneys may impair kidney recovery 
and increase the progression of CKD [73].
Because of the lack of evidence, the KDIGO 
recommendations concerning timing of 
RRT in AKI are not graded. Initiation of RRT 
is advised in life-threatening changes in 
fluid, electrolyte and acid-base balance. 
Extracorporeal therapy can either function 
as renal replacement (when no kidney 
function is present) or renal support RRT (as 
an adjunct to kidney function). The following 
list shows potential applications for RRT:
1. Renal replacement: when there 
is no residual kidney function
 a. Life-threatening indications
  i.  Hyperkalemia
  ii.  Academia
  iii.  Pulmonary edema
  iiii.  Uremic complications  
 (pericarditis, bleeding, etc)
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 b. Nonemergent indications
  i.  Solute control
  ii.  Fluid removal
  iii.  Correction of acid-base  
 abnormalities
2. Renal support: RRT is used as an adjunct
 a. Volume control
 b. Nutrition
 c. Drug delivery
 d. Regulation of acid-base 
and electrolyte status
 e. Solute modulation
Historically, timing of initiation of RRT 
was based on serum urea. However, 
serum urea is determined by many other 
variables that have no relation to kidney 
function [74]. In addition, recent studies 
could not demonstrate that urea dif-
ferentiates between outcomes [75-77].
Metabolic acidosis is a complication that 
frequently occurs in ICU patients with 
AKI, but initiation of RRT in ICU patients 
with AKI and metabolic acidosis is still a 
matter of debate. As RRT does not treat 
the underlying cause of the acidosis, it can 
only provide restoration of homeostatic 
equilibrium and fluid balance, enabling 
specific therapeutic measures [78].
Numerous observational studies indicate 
fluid overload as an important determi-
nant of worse outcomes [34-38]. Further, 
a subanalysis from the Randomized 
Evaluation of Normal versus Augmented 
Level Replacement Therapy (RENAL) study 
showed that a negative fluid balance 
during CRRT was associated with better 
survival [79]. Therefore fluid overload may 
be an important determinant for initiation 
of RRT. But also on this topic, prospective 
studies that randomized initiation of RRT 
based upon fluid status are absent.
2. Criteria for stopping  
renal replacement therapy
In literature, data considering the 
decision to stop RRT are even scarcer. 
Therefore KDIGO issues a pragmatic 
and non-graded recommendation that 
RRT should be discontinued when 
kidney function has recovered. 
3. Anticoagulation
Patients without increased bleeding risk 
on intermittent RRT are recommend-
ed anticoagulation with unfractionated 
or low-molecular-weight heparin. 
When CRRT is used, citrate anticoag-
ulation is recommended, unless there 
are contra-indications for citrate such 
as reduced liver function or shock with 
reduced muscle perfusion. Data from 
five randomized studies showed that 
citrate based protocols were associated 
with longer filter life, less bleeding, and 
in 1 study also better survival [80-84].
Regional heparin anticoagulation, in which 
unfractionated heparin is neutralized after 
the filter with protamine is not advised. This 
is because the longer half-life of heparin 
makes it extremely difficult to titrate.
In patients with heparin induced thrombo-
cytopenia, heparin must be stopped, and 
thrombin inhibitors such as argatroban, 
or Factor Xa inhibitors (danaparoid or 
fondaparinux) are recommended.
4. Vascular access for  
renal replacement therapy in AKI
As in ESRD patients, central vein stenosis is 
more frequently seen in subclavian dialysis 
catheters [85,86], KDIGO recommends the 
right jugular vein, followed by the femoral 
vein as the optimal insertion place. 
5. Modality of RRT in AKI patients
Generally, the choice of modality of RRT 
is based on the availability of a specific 
modality or local experiences. A Cochrane 
Collaboration meta-analysis including 
randomized controlled trials (RCT) that 
compared continuous RRT (CRRT) to 
intermittent hemodialysis (IHD) in AKI 
patients, could not demonstrate differ-
ences in hospital and ICU mortality, length 
of hospital stay or renal recovery [87,88]. 
CRRT and IHD should therefore be seen 
as complementary therapies except for 
patients with AKI who are hemodynami-
cally unstable or present with increased 
intracranial pressure. In these cases, CRRT 
is considered the optimal modality of RRT. 
6. Dose of renal replacement 
therapy in patients with AKI
The concept of dialysis dose is frequent-
ly addressed in literature. However, the 
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available evidence is limited and con-
flicting because of differences in study 
design and poor quality of reporting data 
[89]. Two recently published trials have 
assessed dialysis dose in critically ill 
patients with AKI. Both the RENAL and ATN 
trial compared high dose versus normal 
dose RRT and could not demonstrate 
differences in mortality or renal recovery 
[90,91]. On the basis of these data, KDIGO 
recommends in IHD and extended dialysis 
to deliver a weekly Kt/V of 3.9. For CRRT 
an effluent volume of 20-25 mL/kg/min 
is recommended. Because of downtime, 
this will require a higher prescription.
4.1.11 Conclusion   The guidelines proposed 
by KDIGO propose an extensive overview 
of the current state of the art for AKI. The 
RIFLE and AKIN definitions for AKI have 
been modified into an updated version: the 
KDIGO definition and grading system. Simi-
lar to, for example, sepsis, early application 
of a bundle of measures is proposed for the 
prevention of AKI: the “KDIGO AKI bundle”. 
These include avoidance of nephrotoxic 
agents, optimizing hemodynamic status, 
guidelines for the prevention of CA-AKI and 
guidelines for the processes of care for RRT.
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ADDENDUM
Guideline 3.1.3 was predominantly based 
on the landmark study by Rivers et al [41]. 
However, three large randomized con-
trolled trials were recently completed 
to reexamine the effect of EGDT on 
outcomes in patients with septic shock: the 
Protocolized Care for Early Septic Shock 
(ProCESS) trial conducted in the United 
States [93], the Australasian Resuscitation 
in Sepsis Evaluation (ARISE) trial [94] and 
the Protocolized Management of Sepsis 
(ProMISe) trial in England [95]. These trials 
concluded that EGDT did not significant-
ly decrease mortality in patients with 
septic shock compared with conventional 
care. In addition, an ancillary study to 
the ProCESS trial found no benefit for 
EGDT on renal outcome in terms of 
development or severity of AKI, admin-
istration of RRT and renal recovery [96].
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4.2  RENAL REPLACEMENT  
  THERAPY IN CRITICALLY  
  ILL PATIENTS WITH ACUTE  
  KIDNEY INJURY
Critically ill patients commonly suffer from 
multi-organ failure. The kidneys are often 
involved in such a syndrome. When AKI 
is severe, renal replacement therapy is 
routinely used in the ICU to treat severe AKI.
4.2.1. A brief history   The concept of 
“dialysis” was first described in 1861 by 
the chemist Graham at the Anderson’s 
University in Glasgow. He was able to ex-
tract urea from urine by diffusion through a 
vegetable parchment coated with albumin. 
The first artificial kidney was developed and 
tested on animals in 1913 by Abel and his 
colleagues at the John Hopkins University. 
The device passed blood from an arterial 
cannula through celluloid tubes which 
were contained in a glass jacket filled with 
saline or artificial serum. It was never used 
on humans. It was not until 1924 when the 
first human hemodialysis was performed 
in a uremic patient by Haas at the Giessen 
University in Germany. The dialysis lasted 
less than 15 minutes using a tubular device 
made of collodion (cellulose trinitrate). 
Hirudin was used for anticoagulation [1]. 
Dialysis as we know it today is based on 
the work by the Dutch physician Kolff 
who constructed an artificial kidney 
for acute dialysis in humans in 1943. 
His rotating drum kidney consisted of 
30-40 meters of cellophane tubing in 
a stationary 100-litre tank [2]. Alwall 
then further modified and improved the 
original Kolff dialysis apparatus [3].
The development of the arteriovenous 
shunt by Quinton and sCribner in 1960 
made maintenance dialysis of patients 
with chronic renal failure possible [4].
In 1977, Kramer described the first contin-
uous form of dialysis specifically dedicated 
to critically ill patients: continuous arteri-
ovenous hemofiltration (CAVH). In CAVH, 
blood flow in the circuit was driven by 
a spontaneous arteriovenous pressure 
gradient and spontaneous ultrafiltration 
(UF) occurred depending on the trans-
membrane pressure gradient (TMP). If 
needed, fluid losses were replaced by an 
equivoluminous saline solution [5]. CAVH 
was in the nineties gradually replaced 
by continuous venovenous replacement 
therapies, by use of a simple especially 
dedicated and developed CRRT machine.
Further improvements in monitoring,  
membrane biocompatibility and dialyzer  
design were made during the past  
decades [1]. 
4.2.2. Principles of dialysis   Dialysis liter-
ally means “to pass across”. It consists of 
blood purification based on the physico-
chemical process of allowing water and 
solute transport through a semipermeable 
membrane and then discarding the waste 
products. The separation mechanisms 
involved in renal replacement therapy are 
based on the principle of water and solute 
transport according to two fundamental 
principles: diffusion (solutes) and convec-
tion (water and solutes). During dialysis 
there are interactions between convection 
and diffusive modes of solute transport [6].
Hemodialysis (HD) is based on the 
diffusion principle. It is a passive process 
by which solute moves from an area of 
high concentration to an area of low con-
centration down a concentration gradient. 
During IHD and continuous venovenous 
hemodialysis (CVVHD) solutes cross the 
membrane driven by the concentration 
gradient between blood and dialysate. 
The solute flux (J) depends on the 
diffusion coefficient of the solute in the 
solvent (DAB), the concentration gradient 
(∆C) and the area (A) and thickness (∆X) 
of the semipermeable membrane:
 
J = -DAB*∆C*A/∆X
The negative sign indicates the direction of the solute 
flux towards the lower solute concentration.
In this process, the total volume of plasma 
water cleared from solute per unit of 
time (or “clearance”) mainly depends 
upon the molecular weight of the solute, 
the properties of the membrane, and 
the dialyzer dialysate and blood flows. 
The diffusive nature of HD, and the high 
dialysate flow rates, makes it a highly 
effective “blood purification strategy”, 
which allows intermittent therapy. 
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Hemofiltration (HF) is based upon con-
vection during which solutes and water 
are transported across a semi-permeable 
membrane driven by the TMP. The process 
is called ultrafiltration UF. In other words, 
during hemofiltration plasma water is 
ultrafiltered across the membrane driven 
by the TMP and solutes are carried with 
it (solute drag). The UF rate depends on 
the TMP, which is typically adjusted by 
application of variable negative pressure 
at the dialysate side of the membrane, 
and the membrane’s permeability to water 
(indicated by the UF coefficient Kuf). 
During continuous venovenous hemofiltra-
tion (CVVH), the volume of the ultrafiltrate 
is continuously substituted by replacement 
fluid which can be delivered in ready-to-use 
bags. When the substitution fluid is admin-
istered downstream of the filter outlet, it is 
referred to as postdilution HF. When infused 
upstream of the filter, it is referred to as 
predilution HF. In general, convection con-
tributes little to the clearance of rapidly dif-
fusible small solutes such as urea, but can 
add significantly to the diffusive clearance 
of the larger middle molecules by high-flux 
membranes. During continuous venovenous 
hemodiafiltration (CVVHDF) both con-
vection and diffusion are applied [7].
All forms of RRT rely on the above 
mentioned principles of diffusion and/or 
convection. Over the past years, various 
techniques for RRT, either intermittent 
or continuous, have become available for 
critically ill patients with AKI [8]. Classically, 
two major dialysis techniques are used 
in the ICU: conventional IHD and CRRT. 
More recently, hybrid therapies such as 
Slow Extended Daily Dialysis (SLEDD) 
combining aspects from both IHD and 
have found their way into the ICU [9]. 
IHD has been used in the ICU since the 
1960s and was until the early 1980s the 
only treatment option for AKI in the ICU. 
IHD was first developed for chronic renal 
failure patients as a mainly diffusive but 
highly efficient therapy for toxin and fluid 
removal. It necessitates on-line dialysate 
production, a water-treatment module and 
a dialysis monitor. As its name suggests, 
IHD is applied on an intermittent base. In 
critically ill patients possible drawbacks 
of the intermittent nature are a “saw-
tooth” pattern of metabolic control and 
the potential for hemodynamic intolerance 
resulting in difficulties to reach volume. 
This led to the development of CRRT 
which is a convective but low-efficiency 
therapy applied applied continuously using 
industrially prepared substitution fluids in 
bags. It was therefore proposed as an al-
ternative to IHD in critically ill patients with 
sepsis, shock and multi-organ failure [10]. 
To counter these disadvantages “hybrid 
techniques” have been developed. SLEDD 
combines the advantages of CRRT and 
IHD by using a dialysis monitor and 
water-treatment module for on-line 
production of dialysate to perform 
slow, but extended and daily, HD [8].  
4.2.3. Epidemiology of AKI treated with RRT 
in the ICU   The Finnish Acute Kidney Injury 
(FINNAKI) trial reported an incidence of RRT 
in critically ill patients with AKI of 10.2% 
[11]. According to the recent multinational 
AKI-EPI study, AKI treated with RRT (AKI-
RRT) occurs in 13.5% of ICU patients [12]. 
This rate is higher compared to previous 
studies that reported a population-based 
incidence of RRT utilization among criti-
cally ill patients with AKI of 11-19 cases per 
100,000, representing 4-8% of all critically 
ill patients [13-15]. AKI-RRT is associated 
with adverse outcomes such as increased 
length-of-stay, short- and long-term mor-
tality and end-stage kidney disease (ESKD). 
4.3  CONTROVERSIAL ISSUES 
  REGARDING RRT IN CRITICALLY  
  ILL PATIENTS WITH ACUTE  
  KIDNEY INJURY
Although RRT has been in use for more 
than half a century, many aspects of this 
therapy remain controversial. Whether or 
not to provide RRT, and when to initiate 
RRT are two fundamental issues in most 
cases of severe AKI [16]. In particular, 
no consensus has been reached on the 
timing of initiation and discontinuation of 
RRT, modality and intensity of RRT [17]. 
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4.3.1. Indications and timing of initiation 
of renal replacement therapy in critically 
ill patients with acute kidney injury   The 
concept of timing of RRT is based on two 
fundamental questions: i) whether or not 
to provide RRT and ii) when to initiate RRT. 
All aspects of current treatment of AKI are 
basically supportive. The primary goal of 
RRT is to compensate for the loss of renal 
function that characterizes AKI. In 2012 the 
KDIGO work group formulated practice 
guidelines concerning prevention and 
treatment of acute kidney injury [16]. The 
treatment of AKI with RRT has the following 
goals: i) to maintain fluid and electrolyte, 
acid-base, and solute homeostasis; ii) to 
prevent further insults to the kidney; iii) 
to permit renal recovery; and iv) to allow 
other supportive measures (e.g. nutrition 
support, antibiotics) to proceed without 
limitation or complications. Ideally, thera-
peutic interventions should be designed to 
achieve the above goals and a systematic 
assessment of all these factors is key to 
determine the optimal timing for initiation 
of dialysis. In addition, the concept of 
“primum non nocere” – do no harm – may 
overrule the obvious benefits of RRT. 
At present there is no widely accepted 
definition of “timing of initiation” of RRT. 
Timing of initiation of RRT can be described 
by qualitative criteria e.g. time from hospital 
admission to RRT, or by a more quanti-
tative characterization based on severity 
of illness or stages of kidney failure, e.g. 
absolute values of or serum urea or serum 
creatinine concentration or changes to the 
same versus a predefined baseline point. 
Traditionally accepted indications for 
RRT are electrolyte disorders, progressive 
uremia, acid-base disorders, oligoanuria 
and fluid overload. Although also being 
considered indications to initiate RRT, 
uremic complications due to severe AKI 
are rarely seen in modern day ICU patients. 
In daily practice, the precise timing of RRT 
is usually a matter of clinical judgment 
and often based on clinical features of 
volume overload and biochemical param-
eters such as azotemia, hyperkalemia and 
severe acidosis [18]. In a survey by Ricci et 
al, 90 different criteria to initiate RRT are 
reported, with oligo-anuria the most fre-
quently reported, in 27% [19]. More recently, 
Clark et al. found in a prospective study 
and in a survey, both conducted in Canada, 
that RRT was initiated early after hospital 
presentation and ICU admission. At initia-
tion of RRT, patients already had advanced 
AKI, were severely ill and suffered from 
multiorgan failure [20]. Another non-renal 
indication for initiation of RRT in the ICU 
is AKI caused by drug overdose and intox-
ications. Severe sepsis and septic shock 
are associated with AKI in up to 50% of the 
ICU patients. Prophylactic dialysis in sepsis 
has been discussed in association with the 
hypothesis that it can possibly influence 
inflammatory mediator concentration. 
However, there is no evidence supporting 
the use of prophylactic RRT in sepsis [21]. 
Historically, timing of initiation of RRT was 
based on serum urea. The initial goal was 
to prevent the occurrence of overt uremic 
symptoms such as pericarditis, neuropathy 
or coma. This extent of uremia is no longer 
observed in the current setting of AKI in 
critically ill patients. However, at present 
the optimal threshold for serum urea to 
initiate RRT is still unknown. Landmark 
studies on this topic were performed 10 
to 38 years ago and currently have limited 
value. Firstly, the individual studies were 
underpowered and included patients from 
very specific cohorts [22-26]. Secondly, the 
biological rationale that urea is a good 
biomarker for severity and duration of 
AKI is highly debatable. Serum urea is 
determined by many other variables that 
have no relation to kidney function, such 
as dehydration, catabolism, ARDS, gas-
trointestinal bleeding etcetera [27]. Finally, 
the association between serum urea as 
a cut-off biomarker for initiation of RRT 
and outcome is unclear. So despite being 
pointed out as a parameter for initia-
tion of RRT according to the archetypal 
textbooks, AKIN and KDIGO guidelines, 
further research is needed to clarify the 
validity of serum urea as a biomarker for 
assessment of timing of initiation of RRT. 
Likewise the use of a sCr threshold as 
RRT initiation trigger is debatable. Clark 
et al. demonstrated that 64.0% of the 
patients had severe AKI (AKIN-3, based 
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on sCr concentrations) at initiation of RRT. 
This suggests that the impact of sCr in the 
decision whether or not to initiate RRT is 
rather limited [20]. These data are in line 
with the results of the BEST Kidney trial, in 
which almost half of the clinicians did not 
consider sCr concentrations as a trigger for 
initiation of RRT [13]. These findings should 
be taken into consideration when designing 
research protocols for future interventional 
studies on the optimal timing of initiation 
of RRT in critically ill patients with AKI [20].
Over the years, initiation of RRT has become 
more frequently guided by oliguria and 
volume overload. Fluid overload is a frequent 
complication of AKI. A sub-analysis of the 
Sepsis Occurrence in Acutely Ill Patients 
(SOAP) database showed that after cor-
rection for other covariates, a positive fluid 
balance was associated with an increased 
60-day mortality in AKI patients (OR=1.21, 
95% CI=1.19, 1.28) [28]. Others have confirmed 
the association between volume overload 
and mortality in AKI patients [29, 30]. It is 
uncertain whether volume overload serves 
as a surrogate marker for severity of illness 
or is a contributing factor in itself. Volume 
overload may therefore be an important 
parameter for the timing of initiation of 
RRT. Although diuretics are frequently 
administered in oliguric patients with AKI, 
their benefit has not been proven [16, 31]. 
Acid-base abnormalities are a frequent 
clinical problem in patients with severe 
AKI. In critically ill patients these acid-base 
disturbances frequently appear as metabolic 
acidosis with elevated lactate concentration. 
This possible life-threatening condition is 
associated with high mortality rates, making 
this an accepted indication for initiation of 
RRT [16]. Therefore, already since the 1960s, 
RRT has been used for the correction of 
acid-base disturbances as an adjunct to 
the treatment of the underlying cause [32]. 
In addition, where hemodynamic instability 
is observed, CRRT is often used to correct 
acidosis [33, 34]. Surprisingly, despite more 
than 50 years of practice with the use 
of RRT in AKI patients with severe lactic 
acidosis (SLA), evidence concerning dialysis 
for life-threatening SLA is lacking. The most 
recent study on this topic was published 
more than 15 years by Hilton et al [35]. They 
didn’t report the incidence of lactic acidosis 
in critically ill patients with AKI but found 
that patients with SLA and AKI supported 
with bicarbonate buffered hemofiltration 
had a mortality of 71.5%. During the study 
period, mortality in AKI patients without lactic 
acidosis was 25.6%. The authors experienced 
a temporary physiological benefit in patients 
with lactic acidosis treated by bicarbonate 
buffered hemofiltration. A survival benefit 
could not be demonstrated in these patients. 
Due to a lack of evidence of outcome benefit, 
no standard criteria for initiating RRT in 
acidotic patients exist. On the one hand, 
metabolic acidosis associated with AKI can 
usually be corrected with bicarbonate and 
should rarely require urgent dialysis if not 
accompanied by oligo-anuria and volume 
overload or uremia [36]. On the other hand, 
it is widely accepted that patients with life 
threatening severe acidosis and AKI should 
be dialyzed emergently [16]. However, in the 
latter case, many clinicians hesitate to initiate 
RRT as it may be seen as futile because of 
the high mortality rates. Research should 
not only focus on the current epidemiology 
of SLA in critically ill patients with AKI-RRT, 
but should also assess possible determi-
nants of outcome in this group of patients.
From a pathophysiological viewpoint it 
seems logical that timing should be defined 
on severity of AKI and associated organ 
failure rather than on a temporal definition. 
However, due to the conflicting literature 
and because of concern for the well-known 
risks associated with the RRT procedure, 
clinicians tend to disregard quantitative 
data and therefore delay RRT when they 
suspect that patients may recover. The 
decision-making on the initiation of RRT is 
further hampered by the fact that the appli-
cation of RRT itself may compromise renal 
recovery. RRT-associated hemodynamic 
instability, vascular catheter-related bac-
teremia and sepsis and cytokine activation 
exposure to the extracorporeal circuit may 
delay recovery of renal function and increase 
the progression of CKD [37]. Whether these 
risks outweigh the potential benefits of early 
initiation of RRT is still unclear. Therefore, 
additional research to define the optimal 
timing of initiation of RRT is needed. 
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4.3.2. Modality of RRT    Both CRRT and 
IHD may achieve a satisfactory degree of 
metabolic control in most patients. Ideally, 
IHD may be indicated for correction of 
acute metabolic or toxic derangements 
in hemodynamically stable patients. 
As such it also provides mobility of the 
patient and may be a more suitable option 
when patients are soon to leave the ICU. 
If needed, it can be performed without 
anticoagulation, which offers an extra 
advantage in patients at risk of bleeding. 
Although not supported by hard evidence, 
CRRT has been suggested to offer more 
hemodynamic stability and easier fluid 
management, better solute control 
and more stable intracranial pressure, 
compared with standard IHD [10]. Being 
a hybrid modality, SLEDD offers a con-
venient way to control electrolytes and 
fluid balance in combination with hemo-
dynamic stability [8]. Despite these “theo-
retical” advantages, there is no evidence 
in favour for a specific RRT modality [17]. 
Peritoneal dialysis (PD) remains wide-
spread, especially in low-income countries. 
A systematic review based on limited 
quality data on PD for AKI was set up 
by Chionh et al [38]. They found no dif-
ferences in mortality between PD and 
extracorporeal blood purification in AKI, 
suggesting that PD may be a viable option. 
4.3.3. Dialysis dose   Strategies to improve 
outcome in critically AKI-RRT patients 
may include optimization of delivered 
RRT dose. However, this topic lies 
outside the scope of this work, and will 
therefore not be addressed in depth. 
In brief, the RENAL and ATN trial showed 
that increased intensity of RRT was 
not associated with improved patient 
or kidney outcomes [39, 40]. Also, a 
recent meta-analysis including these 
trials was similarly negative [41]. 
5.  Studying outcomes 
  and defining end- 
  points of acute kidney 
  injury treated with 
  renal replacement 
  therapy in critically 
  ill patients
The above-mentioned controversies are 
not merely academic but may impact 
outcomes. Currently there is an emerging 
spectrum of outcome measures in 
ICU epidemiological studies. The term 
endpoint refers to an outcome to be 
measured in a classical clinical trial. 
These outcome measures can be cate-
gorized as clinical endpoints, surrogate 
endpoints and composite endpoints [42]. 
5.1  CLINICAL ENDPOINTS
A clinical endpoint is an aspect of a 
patient’s clinical or health status that can 
be measured. It is, as it suggests, clini-
cally relevant and is both accepted and 
used by physicians and patients. Clinical 
endpoints may be a clinical event (such as 
mortality), a measure of clinical status (e.g. 
dialysis dependency (DD)) or health related 
quality of life (HrQOL). Endpoints such as 
mortality are considered hard endpoints, in 
contrast with “soft” endpoints like patient 
reported outcomes (PRO), e.g. HrQOL [43]. 
5.1.1. Mortality   Mortality as an endpoint 
measure can be reported as a dichoto-
mous outcome measure and is as such 
a clear and easy to handle endpoint. This 
is an advantage over endpoints like renal 
recovery which require measuring whether 
the kidney function is increasing or de-
creasing. The success of intensive care 
medicine has traditionally been gauged by 
the proportion of patients alive at hospital/
ICU discharge or at day 28. However, these 
endpoints may underestimate the true 
burden of disease, including kidney disease. 
In modern-day ICU care, we should aim for 
more relevant endpoints such as long-term 
mortality (90 days, 6 months, one-year). 
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Initially, studies focused on long-term 
mortality were mostly performed in patients 
with “AKI defined by treatment with RRT”. 
The RENAL study reported a 44.7% mortality 
rate three months after initiation of RRT 
[39]. Bagshaw and co-workers described 
a 1-year mortality of 63.8% in a popula-
tion-based study [14]. Korkeila reported 65% 
mortality at 5 years in a mixed Finnish ICU 
population with AKI without pre-existing 
renal failure [44]. Ahlström confirmed these 
findings in a cross-sectional cohort study 
on patients from a mixed ICU and dialysis 
unit with a 5 years mortality of 70% [45]. 
However, assessing long-term mortality 
based on “AKI defined by RIFLE criteria” 
highlights the stepwise adverse long-term 
mortality associated with different stages 
of AKI. This has been confirmed by several 
more recent studies in which the modern 
RIFLE, AKIN and KDIGO definitions for AKI 
were used. For instance, recently, Fuchs 
and co-workers described the strong re-
lationship between AKI and mortality in a 
large retrospective study including more 
than 15,000 ICU patients with no history of 
end stage kidney disease (ESKD). Patients 
with AKIN 3 had 61% higher mortality risk 
2 years after ICU discharge compared with 
patients without AKI [46]. Finally, Coca et al 
demonstrated in a systematic review and 
meta-analysis of 49 studies that even mild 
increases in serum creatinine were asso-
ciated with adverse short and long-term 
outcomes [47]. More recently, Linder et al 
demonstrated in a prospective cohort study 
of more than 2,000 critically ill patients 
with AKI an adjusted 10-year mortality risk 
of 1.26. Even stage 1 AKI was associated 
with 10-year decreased survival [48]. 
5.1.2. Patient associated morbidity 
endpoints
Renal recovery
Until recently, it was widely accepted that 
most patients surviving AKI fully recovered 
renal function. From a pragmatic perspec-
tive renal recovery was usually defined as 
the absence of dialysis. Due to the recent 
standard definitions of AKI, it has become 
clear that AKI survivors may develop CKD 
and that some will progress to ESRD [16,49].  
To this date no uniform definition for renal 
recovery exists. This lack of standard defi-
nition explains the wide variation in renal 
recovery rates reported in literature ranging 
from 1 to 40% [50]. Definitions of renal 
recovery are often based on sCr. A major 
weakness in this respect is the frequent 
absence of a standard or “baseline” 
sCr. Ideally, this baseline sCr should be 
measured in the 3-12 months prior to the 
event. Several approaches (e.g. the MDRD 
backcalculation of sCr) have been used to 
determine a reference value of sCr, but they 
are subject to discussion [51]. An additional 
problem with this definition is the poor 
sensitivity of sCr. A loss of more than half 
of the nephrons is needed to alter sCr con-
centrations. Ideally, the definition of renal 
recovery should quantify lost preexisting 
kidney function, as well as current residual 
kidney function and reserve, identify when 
recovery is complete and provide infor-
mation related to outcome. Very recently, 
the ADQI 16 Work group proposed an 
operational definition of renal recovery as 
a reduction in peak AKI stage (based on 
KDIGO criteria) further refined by change 
in sCr level, GFR, biomarkers of injury or 
repair and/or return of renal reserve [52]. 
The epidemiological data on renal recovery 
are very heterogenous depending on the 
study cohort, the definition used and 
the timing of assessment.  Chertow et al 
demonstrated that 33% of patients surviving 
AKI treated with RRT were still on RRT after 
one year [53]. Schiffl et al reported that 
maximal improvement or normalization of 
renal function took place within the first 
year [54]. Bagshaw et al evaluated renal 
recovery in critically ill patients, including 
45% with preexisting CKD. At hospital 
discharge, 32% of the patients was dialysis 
dependent [55].The link between AKI, CKD 
and ESKD was demonstrated in a large 
population study by Ali et al. They reported 
an incidence of ESKD after 90 days of 
0.6% in AKI patients without preexisting 
CKD versus 6.0% in patients with previous 
renal dysfunctioning [56]. Further, patients 
suffering from an episode of acute-on-
chronic kidney disease have an increased 
risk of progression towards ESKD [57]. Given 
the fact that CKD stage is associated with 
a proportionally higher risk of developing 
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new episodes of AKI [53], these patients 
may eventually be trapped in a downward 
spiral as their renal functional reserve 
progressively reduces [58]. Interestingly, the 
progression to CKD is determined by the 
frequency of AKI episodes and the severity 
of the AKI [59]. Aside from preexisting CKD, 
advanced age could be identified as major 
risk factor for incomplete renal recovery 
[60]. Other well-defined risks for poor renal 
recovery are the presence of diabetes, con-
gestive heart failure, hypertension, protein-
uria but also the general comorbidity status 
of the patient, expressed by the Charlson 
Comorbidity Index score [61,62]. Whether RRT 
modality influences renal outcome after an 
AKI-RRT episode remains controversial. 
A meta-analysis by Schneider et al 
analyzed data on dialysis dependency 
among critically ill patients who survived 
an AKI-RRT episode. They found that 
initial support with IRRT might be as-
sociated with a higher rate of dialysis 
dependency. However, this finding was 
largely based on data from observational 
trials and therefore prone to bias [63].
Given the fact that renal recovery implies 
more than absence of dialysis, some in-
vestigators suggest that hospital survivors 
of severe AKI should be followed by a 
nephrologist or an “AKI Follow-Up Clinic” 
after hospital discharge to prevent that CKD 
remains undiagnosed in these patients [64].
Health related Quality of Life 
There has been a historic emphasis on 
mortality outcomes after critical illness. 
Naturally, mortality is considered a decisive 
endpoint, but it may distract the attention 
from the reality of the post-ICU experience 
with long-term physical and physiological 
dysfunctioning. The notion that mortality 
beyond hospital discharge is not the only 
relevant clinical endpoint has led to an 
increasing interest in HrQOL in patients 
surviving ICU. HrQOL measures the impact 
of disease and treatment on the lives of 
patients and is defined as “the capacity 
to perform the usual daily activities for 
a person’s age and major social role” [60]. 
HrQOL is a multidomain concept including 
physical functioning, psychological well- 
being, and social role functioning. It is an 
example of a PRO which is based on data 
provided by patients or by people who 
can report on their behalf (proxies). The 
Food and Drug Administration (FDA) nicely 
defines a PRO as “a measurement based 
on reports that comes directly from the 
patient about the status of a patient’s 
health condition without amendment or 
interpretation of the patient’s response 
by a clinician or anyone else” [66]. A PRO 
can be measured by self-report or by 
interview provided that the interviewer 
records only the patient’s response [43]. 
Health-related quality of life is determined 
by i) the side effects of treatment, and ii) 
symptoms of the disease. A treatment with 
RRT is likely to improve HrQOL by pre-
venting AKI associated symptoms. On the 
contrary, the side effects of RRT obviously 
affect the HrQOL of the patient, making 
this a much nebulous endpoint than for 
example mortality [62]. HrQOL is classically 
measured using a brief questionnaire in 
which patients rate their ability to function 
in various ways. Patients typically fill out 
the questionnaire several times during 
the course of the trial. Studies describing 
HrQOL in patients recovering from AKI 
commonly use the Short Form-36 (SF-36), 
the Nottingham Health Profile (NHP) and the 
European Quality of Life score (EQ-5D) [68].
Unfortunately, data on long-term HrQOL 
in ICU patients with AKI-RRT are scarce. 
Oeyen et al presented a detailed system-
atic review of the literature concerning 
HrQOL after ICU discharge [69]. HrQOL is 
affected in critically ill patients suffering 
from conditions frequently associated with 
AKI-RRT such as acute respiratory distress 
syndrome severe ARDS, severe sepsis and 
major trauma, all conditions associated 
with AKI. Data regarding HrQOL in AKI-RRT 
show that these patients have decreased 
HrQOL compared to the general popula-
tion but perceie HrQOL as good [45,70]. As 
Oeyen et al demonstrated, most studies 
investigating HrQOL have many drawbacks 
[69]. Their design is often retrospective [44, 
71-73], they are characterized by short-term 
HrQOL evaluation [15, 44, 45, 70, 71, 73-76], lack 
baseline HrQOL assessment [44, 45, 71, 72, 75, 78] 
or are outdated [44, 71, 72, 74, 78]. A significant 
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proportion of critically ill patients with AKI 
treated with RRT will develop ESKD. DD is 
not only associated with substantial health 
care costs, but is likely to affect HrQOL. 
It is therefore of great interest to assess 
HrQOL in this specific group of patients. 
5.2  SURROGATE ENDPOINTS
A surrogate or intermediate endpoint is 
an endpoint that is intended to replace a 
clinical endpoint of interest that cannot be 
observed. A surrogate endpoint may be a 
biomarker (e.g. serum urea or lactate con-
centration) that is intended as substitute 
for a clinical endpoint. A surrogate endpoint 
usually tracks the progress or extent of the 
disease. Investigators choose a surrogate 
endpoint when the definite endpoint is 
inaccessible due to cost, time or difficulty 
of measurement [43]. The problem with a 
surrogate endpoint is its validity as it may 
provide an incomplete picture of the clinical 
endpoint it reflects. Therefore, choice of the 
surrogate endpoint should be approached 
with caution, since these measures may be 
crude or relatively reflective surrogates for 
the primary endpoint [79]. Piantadosi gives 
the following characteristics of a useful 
surrogate endpoint: i) it can be measured 
simply and without invasive procedures 
ii) it is related to the causal pathway for 
the definite endpoint iii) it yields the same 
statistical interference as the definite 
endpoint iv) it should be responsive to the 
effects of treatment [80]. Even a validated 
biomarker may have substantial variability 
in both its physiological expression and its 
association with the clinical outcomes of 
interest which may adversely affect the 
study and can lead to misleading results.
5.3  COMPOSITE ENDPOINTS
A composite or aggregated endpoint 
combines two or more single events. 
Patients who have experienced any of 
the components of a composite endpoint 
are considered to have experienced the 
composite endpoint. This concept has 
been adopted from cardiovascular lit-
erature, where composite endpoints as 
Major Adverse Cardiac Events (MACE) are 
widely used [81]. A composite endpoint is 
often used when it makes clinical sense 
to group them. Further, the composite 
endpoint will occur more frequently than 
any of the individual components. So 
this is particularly interesting when the 
individual events included in the score 
are rare. They usually refer to combined 
morbidity and mortality endpoints [82]. The 
2011 Workshop of the National Institute 
of Diabetes and Digestive and Kidney 
Diseases on Clinical Trial Design presented 
a kidney composite endpoint of death, 
dialysis administration and incomplete 
renal recovery for AKI [83]. More recently 
this renal composite endpoint – Major 
Adverse Kidney Events (MAKE) – was further 
operationalized including death, dialysis, or 
worsened renal function, which was defined 
as a 25% or greater decline in estimated 
glomerular filtration rate (eGFR) [84,85].
Ideally, these “pooled” endpoints have a 
higher incidence than each of their com-
ponents, reducing required sample size 
and increasing statistical efficiency [86]. In 
addition, by combining these outputs into 
a single outcome measure, competing 
risk between the individual components 
is avoided. However, pooled endpoints 
such as MAKE have to be well defined and 
meticulously constructed. The unclear 
definition of renal recovery as one of 
the components of MAKE may hamper 
correct interpretation. Furthermore, the 
use of composite endpoints in clinical 
trials can easily be biased as component 
endpoints may be selected to ensure 
statistical significance [82]. Future research 
evaluating these “newer” endpoints 
in the field of AKI is imperative.  
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CHAPTER 2    Objectives and methodology
1.  Objectives
1.1  OBJECTIVE 1
To describe the epidemiology of AKI 
treated with RRT in critically ill patients. 
1.2  OBJECTIVE 2
To explore timing of initiation of RRT 
in the light of patient outcome by 
investigating some “classical” indica-
tions of RRT in critically ill patients.
1.3  OBJECTIVE 3
To assess the short- and long-term 
patient and kidney outcome in ICU 
patients with AKI treated with RRT. 
In addition, the recently proposed 
composite endpoint MAKE was studied. 
1.4  OBJECTIVE 4
To evaluate the quality of life in ICU 
patients with AKI treated with RRT. This 
topic will be addressed in Study IV.
To address these objectives four studies 
were performed. Study I evaluates whether 
conventional serum urea cut-off values as 
described in the literature were associated 
with outcome at time of initiation of RRT for 
AKI. It explores the impact of timing of initi-
ation of RRT in the light of patient outcome. 
Study II explores the epidemiology of 
severe lactic acidosis in critically ill patients 
with AKI treated with RRT. Factors that may 
influence outcome in these patients were 
evaluated. Study III describes the long-term 
patient and kidney outcomes in critically 
ill patients with AKI-RRT and evaluates 
possible modifying factors of outcome such 
as CKD, timing of initiation of RRT and RRT 
modality. Study IV assesses the long-term 
outcomes and quality-of-life of critically 
ill AKI-RRT patients at baseline, and at 
3 months, 1 year and 4 years after ICU 
discharge and comparing quality of life with 
a cohort of matched non-AKI-RRT patients.
2.  Methodology
2.1  DESIGN OF THE STUDIES
This doctoral thesis comprised 4 single 
center cohort analysis studies of critically 
ill patients with AKI-RRT at a tertiary care 
hospital. The Ghent University Hospital ICU 
consists of a 22-bed surgical ICU, a 14-bed 
medical ICU, an 8-bed cardiac surgery ICU 
and a 6-bed burn ICU. Study I and II had a 
retrospective design, study III and IV were 
prospective observational studies (Table 1). 
2.2  STUDY COHORT
The inclusion criteria were ICU patients 
aged ≥15 years who had AKI and were 
treated with RRT and who had follow-up 
data after hospital discharge. During the 
study period, an electronic patient data 
management system (PDMS) was gradually 
introduced. Only patients who were reg-
istered in the PDMS were included in the 
study. Exclusion criteria were extracorpore-
al blood purification techniques for reasons 
other than AKI, patients with CKD receiving 
chronic RRT, RRT initiated before admission 
to the ICU, and RRT immediately after 
kidney transplant. In the cases where a 
patient had several ICU episodes of AKI-RRT 
during the same hospital admission, 
we considered only the first episode.
Indications for RRT, as well as the 
modality chosen (IHD, duration 2–4 h 
per treatment session; SLEDD, duration 
6–12 h per treatment session; or CRRT 
(continuous venovenous hemofiltration 
or hemodialysis), were determined by 
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consensus between the attending inten-
sivists and nephrologists and based on 
the clinical status of the patient (hemod-
ynamic stability, fluid balance, respiratory 
status, acid-base balance). Continuous 
modalities are preferentially used in 
patients with severe shock, patients who 
are at risk for cerebral edema (e.g., liver 
cirrhosis), or patients for whom intensive 
and consistent fluid removal is pursued. 
2.3. DATA COLLECTION
Data were recorded during the hospital 
stay. Baseline demographic parameters 
were retrieved from the hospital’s elec-
tronic database and the ICU’s electronic 
PDMS. Data on comorbidity and diagnos-
tic categories were retrieved from the 
hospital administration’s International 
Classification of Diseases, Ninth Revision 
(ICD-9), electronic coding system. Data on 
long-term follow-up were gathered from 
the patients’ electronic medical records 
(e.g., during follow-up consultation or, in 
cases of absence of such a consultation, 
by contacting the primary care physician 
of the patient by e-mail or telephone).
STUDY I STUDY II STUDY II I STUDY IV
STUDY DESIGN
Single Center  
Cohort Retrospective
Single Center  
Cohort Retrospective
Single Center  
Cohort Prospective
Single Center Matched 
Cohort Prospective
INCLUSION PERIOD
2004-2007 2004-2007 2004-2012 2008-2012
STUDY COHORT
AKI-RRT 
N= 302
AKI-RRT 
N= 342
AKI-RRT 
N= 959
AKI-RRT 
N= 121
FOLLOW-UP PERIOD
hospital stay 24 hours up to 8 years 4 years
CLINICAL ENDPOINTS
MORTALITY
hospital mortality ICU mortality icu mortality 
hospital mortality 
long-term mortality
long-term mortality
PATIENT ASSOCIATED MORBIDITY ENDPOINT
renal recovery 
dialysis dependency
long-term mortality
SURROGATE ENDPOINTS
serum urea lactate serum creatinine 
GFR
SF-36 
EuroQOL-5D
COMPOSITE ENDPOINTS
MAKE
Table 1.
Original studies included in the thesis: design, patient cohort and outcome measures.
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BACKGROUND
AKI is a common complication in patients 
admitted to the intensive care unit (ICU). 
Among other variables, serum urea con-
centrations are recommended for timing 
of initiation of RRT. The aim of this study 
was to evaluate whether serum urea 
concentration or different serum urea 
concentration cut-offs as recommended in 
literature were associated with in-hospital 
mortality at time of initiation of RRT for AKI.
  
METHODS
This is a retrospective, single-centre study 
during a 3-year period (2004-2007), in a 
44-bed tertiary care centre ICU on adult 
AKI patients who were treated with RRT. 
RESULTS
Three hundred and two patients were 
included: 68.9% male, median age 65 y and 
APACHE II score of 21. The overall in-hos-
pital mortality was 57.9%. Non-survivors 
were older (67 vs. 64 y, P=0.016), and had a 
higher APACHE II score (22 vs. 20, P<0.001). 
At time of initiation of RRT, they were more 
severely ill and had a lower serum urea 
concentration compared to survivors (130 
vs.141 mg/dL, p=0.038). Serum urea concen-
tration, as well as the different historical 
serum urea concentration cut-offs had 
low area under the curves for the receiver 
operating characteristic curve for prediction 
of mortality. In multivariate analysis, age, 
and at time of initiation of RRT, potassium, 
SOFA score with exclusion of points for 
AKI, and RIFLE class were associated with 
mortality, but serum urea concentration 
and the different cut-offs were not.
CONCLUSION
This retrospective study suggests that 
serum urea concentration and serum urea 
concentration cut-offs at time of initiation 
of RRT have no predictive value for in-hos-
pital mortality in ICU patients with AKI. 
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1. Introduction
AKI treated with (RRT occurs in approximately 
5% of ICU patients and has an incidence 
of approximately 200 - 300 patients per 
million inhabitants, comparable to the 
incidence of acute lung injury and acute 
respiratory distress syndrome [1-7]. It is 
associated with worse outcomes, such as 
increased length of stay, end-stage renal 
disease, cost and short- and long-term 
mortality [2,3]. Despite over five decades of 
experience with RRT for AKI, there is still no 
firm evidence on the criteria for initiation of 
RRT. According to an expert working group 
of the Acute Kidney Injury Network (AKIN), 
who summarized the available evidence, 
absolute indications for initiation of RRT 
include a serum urea concentration greater 
than 224 mg/dL (BUN>100 mg/dL), hyperkal-
aemia (>6 mmol/L and ECG abnormalities), 
hypermagnesaemia (>8 mEq/L), severe 
acidosis (pH<7.15), lactic acidosis related to 
methformin use, and anuria with diuretic 
resistant volume overload. In patients with 
AKI who do not fulfil absolute indications, 
serum urea concentration greater than 170 
mg/dL (BUN>76 mg/dL) is considered a 
relative indication for initiation of RRT [8]. 
Serum urea concentrations have been used 
for timing of initiation of RRT since the early 
days of treatment of AKI patients. Since 
the 1960s, there is a trend to initiate RRT 
at lower serum urea concentrations (Table 1). 
One recent and several older studies found 
that a lower serum urea concentration 
at initiation of RRT was associated with 
better outcome [9-15]. Only 3 prospective 
intervention studies have evaluated this 
issue. None of these could demonstrate 
that initiation at lower serum urea con-
centration had an impact on outcome.
In view of the contradictions reported in lit-
erature we aimed to assess the relationship 
between serum urea concentration at time 
of initiation of RRT and in-hospital mortality.
 KEY MESSAGE
The actually 
recommended serum 
urea concentration cut-
offs at time of initiation 
of RRT have no predictive 
value for in-hospital 
mortality in critically ill 
patients with AKI.
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2. Subjects  
 and methods
This is a retrospective analysis of pro-
spectively collected data to study the 
effect of serum urea concentration at 
initiation of RRT on in-hospital mortality. 
2.1 STUDY POPULATION
We analyzed all ICU patients, age 15 year 
and older who had AKI and were treated 
with RRT during the period 2004-2007 at 
the Ghent University Hospital ICU and who 
were included in the electronic ICU PDMS. 
The ICU includes a 22 bed Surgical, a 14 
bed Medical, a 6 bed Burn, and an 8 bed 
Cardiac Surgery ICU. Patients admitted at 
the Burn ICU were excluded from analysis 
because serum urea concentration in this 
cohort may be disproportionally increased 
compared to other types of ICU patients. 
Other exclusion criteria were extracorporeal 
blood purification techniques for other 
reasons than AKI, patients on chronic RRT, 
RRT initiated before admission to the ICU, 
and RRT immediately post kidney trans-
plant. Treatment episodes with peritoneal 
dialysis, a modality incidentally used in our 
ICU, were also not considered. Indications 
for RRT, as well as the modality chosen 
[i.e. intermittent (duration 2 to 4 h per 
treatment session) or continuous hemodi-
alysis (IHD/CHD), CVVH, or SLEDD (duration 
6 to 12 h per treatment session)], were 
determined in consensus between the 
attending intensivists and nephrologists [19].
2.2 DATA COLLECTION
Demographic data were retrieved from the 
electronic hospital database, laboratory 
data from the laboratory database and 
patient data from the electronic ICU PDMS. 
Data were prospectively recorded at time 
of ICU admission and at time of initiation 
of RRT. For every parameter, the most 
abnormal value per day was registered. 
Serum concentrations of urea, creatinine, 
sodium and potassium were collected on 
admission at ICU, and at the start of RRT. 
Serum creatinine was collected at time 
of hospital admission. SAPS II (Simplified 
Acute Physiology Score) and APACHE II 
(Acute Physiologic Assessment and Chronic 
Health evaluation) scores were calculated 
on data collected during the first day of 
admission [20,21]. At time of initiation of RRT 
we calculated the SOFA score (Sequential 
Organ Failure Assessment) [22], and a SOFA 
score with omission of points for kidney 
insufficiency (SOFA non-renal) [23]. Severity of 
AKI was also assessed at time of initiation 
of RRT by the RIFLE classification subdi-
viding AKI into three categories of severity 
(Risk, Injury and Failure) and two categories 
of clinical outcome. RIFLE severity class 
was assessed on serum creatinine criteria 
only. For patients without chronic kidney 
insufficiency as reported in the medical 
history, we calculated a serum creatinine 
level using the MDRD equation as recom-
mended by the ADQI, by solving the MDRD 
equation for serum creatinine assuming 
a glomerular filtration rate of 75 ml/
minute/1.73 m2 [24]. Baseline serum creati-
nine was the lowest of either creatinine at 
time of hospital admission or the MDRD-
based estimation of baseline creatinine [23].
2.3 STATISTICAL ANALYSIS
Data are expressed as number (percentage), 
or median (interquartile range). Bivariate 
analysis was performed with the Mann-
Whitney U test, Fisher exact test, and Chi2 
test as appropriate. In addition, we calcu-
lated odds ratios, and sensitivity and speci-
ficity for serum urea concentration cut-offs 
for timing of initiation of RRT mentioned 
in Table 1. The median serum urea concen-
tration of the whole cohort was taken as 
a cut-off concentration for the bivariate 
analysis on patients with low and high 
serum urea concentration. The relationship 
between serum urea concentration at time 
of initiation of RRT and in-hospital mortality 
was explored by construction of receiver 
operating characteristic curves (ROC) and 
calculation of the area under the ROC curve 
(AUC). ROC graphs are constructed by 
plotting sensitivity and specificity of serum 
urea concentration at time of initiation of 
RRT (as continuous variable) and serum 
urea cut offs that are described in literature 
(as categorical variables) for in-hospital 
mortality. An AUC of 0.5 indicates that the 
test has low sensitivity and specificity and 
performs as good as tossing a coin, and an 
AUC of 1 indicates an ideal test with 100% 
sensitivity and specificity for the outcome 
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variable. Multivariate logistic regression 
analysis was used to examine which 
variables were associated with mortality. 
Variables selected for inclusion in the re-
gression model were these with a P value of 
≤0.25 in bivariate analysis when comparing 
survivors and non-survivors. We analyzed 
for co-linearity by assessing correlation 
between covariates, also interaction was 
explored. Goodness of fit was assessed 
according to the method described by 
Hosmer and Lemeshow. Statistical signifi-
cance was accepted when the P value was 
< 0.05. A propensity model was included 
in the final model. A power analysis to 
define sample size was performed. 
A power calculation showed that 2 groups 
of 154 patients would be needed to give 
80% power to detect a difference in 
mortality based on a 5% level of signifi-
cance. These analyses were performed with 
use of the statistical software packages 
SPSS (SPSS for Windows, version 15.0.0), 
and MedCalc for Windows, version 9.6.0.0 
(MedCalc Software, Mariakerke, Belgium). 
The study was approved by the Ethics 
Committee of the Ghent University 
Hospital, and conducted in accordance 
with the declaration of Helsinki. Informed 
consent was waived for this study. 
3. Results
3.1 BASELINE CHARACTERISTICS
From a total of 482 ICU patients who 
were treated with RRT, 302 patients were 
included in the study. A total of 180 patients 
who underwent RRT could not be included 
because of the gradual introduction of the 
patient database management system over 
the three different ICUs during the study 
period. Median age of the patients was 65 
years (55, 73), 208 were male (68.9%). At 
time of ICU admission, the APACHE II score 
was 21 (16, 26), the SAPS II score was 45 
(34, 62). One hundred twenty-nine patients 
(42.7%) were treated in the Surgical ICU, 
100 patients (33.1%) in the Medical ICU and 
73 patients (24.2%) in the Cardiac Surgery 
ICU. The initial mode of RRT was IHD in 162 
patients (53.6%), CHD in 71 (23.5%), CVVH 
in 44 (14.6%), and SLEDD in 25 (8.3%). At 
time of initiation of RRT the SOFA score 
and the SOFA non-renal score were 10 (7, 
12), and 6 (4, 8) respectively. RIFLE criteria 
were not met in 10 patients (3.3%), 21 
patients were RIFLE-Risk (7%), 62 patients 
RIFLE-Injury (20.5%), and 209 patients 
were RIFLE -Failure (69.2%). Diuretics were 
administered in 135 patients (44.7%), 171 
patients (56.6%) were mechanically venti-
lated, and 209 (69.2%) were treated with 
vasoactive drugs. The overall in-hospital 
mortality of this study cohort was 57.9 %.
3.2 COMPARISON OF SURVIVORS  
 AND NON-SURVIVORS
Non-survivors were older (67 vs. 64 
years, P= 0.016), and sicker at time of ICU 
admission as illustrated by the higher 
APACHE II and SAPS II scores (Table 2). There 
was no difference in mortality between 
patients admitted to the different ICUs. 
Non-survivors had a different pattern of 
kidney failure with at time of initiation of 
RRT, a lower pH, serum creatinine, RIFLE 
class, and serum urea concentration. There 
was no difference in the proportion of 
patients with oliguria, or patients treated 
with diuretics. Organ dysfunction, other than 
that of the kidneys, was more severe in the 
non-survivor group. A greater proportion 
was treated with vasoactive drugs, platelet 
count was lower, and there was a trend 
for a greater proportion of patients treated 
with mechanical ventilation. Continuous 
RRT modalities (CHD and CVVH) that may 
serve as a surrogate marker for hemody-
namic instability were associated with an 
increased in-hospital death compared to in-
termittent RRT modalities (IHD and SLEDD) 
(85/115 [73.9%] vs. 90/187 [48.1%], p<0.001).
3.3 SERUM UREA CONCENTRATION 
 AT TIME OF INITIATION OF  
 RRT AS A PREDICTOR FOR  
 OUTCOME
Patients with a low serum urea concentra-
tion were more severely ill on admission. 
Differentiation in low versus high serum 
urea concentration was based on the 
median serum urea concentration at ini-
tiation of RRT (Table 2). Patients were more 
acidotic, had higher serum potassium, and 
a lower serum creatinine. RIFLE class was 
lower in patients with lower serum urea 
concentration. A greater proportion was 
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Table 1.
Studies that evaluated timing of initiation 
of renal replacement therapy based on 
low or high serum urea concentration*.
* serum urea concentration has been recalculated to serum 
urea concentration in mg/dL. The conversion factor for serum 
urea (mg/dL) to Blood Urea Nitrogen (mg/dL) is multiplying by 
0.446, and the conversion factor for serum urea in mmol/L to 
serum urea in mg/dL is to multiply by 0.167. 
** Comparison to predicted mortality based on the Liaño model. 
*** There was only a serum urea concentration cut-off for the 
high urea group. The concentrations in the table for the 2 low 
serum urea concentration groups are the median serum urea 
concentration concentrations at time of initiation of RRT. The P 
value was calculated on the pooled results of the 2 groups with 
low serum urea concentration (low volume and high volume 
hemofiltration) compared to the group with late initiation. 
YEAR N SERUM UREA 
CONCENTRATION 
(mg/dL)
28d 
MORTALITY
(%)
P
LOW HIGH LOW HIGH
RETROSPECTIVE STUDIES ON EARLY OR LATE INITIATION
PARSONS [9] 1961 33 <336 >448 25 88 <0.001
FISHER [10] 1966 162 ≤336 ≤448 51 77
KLEINKNECHT [11] 1970 500 <200 >350 29 39 <0.02
GETTINGS [12] 1999 100 <135 >135 61 80 0.04
BENT [13] 2001 65 ≤154 40 0.003**
LIU [14] 2006 243 ≤170 >170 35 41 0.400
CARL [15] 2010 147 100 ≥100 52 68 <0.05
PROSPECTIVE STUDIES ON EARLY OR LATE INITIATION
CONGER [16] 1975 18 <157 ≥224 36 80 0.062
GILLUM [17] 1986 34 <135 >240 59 47 0.732
BOUMAN [18]*** 2002 106 <98 <102 ≥224 26 31 25 0.680
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Table 2.
Comparison of patients with low and 
high serum urea concentrations at time 
of initiation of renal replacement therapy 
and survivors and non-survivors.  
CSICU | Cardiac Surgery Intensive Care Unit, MICU | Medical 
Intensive Care Unit, SICU | Surgical Intensive Care Unit,serum 
urea concentration | Blood urea nitrogen, LOSICU | Length 
of stay in the ICU, RRT | Renal replacement therapy, 
SOFA NON RENAL score | SOFA score without points for kidney 
insufficiency, CHD | Continuous hemodialysis, CVVH | 
Continuous veno-venous hemofiltration, IHD | Intermittent 
Hemodialysis, SLEDD | Slow Extended Daily Dialysis
SERUM UREA 
CONCENTRATION 
≤136 mg/dL
SERUM UREA 
CONCENTRATION 
>136 mg/dL
P SURVIVORS NON-
SURVIVORS
P
BASELINE CHARACTERISTICS
N 152 (50,3%) 150 (49.7%) 127 (42.1%) 175 (57.9%)
AGE (Y) 60 (54, 73) 65 (55, 73) 0.955 64 (52, 72) 67 (56, 74) 0.016
MALE GENDER 96 (63.2%) 112 (74.7%) 0.031 91 (71.7%) 117 (66.9%) 0.382
APACHE II 21 (18, 29) 21 (16, 24) 0.015 20 (16, 24) 22 (17, 30) 0.001
SAPS II 49 (38, 67) 41 (32, 56) 0.001 41 (33, 51) 51 (36, 69) <0.001
SEPSIS 53 (34.9%) 69 (46.0%) 0.060 46 (36.2%) 76 (43.4%) 0.235
TYPE OF ICU
CSICU 41 (56.2%) 32 (43.8%)
0.255
33 (45.2%) 40 (55.8%)
0.256MICU 44 (44.0%) 56 (56.0%) 47 (47.0%) 53 (53.0%)
SICU 67 (51.9%) 62 (48.1%) 47 (36.4%) 82 (63.6%)
CHARACTERISTICS AT TIME OF INITIATION OF RRT
LOS ICU TILL RRT (D) 0.9 (0.1, 1.5) 2.8 (0.4, 6.4) <0.001 1.5 (0.1, 3.2) 1.3 (0.3, 3.5) 0.575
MODALITY OF RRT
CHD 57 (37.5%) 14 (9.3%)
<0.001
17 (13.4%) 54 (30.9%)
<0.001CVVH 25 (16.4%) 19 (12.7%) 13 (10.2%) 31 (17.7%)
IHD 58 (38.2%) 104 (69.2%) 85 (66.9%) 77 (44.0%)
SLEDD 12 (7.9%) 13 (8.7%) 12 (9.4%) 13 (7.4%)
RIFLE CLASS
No RIFLE class 9 (5.1%) 1 (0.7%)
<0.001
6 (4.7%) 4 (2.3%)
<0.001Risk 18 (11.8%) 3 (2.0%) 3 (2.4%) 18 (10.3%)
Injury 50 (32.9%) 12 (8.0%) 11 (8.7%) 51 (29.1%)
Failure 75 (49.3%) 134 (89.3%) 107 (84.3%) 102 (58.3%)
Creatinine MAX (mg/dL) 2.92 (2.03, 4.29) 4.51 (3.55, 5.95) <0.001 4.77 (3.71, 6.27) 3.18 (2.26, 4.10) <0.001
Urea MAX (mg/dL) 90 (70, 114) 195 (156, 262) <0.001 141 (101, 206) 130 (83, 184) 0.038
Oliguria 74 (48.7%) 60 (40.0%) 0.129 57 (44.9%) 77 (44.0%) 0.879
Diuretic therapy 61 (40.1%) 74 (49.3%) 0.108 57 (44.9%) 78 (44.6%) 0.957
pH MIN 7.22 (7.13, 7.29) 7.26 (7.19, 7.33) 0.001 7.27 (7.21, 7.33) 7.22 (7.13, 7.29) <0.001
Potassium MAX (mmol/L) 5.1 (4.6, 5.8) 4.9 (4.3, 5.4) 0.030 5.0 (4.3, 5.4) 5.0 (4.5, 6.0) 0.040
Phosphorus MAX (mg/dL) 6.2 (4.7, 7.8) 6.3 (4.8, 7.8) 0.948 6.1 (4.7, 7.6) 6.4 (4.8, 7.9) 0.220
Mechanical ventilation  83 (54.6%) 88 (58.7%) 0.476 65 (51.2%) 106 (60.6%) 0.104
PaO2/FiO2 101 (126.0) 133 (100.1) 0.198 104 (66, 156) 124 (79, 190) 0.111
Vaso-active drugs 113 (74.3%) 96 (64.0%) 0.052 70 (55.1%) 139 (79.4%) <0.001
Platelets (x103/µL) 120 (79, 178) 131 (74, 210) 0.375 138 (93, 211) 118 (65, 181) 0.015
Bilirubin (mg/dL) 1.3 (0.6, 2.6) 1.3 (0.5, 4.3) 0.827 1.4 (0.5, 2.7) 1.3 (0.6, 3.2) 0.248
SOFA score 9 (6, 13) 10 (6,13) 0.476 9 (5,12) 10 (7,13) 0.012
SOFA NON RENAL score 6 (4, 8) 6 (4, 9) 0.902 5 (3,7) 7 (4, 9) <0.001
OUTCOME
MORTALITY 95 (62.5%) 80 (53.3%) 0.107
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hemodynamically unstable, as illustrated by 
the greater proportion of treatments with 
a continuous RRT modality and the clear 
trend for more patients on vasoactive drugs. 
There was a trend for worse outcome in 
patients with low serum urea concentration. 
3.3.1. Bivariate analysis   We explored the 
different serum urea cut-offs as reported 
in literature (Table 1) in our cohort. In 
present time, there is a trend to initiate 
RRT earlier in the course of AKI. Therefore, 
we also analysed two other serum urea 
concentration cut-offs (serum urea 
concentration 70 mg/dL and 100 mg/dL). 
None of the serum urea concentration 
cut-offs, except serum urea > 100 [15] 
and >170 mg/dL [14 ] and were associated 
with mortality in bivariate analysis (Table 3). 
However, in our study cohort, patients 
with higher serum urea had lower instead 
of higher, in-hospital mortality. Serum 
urea concentration at time of initiation 
of RRT, measured as a continuous 
variable, as well as the different serum 
urea concentration cut-offs that are 
mentioned in literature (Table 1) had poor 
sensitivity and specificity, and therefore 
low AUC for the ROC curves for prediction 
of in-hospital mortality (Fig. 1 and 2). 
3.3.2. Multivariate analyses   We evaluated 
if serum urea concentration at time of 
initiation of RRT was associated with in-
hospital mortality. We analyzed different 
multivariate logistic regression models 
(Table 4). In model 1 covariates used for 
adjustment were age, APACHE II score and 
type of ICU (medical ICU, surgical ICU, and 
cardiac surgery ICU). Covariates used for 
adjustment in model 2 were variables in 
model 1, and variables at time of initiation 
of RRT: modality of RRT, SOFA non-renal , RIFLE 
class, lowest pH, maximum potassium 
and phosphorus. Finally, we included a 
propensity score in the multivariate model 
to correct for possible bias leading to 
some patients put earlier in RRT. In our 
propensity model we included following 
data: sex, APACHE II, RIFLE, ICU type, 
urine output (24hours) and creatinine on 
admission. Including this propensity score 
in our model we still found no association 
between serum urea and in-hospital 
mortality (Table 5, and Fig. 3). We performed a 
sensitivity analysis, and analysed the same 
model in subgroups of patients with low 
and high serum urea concentration. This 
demonstrated in the two subgroups that 
serum urea concentration and mortality 
were not associated (data not shown).
4. Discussion
Timing of initiation of RRT for AKI and 
outcome have been traditionally linked 
to serum urea concentration cut-offs. 
This could not be confirmed in our 
dataset of ICU patients with AKI who 
were treated with RRT. Serum urea con-
centration at time of initiation of RRT 
as a continuous variable was also not 
associated with in-hospital mortality.  
Despite the limitations of serum urea con-
centration as a marker for kidney function 
[25], it is traditionally used as a surrogate 
marker for severity and duration of the 
AKI episode. Several studies dating back 
from the 1960s until 2001 suggested that 
certain serum urea concentration cut-offs 
were predictive for in-hospital mortality. 
In the 1960’s, Teschan et al. introduced 
the concept of prophylactic dialysis based 
on serum urea concentration, i.e. initia-
tion of RRT before occurrence of uremic 
symptoms [26]. Several retrospective studies 
published from then on, suggested that 
initiation of RRT at lower serum urea con-
centrations or more early in the course of 
Fig. 1.
Receiver Operating Characteristic curve for 
serum urea concentration at time of initiation 
of RRT and in-hospital mortality.
AUC | Area under the curve
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Table 3.
Risk for hospital mortality and predictive 
value in our study cohort when traditionally 
used blood urea nitrogen cut-off levels 
(indicated by the first author) are applied.
SERUM  
UREA  
CONCENT. 
CUT-OFF  
(MG/DL)
SOURCE 
AUTHOR
≤ CUT-OFF ≤ CUT-OFF P SENSI- 
TIVITY
SPECI- 
FICITY
MORTALITY
N (%)
MEDIAN  
SERUM 
UREA 
CONCENT.  
(MG/DL)
MORTALITY
N (%)
MEDIAN  
SERUM 
UREA 
CONCENT. 
(MG/DL)
75 STUDY COHORT 31 (68,9) 59,0 144 (56,2) 145,5 0,113 82,3% 11,1%
100 CARL [15] 67 (69,1) 78,0 108 (52,9) 164,5 0,008 61,7% 23,8%
135 GETTINGS [12] 94 (63.1) 89,0 81 (53.3) 193,5 0.085 46.3% 43.7%
157 CONGER [16] 117 (61.3) 99,0 58 (52.7) 216,5 0.149 33.1% 58.7%
170 LIU [14] 126 (62.1) 103,0 49 (50.0) 228,5 0.047 28.0% 61.1%
200 KLEINKNECHT [11] 141 (60.8) 116,0 34 (49.3) 266,0 0.089 19.4% 72.2%
224 GILLUM [17] 149 (59.4) 123,0 26 (52.0) 299,0 0.335 14.9% 81.0%
240 BOUMAN [18] 152 (59.4) 125,0 23 (51.1) 301,0 0.300 13.1% 82.5%
336 PARSONS 
/ FISCHER [9,10]
170 (58.6) 133,0 5 (45.5) 424,0 0.385 2.9% 95.2%
Table 4.
Association of serum urea at time 
of initiation of renal replacement 
therapy. Comparison of univariate 
analysis and different multivariate 
logistic regression models. 
Covariates used for adjustment in Model 1 
age, APACHE II score, type of ICU (medical ICU, 
surgical ICU, and cardiac surgery ICU). 
Covariates used for adjustment in Model 2 
Variables in Model 1, and variables at time of 
initiation of RRT: modality of RRT, SOFA non-renal , 
RIFLE class, lowest pH, maximum potassium  
and phosphorus. 
Covariates used for adjustment in Model 3 
Variables in Model 2, and a propensity score.
OR 95% CI P
UNIVARIATE ANALYSIS 0.800 0.614, 1.042 0.970
MULTIVARIABLE ANALYSIS
Model 1 0.793 0.598, 1.053 0.109
Model 2 1.202 0.841, 1.716 0.313
Model 3 1.206 0.838, 1.733 0.313
Model 1 Goodness of fit (Hosmer and Lemeshow) Chi2 = 7.079, df = 8, P = 0.528. 
Overall percentage correct predicted = 62.5%
Model 2 Goodness of fit (Hosmer and Lemeshow) Chi2 = 4.579, df = 8, P = 0.801. 
Overall percentage correct predicted = 75.3%
Model 3 Goodness of fit (Hosmer and Lemeshow) Chi2 = 9.388, df = 8, P = 0.311. 
Overall percentage correct predicted = 73.7 %
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AKI indeed were associated with improved 
outcome (Table 1) [9-14]. Although the first 
prospective randomized study on this 
topic did not reach statistical significance, 
a clear trend supported this concept [16]. 
Two other prospective studies could not 
demonstrate that early initiation of RRT 
at lower serum urea concentrations was 
associated with better outcomes [17,18].
Despite this, the current paradigm is that 
timing of initiation of RRT for AKI may be 
based on a series of clinical and biochem-
ical variables, including certain serum urea 
concentrations. Also, a recent meta-anal-
ysis concluded that early initiation of RRT 
may be associated with improved survival. 
Thirteen of the 23 included studies used 
serum urea as a criterion for initiation 
of RRT [27]. In 2008 the AKIN consensus 
group proposed, based on the existing 
literature, serum urea > 224 mg/dL as an 
absolute and serum urea > 170 mg/dL as a 
relative indication for initiation of RRT [8]. 
Our findings shed new light on this dis-
cussion. Serum urea was not a good 
predictor for worse outcome in ICU 
patients with AKI. Several elements 
may be involved in these findings. 
First, the serum urea concentration 
paradigm for timing of initiation of RRT is 
based on limited evidence and mostly old 
studies. The patient cohorts described in 
these hallmark studies are not compara-
ble to the AKI patients we are nowadays 
treating. The prospective studies on this 
topic have been performed 10 - 38 years 
ago, are underpowered, and include 
very specific cohorts of patients that do 
not have necessarily external validity. 
Second, serum urea concentration is de-
termined by numerous other variables that 
have no relation to kidney function, such 
as catabolism, administration of corticos-
teroids, gastrointestinal bleeds, etc. Also, 
increased serum urea concentrations very 
likely have limited biological effects as 
observed in current clinical conditions [28,29]. 
Third, patients with higher serum urea con-
centration at time of initiation of RRT in our 
cohort were less severely ill compared to 
the low serum urea concentration cohort. 
In most patients RRT will be initiated im-
mediately and early in the course of AKI 
for indications such as severe acid-base 
disturbances, severe hyperkalaemia or fluid 
overload. In this setting, serum urea con-
centration at time of initiation of RRT is rel-
atively low, although this group of patients 
is severely ill and has worse prognosis. 
The most plausible explanation for the 
absence of a relation between serum urea 
concentration and outcome is the fact that 
RRT is initiated early in the group of more 
severely ill patients, i.e. before serum urea 
concentration has had the time to rise. 
In contrast to our findings concerning 
the impact of serum urea concentra-
tions on outcome, multivariate analysis 
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Fig. 2.
Receiver Operating Characteristic curves for different historical 
serum urea concentration cut-offs at time of initiation of 
RRT and in-hospital mortality applied to our study cohort.
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SOURCE 
/AUTHOR
SERUM UREA 
CONCENTRATION 
CUT-OFF (mg/dL)
AUC 95% CI
STUDY COHORT 75 0,47 0.40, 0.53
CARL [15] 100 0,43 0.36, 0.49
GETTINGS [12] 135 0.45 0.38, 0.52
CONGER [16] 157 0.46 0.39, 0.53
LIU [14] 170 0.45 0.38, 0.51
KLEINKNECHT [11] 200 0.46 0.39, 0.53
GILLUM [17] 224 0.48 0.41, 0.55
BOUMAN [18] 240 0.48 0.41, 0.55
PARSONS 
 /FISCHER [9,10]
336 0.49 0.42, 0.56
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demonstrated that factors as age and 
severity of non-renal illness did have 
an important impact on mortality.
Finally, our data revealed an inverse asso-
ciation between increasing RIFLE class and 
outcome.This may seem against intuition, 
but is in line with current literature. 
Increasing severity of maximum RIFLE class 
has been shown repeatedly to be associat-
ed with a stepwise increase in mortality and 
length of ICU stay [23,30-32]. However, RIFLE 
class determined at time of RRT initiation 
was never associated with outcome [33,34]. 
Serum creatinine at time of initiation of RRT 
has an inverse relationship with outcome, 
possibly explained by the fact that serum 
creatinine also serves as a surrogate 
marker for other comorbid disease that 
may impact outcome. For instance, older 
patients with chronic disease or patients 
who were already hospitalized for longer 
time, have less muscle mass, leading 
to lower creatinine concentration for a 
given glomerular filtration rate [25,35]. 
This is to the best of our knowledge the 
only study that exclusively focuses on the 
prognostic value of serum urea concen-
tration for timing of initiating of RRT in 
general ICU patients, as recently recom-
mended by AKIN. Subsequently, this study 
meticulously evaluates the numerous and 
widespread used serum urea concentration 
cut-offs recommended in literature. The 
strengths of this study include the high 
quality of the electronically collected data, 
the fact that recent data were collected 
on a relative large and well-powered study 
population that was representative for a 
tertiary ICU in a developed country, and 
that in-hospital mortality (and not ICU 
mortality) was assessed as outcome.
The study also includes several limitations. 
First, its retrospective design can only be 
hypothesis generating on the topic of timing 
of initiation of RRT. Multivariate analysis is a 
tool that may correct for the observational 
design of the study. But such an analysis 
is only as good as the type and quality of 
the covariates that are entered into the 
model. Therefore we analysed different 
multivariate logistic regression models. We 
also included a propensity score to correct 
for bias. Our database consisted of data on 
baseline characteristics of the patients, and 
data recorded at time of initiation of RRT. 
However, covariates that were not available 
such as volume balance, may also have 
had an important impact on outcome [36].
Fig. 3.
Adjusted risk for in-hospital death for the different serum 
urea concentration cut offs as mentioned in literature 
(indicated by the first author), applied to our study 
cohort. A multivariate logistic regression analysis with 
adjustment for the same covariates as in table 5.
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Table 5.
Covariate adjusted association of 
serum urea concentration with 
in-hospital death. A multivariate 
logistic regression model with 
inclusion of a propensity score.
OR 95% CI P
DEMOGRAPHIC DATA
Age (per year) 1.049 1.025, 1.073 <0.001
APACHE II (per point) 1.028 0.961, 1.099 0.424
TYPE OF ICU (ref. cardiac surgery ICU) 0.352
Medical ICU 1.116 0.397, 3.138 0.835
Surgical ICU 1.662 0.756, 3.652 0.206
urea (per g/dL) 1.206 0.838, 1.733 0.313
RIFLE CLASS (ref. not fulfilling    
 RIFLE classification criteria)
<0.001
Risk 7.976 1.059, 60.069 0.044
Injury 5.146 0.916, 28.912 0.063
Failure 0.770 0.153, 4.017 0.770
RRT MODALITY (ref. CHD) 0.091
CVVH 1.047 0.341, 3.215 0.936
IRRT 0.425 0.168, 1.078 0.072
SLEDD 0.387 0.110, 1.359 0.139
SOFA NON- RENAL (per point) 1.162 1.053, 1.282 0.003
SEPSIS 1.220 0.527, 2.825 0.642
POTASSIUM (per mmol/L) 1.383 1.005, 1.902 0.047
pH 2.114 0.133, 33.697 0.596
PHOSPHORUS (per mg/dL) 1.076 0.946, 1.225 0.265
Goodness of fit (Hosmer and Lemeshow) Chi2 = 9.388, df = 8, P = 0.311. 
Overall percentage correct predicted = 73.7%
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Also, RIFLE class was assessed on cre-
atinine criteria only as we did not have 
detailed urine output data necessary for 
classifying. The results on RIFLE could 
be different when urine output was used 
as a criterium. However, this limitation is 
present in the majority of studies on the 
epidemiology of AKI [31,37]. Second, similar 
to the majority of the studies on this 
topic, all patients in our study received 
RRT. Including AKI patients without RTT 
could have led to different conclusions. 
For instance, patients with low severity of 
AKI, low serum urea, and without severe 
multiple organ dysfunction syndrome may 
have recovered AKI without RRT. Also, AKI 
patients with high serum urea levels may 
have died without RRT. In addition, initiation 
of RRT was in part based on serum urea 
concentrations as we follow consensus 
recommendations. However, the sensitivity 
analysis in the low and high serum urea 
concentration group could not demonstrate 
a difference in outcomes, suggesting that 
this bias was only limited. Further, the 
broad range of serum urea concentrations, 
with a median concentration of 136 mg/
dL permits to evaluate all urea cut-offs 
mentioned in literature. Third, because our 
patients database management system was 
introduced gradually over the 3 different 
ICUs during the study period, we couldn’t 
study all patients who underwent RRT. 
However, as we could not demonstrate 
a difference in outcome or serum urea 
concentration between the different ICUs, 
it is unlikely that this has influenced the 
results profoundly. Finally, the data reflect 
the practice from a single centre, and 
may therefore not be applicable to other 
settings where other practice protocols for 
treatment of ICU patients with AKI are used.
Our findings highlight the need for a well-
set-up prospective randomized trial on the 
timing of initiation of RRT. The design of 
such a trial needs careful consideration. 
We propose that patients in such a study 
are stratified according to severity of 
illness, with different criteria for initiation 
of RRT in the different strata. Given the 
arguments discussed above, we do not 
feel that serum urea concentration should 
still be a criterion in this study. RIFLE or 
AKI criteria have been proposed as alter-
natives [8], and are probably more accurate 
in differentiating early and less severe 
from progressed and more severe AKI. 
In conclusion, this study suggests that 
serum urea concentration cut-offs at time 
of initiation of RRT, as they have been used 
from the early days of acute RRT, and as 
they are actually recommended, have no 
predictive value for in-hospital mortality 
in severely ill ICU patients with AKI. 
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PURPOSE
SLA is frequent in ICU patients with AKI  
treated with RRT. The aim of the study is to  
describe the epidemiology of SLA in this setting.
MATERIALS AND METHODS
An observational single center cohort 
analysis was performed on AKI patients 
treated with RRT. At initiation of RRT, 
SLA patients (serum lactate concen-
tration >5 mmol/l and pH<7.35) were 
compared with non-SLA patients.
RESULTS
Of the 454 patients dialyzed during the 
study period, 342 patients matched 
inclusion criteria (116 with and 226 patients 
without SLA). In SLA patients, lactate 
stabilized/decreased in 69.7% at 4 hours 
(p=0.001) and in 81.8% during the period 
of 4 to 24 hours (p<0.001) after initiation 
of RRT. Mortality during this 24-hours 
period was 31.0%. ICU mortality was 83.6% 
compared to 47.3% in non-SLA patients. 
Initial lactate concentration was not 
related to ICU mortality in SLA patients.
CONCLUSIONS
SLA was frequent in AKI patients treated 
with RRT. SLA patients were more severely 
ill and had higher mortality compared 
with patients without. During the first 
24 hours of RRT, a correction of lactate 
concentration and acidosis was observed. 
In SLA patients lactate concentration at 
initiation of RRT was not able to discrimi-
nate between survivors and nonsurvivors. 
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1. Introduction
Serum lactate has been widely considered 
an important biomarker for evaluation of 
hemodynamic status in critically ill patients. 
It is the reflection of the balance between 
lactate production and clearance. In basal 
metabolic conditions lactate levels vary 
between 0.5 and 1 mmol/L. Historically, 
hyperlactatemia refers to serum lactate 
concentration above 2 mmol/L but lower 
than 5 mmol/L. As a different clinical entity 
lactic acidosis is defined as a blood lactate 
level higher than 5 mmol/l and pH less than 
7.35. Cohen further classified lactic acidosis 
based on the presence (type A) or absence 
(type B) of tissue hypoxia [1, 2]. The relation-
ship between tissue hypoxia and formation 
of lactic acid was already demonstrated 
in the late 1800’s by Araki and Zillessen [3]. 
Apart from the underlying cause of lactic 
acidosis, this may in part be explained by 
the deleterious direct effects of acidosis 
such as decreased myocardial contraction 
by Na+/H+ exchange activation, decreased 
response to vasopressors due to a down 
regulation of beta receptors and impaired 
intracellular calcium signalling, effects on 
endothelial function and effects on the in-
flammatory response [4-10]. Although lactate 
is a non-toxic molecule, the increase in 
concentration indicates important alter-
ations in homeostasis and is, therefore, 
associated with increased mortality [11, 12]. 
Often, lactic acidosis is associated with AKI 
and since the early 1960’s, RRT has been 
used for correction of acid-base homeo-
stasis as an adjunct to the treatment of the 
underlying cause [13]. Where hemodynamic 
instability is observed, continuous RRTs 
are effective at correcting the observed 
acidosis [14, 15]. This is reflected in reviews 
[16, 17] and the recent consensus guidelines 
by the AKIN and the (KDIGO group, which 
considers life-threatening metabolic 
acidosis a possible indication for RRT [18, 19].
 KEY MESSAGE
SLA is common in AKI-RRT 
patients but lactate 
concentration at initiation 
of RRT is not able to 
discriminate between 
survivors and non-survivors.
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Lactate has a molecular weight of 90 
Da, similar to urea (60 Da), and, as 
such, is easily removed by RRT. The 
relatively low molecular weight makes 
diffusion based therapies particularly 
attractive, whereas it can be expected 
also to remove other anions associated 
with lactate acidosis including isoc-
itrate, α-ketoglutarate and malate [20]. 
In the presence of SLA, many clinicians 
hesitate to initiate RRT based on the hy-
pothesis that short-term benefit cannot 
be achieved and that the administration 
of RRT exposes patients to the harm of 
RRT, and administration of bicarbonate by 
dialysis may even worsen clinical state. 
Indeed, despite over 50 years of experience 
with the use of RRT in AKI patients with 
SLA, data on this topic are scarce. The 
most recent study was published over 15 
years ago, where Hilton et al [21] found that 
patients with SLA and AKI supported with 
bicarbonate buffered hemofiltration had 
a mortality of 71.5%. Therefore, the aim of 
this study is to describe the current epi-
demiology of SLA in a cohort of critically 
ill patients with AKI treated with RRT. In 
addition, we evaluate factors that may 
influence outcome in patients with SLA.
2. Materials  
 and Methods
We performed an observational single 
centre cohort analysis over a three-year 
period (August 2004 – July 2007) on 
intensive care unit (ICU) patients who had 
AKI treated with RRT. In this cohort we 
compared patients with SLA at time of 
initiation of RRT (pH < 7.35 or treatment 
with NaHCO3 to correct acidosis, and a 
serum lactate concentration ≥ 5 mmol/L) 
to patients without SLA (serum lactate 
concentration ≤ 5 mmol/L). The adult ICU 
of the Ghent University Hospital comprises 
a 22 bed surgical ICU, a 14 bed medical 
ICU, a 6 bed burn ICU and an 8 bed cardiac 
surgery ICU. These ICUs function inde-
pendently with their own policy concerning 
indications for RRT and modalities used, 
depending on the attending intensivists and 
nephrologists. We included all ICU patients, 
age 15 year and older who had AKI treated 
with RRT. During the study period, the 
electronic PDMS was gradually introduced. 
Only patients who were registered in the 
PDMS were included in the study. Patients 
who had SLA on the day of initiation of 
RRT but had a decrease in serum lactate 
at time of initiation of RRT were excluded. 
Treatment episodes with peritoneal dialysis, 
a modality seldom used in our ICUs in 
selected patients with cirrhosis or decom-
pensated heart failure, were also excluded. 
Indications for RRT, as well as the modality 
chosen were determined in consensus 
between the attending intensivists and 
nephrologists [22] (treatment modalities 
used are presented in Supplemental Table E1). In 
subanalysis, we compared patients with 
SLA to ICU patients without lactic acidosis 
who were initiated on RRT for AKI. Also, we 
compared patients who were treated with 
diffusive IHD, SLEDD, CVVHD versus con-
vective CVVH RRT modalities and patients 
who underwent continuous (CVVH, CVVHD) 
versus intermittent (IHD, SLEDD) RRT.
2.1 DATA COLLECTION
Demographic data were retrieved from the 
electronic hospital database and the paper 
medical files, laboratory data from the 
laboratory database and patient data from 
the electronic ICU PDMS or paper medical 
file. Data on comorbidity and diagnostic 
categories were retrieved from the elec-
tronic hospital administration International 
Classification of Diseases, Ninth Revision, 
coding system. Severity of illness was 
assessed at time of ICU admission by 
the Acute Physiologic Assessment and 
Chronic Health Evaluation II (APACHE II) 
score (based on data recorded during 
the first 24 hours of ICU admission) [23]. 
At time of initiation of RRT, severity of 
illness was assessed by parameters of 
organ dysfunction. Serum concentrations of 
lactate and bicarbonate, pH, blood pressure 
and the use of vasoactive medication 
were retrieved at time of initiation of RRT 
and 4 and 24 hours after initiation of RRT. 
Serum concentrations of creatinine, urea, 
bilirubin and thrombocytes were recorded 
at initiation of RRT and 24 hours later. 
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2.2  STATISTICAL ANALYSIS
Data are expressed as number (percentage), 
or median (interquartile range). Bivariate 
analysis was performed with the Mann-
Whitney U test for continuous variables 
and the Fisher exact test or Chi2 test 
for categorical variables as appropriate. 
Multivariate logistic regression analysis was 
used to examine the association of SLA and 
modality of RRT with mortality. Variables 
selected for inclusion in the regression 
model were these with P ≤ .25 in bivariate 
analysis when comparing survivors and non-
survivors. We analyzed for co-linearity by 
assessing correlation between covariates; 
also, interaction was explored. Goodness of 
fit was assessed according to the method 
described by Hosmer and Lemeshow. In 
addition, we evaluated sensitivity and spec-
ificity for the model by the area under the 
curve of a receiver operating characteristic 
curve. Statistical significance was accepted 
when the P value was less than .05 (double 
sided). In order to explore the impact of 
patients with missing lactate concentra-
tion at time points 4 hours and 24 hours 
after initiation of RRT, a sensitivity analysis 
was performed in which we compared 
baseline characteristics and outcomes 
with those of patients with complete 
data. These analyses were performed with 
use of the statistical software packages 
SPSS (SPSS for Windows, version 19.0.0). 
The study was approved by the Ethics 
Committee of the Ghent University 
Hospital RRT (Ghent University Ethical 
Committee, study B67020072642, date: 
4/10/2007) and conducted in accordance 
with the Declaration of Helsinki. Informed 
consent was waived for this study.
3. Results
During the 3-year study period, 454 patients 
with AKI were treated with RRT. On the 
day of initiation of RRT 148 patients (32.6%) 
were diagnosed with SLA. Thirty-two of 
these patients did not meet inclusion 
criteria (11 patients were not registered in 
PDMS because of its gradual introduction, 
21 patients showed a decrease of serum 
lactate on time of initiation of RRT). We 
registered 306 patients without SLA on 
the day of initiation of RRT. After exclu-
sions, the study cohort comprised 342 
patients: 116 patients (33.9%) with SLA and 
226 patients (66.1%) without SLA (Fig. 1). 
The baseline characteristics of the study 
cohort are described in Table 1. Median 
age was 65 years, and 67.5 % were male. 
Severity of illness as illustrated by the 
APACHE II score at time of ICU admission 
was high (median 21; IQR 16-27). The 
majority of patients were admitted to a 
surgical or cardiac surgery ICU. Patients with 
SLA were more severely ill compared to 
patients without as illustrated by the higher 
APACHE II score at time of ICU admission, 
and at time of initiation of RRT, they had 
serum higher bilirubin, lower platelet count, 
more frequent use of continuous RRT and 
higher need for mechanical ventilation and 
vasoactive therapy. Only 24.6% of patients 
with SLA had sepsis as admission diagnosis 
reported in the hospital administration 
system (Table 1) On the other hand, at time 
of initiation of RRT, as much as 82.8% were 
on mechanical ventilation, and 85.3% were 
on vasopressor therapy. Also, platelet count 
of patients with SLA was decreased to a 
median of 77.5 x 10E9/L. This may indicate 
that the actual proportion of patients who 
had severe sepsis/septic shock at time 
of initiation of RRT actually was higher.
3.1 OUTCOMES
Patients with SLA had a shorter length 
of ICU and hospital stay but a higher 
crude ICU and hospital mortality (83.6% 
vs. 47.3%, p<0.001 and 83.6% vs. 47.8%, 
p<0.001 respectively) (Table 1). In the SLA 
cohort, 3 patients (2.6%) died within 4 
hours and 33 patients (28.4%) died within 
the period between 4 to 24 hours after 
initiation of RRT (Fig. 1). In a multivariate 
logistic regression model, we found that, 
after adjustment for confounders SLA 
was associated with increased hospital 
mortality (odds ratio 3.42 (95% confidence 
interval 1.41 – 8.31; P =0.007)) (detailed 
analysis shown in Supplemental Table E2).
A detailed comparison between ICU 
survivors and nonsurvivors among the 
lactic acidosis group is presented in Table 2. 
Nonsurvivors were older, had higher serum 
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urea and serum creatinine at time of 
initiation of RRT. Other baseline charac-
teristics were similar between groups. 
3.1.1. Evolution of serum lactate 
concentration, pH and bicarbonate during 
the 24 h study period   Serum lactate 
concentration showed a significant 
decrease at 4 and 24 hours after initiation 
of RRT (P < .001, Fig. 2). Bicarbonate 
concentration and pH significantly 
increased at 4 and 24 hours (all P < 0.001, 
Fig. 2, bicarbonate not shown). We found 
that 69.7% of patients had a decrease or 
stabilisation of serum lactate concentration 
after 4 hours of RRT (Supplemental Table E3). 
These individuals were older, less acidotic, 
and a lower proportion was mechanically 
ventilated compared to patients whose 
lactate increased over this period. After 24 
hours of RRT, serum lactate had decreased 
in 81.8% of patients. Baseline characteristics 
and outcomes were similar between 
patients with an increase or a decrease/
stabilization of serum lactate over the 
24-hour study period. Importantly, serum 
lactate concentration at time of initiation 
of RRT was not different between patients 
who had a decline or an increase of lactate 
during the 4- and 24-hour study period.
3.1.2. Convective versus diffusive RRT, 
and continuous versus intermittent RRT 
modalities   Compared with convection, 
diffusive therapy was used in 75.0% of 
patients. Patients treated with diffusive 
RRT were more frequently admitted to 
the surgical and medical ICU and had 
lower serum creatinine and bicarbonate. 
Patients who underwent intermittent 
RRT (23.3%) had a lower serum lactate 
and a higher pH and higher bilirubin 
compared to patients who were treated 
with continuous RRT (Supplemental Table E4).
There were no differences in the evolution 
of serum lactate concentration during 
the 24-hour study period comparing 
patients treated with diffusive and 
convective modality or continuous vs 
intermittent modalities (data not shown). 
In addition, outcomes were compa-
rable in these two subgroup analyses 
(Supplemental Table E4). Furthermore, after 
correction for age, gender, APACHE II, pH, 
urea and serum creatinine, continuous 
RRT (compared with Intermittent RRT) 
and diffusive RRT (compared with con-
vective RRT) were not associated with 
hospital mortality (Supplemental Table E5).
3.1.3. Sensitivity analysis   Not all patients 
who were alive had serum lactate concen-
tration measured at 4 and 24 hours after 
initiation of RRT. To explore if this introduced 
a bias that could impact on this analysis, 
we compared patients with complete and 
incomplete datasets as an additional sensi-
tivity analysis. Here, we found no differences 
in baseline characteristics and outcome 
between patients who had lactate concentra-
tion recorded 4 hours, respectively 24 hours 
after initiation of RRT (n = 99 resp. n = 77) and 
those who had not (n = 14 respectively n = 5).
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4. Discussion
In this cohort of critically ill patients with 
AKI treated with RRT, one-third had SLA 
at time of initiation of RRT. Compared 
with patients without SLA, these patients 
had higher ICU mortality and were more 
severely ill. Multivariate regression analysis 
confirmed the well-known association 
between SLA and adverse outcome 
(Supplemental Table E2) [12]. Most patients with 
SLA had a decrease of serum lactate and 
increase of bicarbonate and pH during 
the 24-hour study period. Importantly, 
in this sub-cohort of patients with SLA, 
initial lactate concentration could not 
differentiate between survivors and 
no-survivors. Therefore, lactate concen-
tration may not be a useful parameter 
for selecting AKI patients with SLA, who 
may benefit of treatment with RRT. 
Furthermore, RRT modality had no impact 
on outcome. Despite the severity of illness, 
short-term survival was reasonable with 
almost three quarters of the patients 
surviving for the first 24-hour period.
The strength of the study is that more than 
a decade after the most recent cohort 
study [21], it provides detailed and actualized 
data on a frequent used indication for initi-
ation of RRT. Therefore, this study updates 
the previous report in a more contemporary 
population, submitted to the therapeutic 
modalities that are currently standard.
The prevalence of SLA at time of initiation 
of RRT is not well established in literature 
[24]. We found that this was a common 
finding in our study population, as one-third 
of ICU patients started on RRT had SLA. 
Retrospective determination of the cause 
and type of SLA is difficult, but given 
the fact that only 9.1% of patients were 
diagnosed with liver disease on admission, 
the majority of patients probably could be 
classified as type A lactic acidosis. Because 
of the single-center design of this study 
one has to be cautious in extrapolating 
these findings, especially, because the 
incidence found may even be an underes-
timation as we cannot rule out that some 
patients with SLA were not initiated on 
RRT, because of limitations in therapy.
The association between lactic acidosis 
and mortality was confirmed in this 
specific cohort of ICU patients. This 
may be explained by SLA itself, but the 
increased mortality may also be the con-
sequence of greater severity of illness 
and organ dysfunction, of which the 
lactic acidosis is the consequence [6, 7].
This high mortality rate is comparable with 
previously reported data in ICU patients who 
had AKI and SLA [21, 25]. Despite advances in 
ICU patient management, mortality of this 
specific cohort has therefore not improved 
during the past decade. Alternatively, we 
cannot rule out that this comparison is 
affected by selection bias. Possibly, severely 
ill patients with important comorbidity 
who were not treated with RRT in the past 
may now have been allocated to RRT. 
Initiation of RRT in ICU patients with AKI 
and SLA is still a matter of debate. It 
may be seen as futile as the mortality is 
so high, and given the fact that the role 
of extracorporeal lactate clearance by 
RRT remains unclear. This study cannot 
give a clear answer at this point. RRT 
does not treat the underlying cause of 
lactic acidosis, which is essential in these 
patients. As such, it can only provide 
restoration of homeostatic equilibrium, 
enabling specific therapeutic measures [15]. 
During the study period, we found an 
improvement of acidosis parameters, and 
observed a 24-hour mortality that was less 
than 1 of 3 patients. These observations 
may be of some importance as prolonged 
duration of SLA for 24 hours or longer is 
strongly associated with mortality in diverse 
cohorts of ICU patients [11, 12]. In addition, 
even moderate increases in serum lactate 
concentration have been found to be as-
sociated with increased mortality [26]. As 
we did not measure lactate clearance by 
RRT, it is uncertain whether the effects 
we observed are explained by enhanced 
clearance of lactate, or are just the 
resultant of the natural course of disease. In 
addition, removal of other small anions such 
as isocitrate, malate and α-ketoglutarate, 
administration of bicarbonate by means of 
RRT; or a combination of both could have 
contributed to the observed clinical course. 
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TOTAL COHORT
AKI-RRT
NO SLA SLA P
N 342 226 (66,1%) 116 (33,9%)
DEMOGRAPHIC DATA
Age (year) 65 (55,73) 65 (55,73) 65 (53,72) 0.349
Male gender 226 (66.1%) 157 (69.5%) 74 (64.0%) 0.289
APACHE II 21 (16,27) 20 (16,24) 24 (18,30) <0.001
CHRONIC COMORBIDITY
Cardiovascular disease 149 (43.6%) 117 (51.8%) 32 (27.6%) <0.001
Diabetes mellitus 80 (23.4%) 56 (24.8%) 24 (20.7%) 0.398
TYPE OF ICU
Medical ICU 104 (30.4%) 82 (36.3%) 22 (18.9%) <0.001
Surgical ICU 153 (44.7%) 82 (36.3%) 71 (61.2%)
Cardiac surgical ICU 80 (23.4%) 62 (27.4%) 18 (15.5%)
Burn unit 5 (1.5%) 0 (0.0%) 5 (4.3%)
ADMISSION CATEGORY
Cardiovascular disease 97 (42.9%) 34 (29.3%) 131 (38.3%) 0.012
Respiratory disease 13 (5.8%) 4 (3.4%) 17 (5.0%)
Gastrointestinal disease 14 (6.2%) 6 (5.2%) 20 (5.8%)
Liver disease 16 (7.1%) 15 (12.9%) 31 (9.1%)
Kidney disease 17 (7.5%) 1 (0.9%) 18 (5.3%)
Hematologic disease 7 (3.1%) 5 (4.3%) 12 (3.5%)
Sepsis/infection 30 (13.3%) 20 (17.2%) 50 (24.6%)
Trauma/burn 11 (4.9%) 10 (8.6%) 13 (6.1%)
Other 20 (8.8%) 21 (18.1%) 41 (12.1%)
PARAMETERS AT TIME 
OF INITIATION OF RRT
LOS ICU before RRT (days) 2.0 (1.1,3.9) 2.1 (1.4,3.1) 1.6 (0.4,4.4) 0.015
Serum creatinine (mg/dL) 3.67 (2.42,4.91) 2.83 (1.74,3.52) 4.58 (3.15,5.42) <0.001
Serum urea (g/dL) 1.51 (1.14,2.13) 1.32 (0.87,1.92) 0.91 (0.61,1.24) <0.001
Bilirubin 1.26 (0.50,2.70) 1.54 (0.30,3.42) 1.90 (0.99,4.70) 0.001
Thrombocytes (×10E9/L) 127.0 (79.8,202.0) 113.0 (65.0,183.0) 77.5 (46.3,138.0) <0.001
pH 7.27 (7.19,7.33) 7.26 (7.18,7.33) 7.23 (7.12,7.33) 0.088
RRT MODALITY
CVVHD 88 (25.7%) 28 (12.4%) 60 (51.7%) <0.001
CVVH 55 (16.1%) 26 (11.5%) 29 (25.0%)
IRRT 167 (48.8%) 151 (66.8%) 16 (13.8%)
SLEDD 32 (9.4%) 21 (9.3%) 11 (9.5%)
Continuous RRT modality 143 (41.8%) 54 (23.9%) 89 (76.7%) <0.001
COMORBIDITY AT 
INITIATION OF RRT
Mechanical ventilation 225 (65.8%) 129 (57.1%) 96 (82.8%) <0.001
Vasoactive therapy 238 (69.6%) 139 (61.5%) 99 (85.3%) <0.001
OUTCOMES
LOS hospital (days) 28.5 (15.0,58.3) 24.2 (10.0,49.0) 12.3 (4.7,39.2) <0.001
LOS ICU (days) 18.0 (8.0,35.0) 14.0 (6.0,32.2) 6.3 (2.9,24.3) <0.001
ICU mortality 204 (59.6%) 107 (47.3%) 97 (83.6%) <0.001
Hospital mortality 205 (59.9%) 108 (47.8%) 97 (83.6%) <0.001
Table 1.
Characteristics of AKI patients 
treated with RRT: comparison 
between patients without and 
with severe lactic acidosis. 
IRRT indicates intermittent renal 
replacement therapy. Data in bold 
are statistically significant.
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Table 2.
Patients with severe 
lactic acidosis: survivors 
versus non-survivors. 
SEVERE LACTIC 
ACIDOSIS
ICU 
SURVIVORS
ICU 
NONSURVIVORS
P
N 116 19 (16.4%) 97 (83.6%)
DEMOGRAPHIC DATA
Age (year) 65 (53,72) 52 (35.67) 65 (55.73) 0.005
Male gender 74 (64%) 9 (47.4%) 65 (67.0%) 0.103
APACHE II 24 (18,30) 20 (16.27) 25 (19.31) 0.066
CHRONIC COMORBIDITY
Cardiovascular disease 32 (27.6%) 8 (42.1%) 24 (24.7%) 0.122
Diabetes mellitus 24 (20.7%) 2 (10.5%) 22 (22.7%) 0.232
TYPE OF ICU
Medical ICU 22 (18.9%) 2 (10.5%) 20 (20.6%) 0.382
Surgical ICU 71 (61.2%) 13 (68.4%) 58 (59.8%)
Cardiac surgical 18 (15.5%) 2 (10.5%) 16 (16.5%)
Burn unit 5 (4.3%) 2 (10.5%) 3 (3.1%)
ADMISSION CATEGORY
Cardiovascular disease 34 (29.3%) 4 (21.1%) 30 (30.9%) 0.359
Respiratory disease 4 (3.4%) 0 (0.0%) 4 (4.1%)
Gastrointestinal disease 6 (5.2%) 3 (15.8%) 3 (3.3%)
Liver disease 15 (12.9%) 3 (15.8%) 12 (12.4%)
Kidney disease 1 (0.9%) 0 (0.0%) 1 (1.0%)
Hematologic disease 5 (4.3%) 0 (0.0%) 5 (5.2%)
Sepsis/infection 20 (17.2%) 3 (15.8%) 17 (17.5%)
Trauma/burn 10 (8.6%) 3 (15.8%) 7 (7.3%)
Other 21 (20.2%) 3 (15.8%) 18 (18.1%)
PARAMETERS AT TIME 
OF INITIATION OF RRT
LOS ICU before RRT (days) 2.1 (1.4,3.1) 1.8 (1.3,2.6) 2.2 (1.5,3.2) 0.237
Serum lactate (mmol/L) 11.1 (7.3,17.9) 10.4 (7.8;18.0) 11.7 (7.3,17.9) 0.976
Serum creatinine (mg/dL) 2.50 (1.70,3.54) 1.93 (1.27,2.92) 2.60 (1.75,3.61) 0.014
Serum urea (g/dL) 0.91 (0.61,1.24) 0.58 (0.47,0.95) 0.93 (0.67,1.34) 0.004
Bilirubin (mg/dL) 1.90 (0.99,4.70) 2.15 (0.64,4.15) 1.90 (1.05,4.85) 0.446
Thrombocytes (×10E9/L) 77.5 (46.3,138.0) 71.0 (48.0,167.0) 78.0 (42.0,134.0) 0.460
pH 7.23 (7.12,7.33) 7.28 (7.21,7.33) 7.22 (7.08,7.33) 0.085
RRT MODALITY
CVVHD 60 (51.7%) 12 (63.2%) 48 (49.5%) 0.607
CVVH 29 (25.0%) 3 (15.8%) 26 (26.8%)
IRRT 16 (13.8%) 3 (15.8%) 13 (13.4%)
SLEDD 11 (9.5%) 1 (5.3%) 10 (10.3%)
Continuous RRT modality 89 (76.7%) 15 (79.0%) 74 (76.3%) 0.802
COMORBIDITY AT 
INITIATION OF RRT
Mechanical ventilation 96 (82.8%) 16 (84.2%) 80 (82.5%) 0.855
Vasoactive therapy 99 (85.3%) 15 (78.9%) 84 (86.6%) 0.389
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Data on lactate clearance by RRT are scarce 
and conflicting. Several researchers suggest 
only a limited therapeutic effect and state 
that increased lactate clearance may be 
the reflection of the improvement of the 
clinical situation rather than the removal 
of large amounts of lactate. These data 
are derived from studies employing lower 
dose of RRT than the ones prescribed 
routinely in our units [21, 27]. For example, 
Levraut et al found that with a relatively 
low dose of RRT (Continuous Veno-Venous 
HemoDiaFiltration with a Qb of 100 mL/
min and Qd of 1000mL/h), RRT constituted 
only 3% of the total body clearance of 
lactate [28]. Interestingly, Bellomo [29] cal-
culated that a Qb of 200 mL/min, lactate 
clearance during dialysis would reach ap-
proximately 20% of endogenous clearance.
Despite this conflicting literature, RRT 
is often used as a strategy in correcting 
severe acidosis as it may act as a bridging 
therapy that buys time to treat the under-
lying cause of the acidosis [30]. The finding 
that the initial lactate concentration was 
not related to mortality in this cohort of 
patients could be of interest to physicians 
attending patients with SLA and AKI. It 
suggests that lactate concentration may 
not be a useful parameter for selecting 
AKI patients with SLA, who will benefit of 
treatment with RRT. Also, no difference 
in mortality between RRT modalities 
was observed. This may be subject to 
selection bias given that the cohorts were 
small and not entirely comparable.
This study has some limitations. This is a 
retrospective single-center study with a 
relatively limited number of patients, which 
may limit external validity of the findings. 
Some data were missing due the gradual 
introduction of the electronic PDMS. In 
some patients we missed lactate concen-
trations at 4 or 24 hours after initiation 
of RRT. However, a sensitivity analysis 
demonstrated these had similar baseline 
characteristics and outcome compared to 
patients who had lactate concentrations 
measured. Therefore, it is unlikely that 
this impacted our findings. Further, only 
patients treated with RRT are studied. We 
do not have data on ICU patients who had 
AKI and SLA and who were not started 
on RRT. As such, we do not have data on 
the natural course of the disease. As we 
have the policy of using RRT as a bridging 
therapy that buys time to treat the un-
derlying disorder, only incidental patients 
were missed for that reason. On the other 
hand, the condition of these patients 
was so severe, that the treating physician 
would have considered not initiating RRT 
unethical unless a decision to withdraw 
active treatment had been made. Therefore, 
we do not think there is clinical equipoise 
to perform a prospective randomized study 
on initiation of RRT in ICU patients with SLA 
and AKI. This situation is similar to many 
interventions in severely ill patients such 
as the initiation of mechanical ventilation.
In conclusion, prevalence of SLA in criti-
cally ill patients with AKI treated with RRT 
is high. During the first 24 hours of RRT, 
acidosis improved and lactate decreased 
in the majority of patients irrespective 
of RRT modality. Although nonsurvivors 
were more acidotic, lactate concentra-
tion at initiation of RRT was not able to 
discriminate between survivors and non-
survivors in the cohort of patients with 
SLA at time of initiation of RRT. In AKI 
patients with SLA, lactate concentration 
at initiation of RRT may therefore not be 
a useful parameter for selecting those 
who will benefit of treatment with RRT.
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SEVERE LACTIC 
ACIDOSIS
ICU 
SURVIVORS
ICU 
NONSURVIVORS
P
N 116 19 (16.4%) 97 (83.6%)
DEMOGRAPHIC DATA
Age (year) 65 (53,72) 52 (35.67) 65 (55.73) 0.005
Male gender 74 (64%) 9 (47.4%) 65 (67.0%) 0.103
APACHE II 24 (18,30) 20 (16.27) 25 (19.31) 0.066
CHRONIC COMORBIDITY
Cardiovascular disease 32 (27.6%) 8 (42.1%) 24 (24.7%) 0.122
Diabetes mellitus 24 (20.7%) 2 (10.5%) 22 (22.7%) 0.232
TYPE OF ICU
Medical ICU 22 (18.9%) 2 (10.5%) 20 (20.6%) 0.382
Surgical ICU 71 (61.2%) 13 (68.4%) 58 (59.8%)
Cardiac surgical 18 (15.5%) 2 (10.5%) 16 (16.5%)
Burn unit 5 (4.3%) 2 (10.5%) 3 (3.1%)
ADMISSION CATEGORY
Cardiovascular disease 34 (29.3%) 4 (21.1%) 30 (30.9%) 0.359
Respiratory disease 4 (3.4%) 0 (0.0%) 4 (4.1%)
Gastrointestinal disease 6 (5.2%) 3 (15.8%) 3 (3.3%)
Liver disease 15 (12.9%) 3 (15.8%) 12 (12.4%)
Kidney disease 1 (0.9%) 0 (0.0%) 1 (1.0%)
Hematologic disease 5 (4.3%) 0 (0.0%) 5 (5.2%)
Sepsis/infection 20 (17.2%) 3 (15.8%) 17 (17.5%)
Trauma/burn 10 (8.6%) 3 (15.8%) 7 (7.3%)
Other 21 (20.2%) 3 (15.8%) 18 (18.1%)
PARAMETERS AT TIME 
OF INITIATION OF RRT
LOS ICU before RRT (days) 2.1 (1.4,3.1) 1.8 (1.3,2.6) 2.2 (1.5,3.2) 0.237
Serum lactate (mmol/L) 11.1 (7.3,17.9) 10.4 (7.8;18.0) 11.7 (7.3,17.9) 0.976
Serum creatinine (mg/dL) 2.50 (1.70,3.54) 1.93 (1.27,2.92) 2.60 (1.75,3.61) 0.014
Serum urea (g/dL) 0.91 (0.61,1.24) 0.58 (0.47,0.95) 0.93 (0.67,1.34) 0.004
Bilirubin (mg/dL) 1.90 (0.99,4.70) 2.15 (0.64,4.15) 1.90 (1.05,4.85) 0.446
Thrombocytes (×10E9/L) 77.5 (46.3,138.0) 71.0 (48.0,167.0) 78.0 (42.0,134.0) 0.460
pH 7.23 (7.12,7.33) 7.28 (7.21,7.33) 7.22 (7.08,7.33) 0.085
RRT MODALITY
CVVHD 60 (51.7%) 12 (63.2%) 48 (49.5%) 0.607
CVVH 29 (25.0%) 3 (15.8%) 26 (26.8%)
IRRT 16 (13.8%) 3 (15.8%) 13 (13.4%)
SLEDD 11 (9.5%) 1 (5.3%) 10 (10.3%)
Continuous RRT modality 89 (76.7%) 15 (79.0%) 74 (76.3%) 0.802
COMORBIDITY AT 
INITIATION OF RRT
Mechanical ventilation 96 (82.8%) 16 (84.2%) 80 (82.5%) 0.855
Vasoactive therapy 99 (85.3%) 15 (78.9%) 84 (86.6%) 0.389
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Table E1.
Characteristics of 
treatment modalities.
Dialyzers used were low flux 
polyethersulfone (Diapes 1.6, Bellco)  
or high flux polysulfone hollow fibre 
cartridges (FX80 Fresenius). 
CVVH | continuous veno-venous 
haemofiltration, IHD | intermittent 
haemodialysis, CVVHD | continuous 
veno-venous hemodialysis, SLEDD 
| slow extended daily dialysis
Table E2.
Impact of the presence of 
severe lactic acidosis therapy 
on mortality: multivariable 
logistic regression analysis.
Multivariate analysis adjusted for APACHE 
II, cardiovascular disease, mechanical 
ventilation, vasoactive therapy, type of 
ICU, RRT modality, serum bilirubin, serum 
thrombocyte count, serum urea, serum 
creatinine and pH at initiation of RRT 
Goodness of fit according to Hosmer en 
Lemeshow | Chi2 = 3.328, df = 8, P = 0.912 
RRT | Renal Replacement Therapy
DIFFUSIVE/
CONVECTIVE
DURATION DIALYSIS 
MACHINE
BLOOD FLOW 
(QB) (ML/MIN)
DIALYSATE FLOW 
(QD) (ML/MIN)
EFFLUENT RATE 
(ML/HOUR)
CVVH convective continuous Edwards 
Lifesciences, Accura
500 mL predilution 
1500 mL postdilution
IHD diffusive 4 Gambro AK200 150-200 500
CVVHD diffusive continuous Gambro AK200 100-200 350-500
Fresenius Genius 100-150 100-150
SLEDD diffusive 6-12 Gambro AK200 100-200 350
Fresenius Genius 100-200 100-200
OR 95% CI P
MODEL Auc ROC: 0.812 (95% CI 0.757 - 0.866)
SEVERE LACTIC ACIDOSIS 
(Compared to no severe lactic acidosis)
3.42 1.41 – 8.31 0.007
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Table E3.
Patient characteristics in severe 
lactic acidosis patients with 
different evolution of serum 
lactate concentration over time.
ICU | Intensive Care Unit, RRT | Renal 
Replacement Therapy, MAP | Mean 
Arterial Pressure, LOS | Length of stay
SEVERE  
LACTIC 
SERUM LACTATE CONCENTRATION
4 HOURS AFTER TIME OF INITIATION OF RRT
SERUM LACTATE CONCENTRATION
24 HOURS AFTER TIME OF INITIATION OF RRT
ACIDOSIS
STABILISATION  
OR DECREASE
INCREASE P STABILISATION  
OR DECREASE
INCREASE P
N 116 69 (69.7 %) 30 (30.3 %) 63 (81.8 %) 14 (18.2 %)
DEMOGRAPHIC DATA
Age (year) 65 (53,72) 66.5 (55.0,74.7) 57.9 (48.4,67.3) 0.028 63.2 (49.9,72.9) 64.3 (55.3,68.1) 0.702
Male gender 74 (64.0%) 46 (66.7 %) 19 (63.3 %) 0.748 41 (65.1 %) 8 (57.1 %) 0.577
APACHE II 24 (18,30) 24.0 (20.3,30.0) 25.5 (17.8,31.0) 0.942 24 (19,31) 25 (20,29) 0.639
Liver cirrhosis 13 (11.2%) 6 (8.7 %) 5 (16.7 %) 0.246 6 (9.5 %) 3 (21.4 %) 0.210
TYPE OF ICU
Surgical ICU 71(61.2%) 39 (81.3 %) 9 (18.8 %) 0.211 39 (81.3 %) 9 (18.8 %) 0.531
Medical ICU 22(18.9%) 12 (85.7 %) 2 (14.3 %) 12 (85.7 %) 2 (14.3 %)
Cardiac Surgical ICU 18 (15.5%) 9 (90 %) 1 (10.0 %) 9 (90 %) 1 (10.0 %)
Burn unit 5 (4.3%) 3 (60 %) 2 (40.0 %) 3 (60 %) 2 (40.0 %)
PARAMETERS AT TIME 
OF INITIATION OF RRT
Serum lactate (mmol/L) 11.1 (7.3,17.9) 12.2 (6.9,19.2) 10.6 (8.0,18.0) 0.846 11.8 (6.9,18.0) 9.1 (7.7,12.8) 0.227
Serum urea (g/dL) 0.91 (0.61,1.24) 0.92 (0.61,1.23) 0.88 (0.58,1.42) 0.879 0.90 (0.58,1.19) 0.90 (0.63,1.42) 0.355
Serum creatinine (mg/dL) 2.50 (1.70,3.54) 2.68 (1.74,3.69) 2.26 (1.63,3.42) 0.283 2.56 (1.59,3.46) 2.84 (1.88,4.95) 0.338
pH 7.23 (7.12,7.33) 7.30 (7.19,7.35) 7.16 (7.03,7.27) 0.002 7.27 (7.18,7.33) 7.26 (7.17,7.33) 0.202
HCO3- mmol/L 16.8 (13.6,21.3) 18.6 (14.5,22.9) 15.1 (8.9,18.1) <0.001 18.0 (13.9,21.5) 15.3 (13.1,17.7) 0.774
Mechanical ventilation 96 (82.8 %) 53 (76.8 %) 29 (96.7%) 0.016 52 (82.5 %) 11 (78.6 %) 0.728
Vasopressor treatment 99 (85.3 %) 57 (82.6 %) 26 (86.7 %) 0.614 55 (87.3 %) 12 (85.7 %) 0.875
Blood pressure MAP (mm Hg) 64 (59,73) 64.0 (58.5,72.5) 65.0 (58.8,74.3) 0.546 66.0 (58.5,77.0) 62.5 (54.5,72.0) 0.238
Serum Bilirubin (mg/dL) 1.90 (0.99,4.70) 1.80 (1.10,4.50) 2.85 (0.93,11.90) 0.132 2.25 (1.00,4.48) 3.16 (1.19,19.76) 0.199
RRT MODALITY
Continuous therapy 
(CHD, CVVH D)
89 (77.0%) 49 (71.0 %) 26 (86.7 %) 0.095 49 (77.8 %) 12 (85.7 %) 0.721
Haemodialysis 
(IHD,SLEDD,CVVHD)
87 (75.0%) 49 (71.0 %) 23 (76.7 %) 0.562 47 (74.6 %) 9 (64.3 %) 0.511
OUTCOME
LOS ICU before  
initiation RRT (days)
2.1 (1.4,3.1) 2.2 (1.5,3.1) 2.1 (1.3,3.8) 0.681 2.1 (1.6,3.0) 1.9 (1.1,4.3) 0.383
LOS hospital before 
initiation RRT (days)
3.7 (2.0,10.3) 3.2 (2.1,9.6) 5.0 (1.9,13.3) 0.532 3.1 (2.0,9.0) 4.8 (2.7,15.9) 0.217
ICU Mortality 97 (83.6%) 59 (85.5%) 23 (76.7%) 0.284 48 (76.6%) 11 (76.9%) 0.978
Hospital Mortality 97 (83.6%) 59 (85.5%) 23 (76.7%) 0.284 48 (76.6%) 11 (76.9%) 0.978
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Table E4.
Comparison of different RRT 
modalities in patients with 
severe lactic acidosis.
Diffusive therapy: continuous haemodialysis 
(CHD) and slow extended daily dialysis 
(SLEDD); Convective therapy: intermittent 
haemodialysis ( IHD) and continuous veno-
venous hemofiltration (CVVH); Continuous 
therapy: CHD and CVVH; Intermittent 
therapy: IHD/SLEDD. ICU | Intensive Care 
Unit, RRT | Renal Replacement Therapy, MAP 
| Mean Arterial Pressure, LOS | Length of stay
DIFFUSIVE  
RRT
CONVECTIVE 
RRT
P INTERMITTENT 
/HYBRID RRT
CONTINUOUS 
RRT
P
N 87 (75.0%) 29 (25.0%) 27 (23.3%) 89 (76.7%)
DEMOGRAPHIC DATA
Age (year) 66 (53,72) 63 (51,74) 0.816 65 (53,72) 65 (53,72) 0.806
Male gender 55 (63.2 %) 19 (65.5 %) 0.823 19 (70.4 %) 55 (61.8 %) 0.417
APACHE II 25 (20,32) 23 (17,28) 0.067 25 (17,29) 25 (19,32) 0.325
Liver cirrhosis 8 (9.2 %) 5 (17.2 %) 0.306 2 (7.4 %) 11 (12.4 %) 0.730
TYPE OF ICU
Surgical ICU 58 (81.7 %) 13 (18.3 %) <0.001 18 (74.6 %) 53 (25.4 %) 0.912
Medical ICU 20 (90.9 %) 2 (9.1 %) 4 (18.2 %) 18 (81.8 %)
Cardiac Surgical ICU 7 (39.9 %) 11 (61.1 %) 4 (22.2 %) 14 (77.8 %)
Burn unit 2 (40.0 %) 3 (60.0 %) 1 (20.0 %) 4 (80.0 %)
PARAMETERS AT TIME 
OF INITIATION OF RRT
Serum Lactate (mmol/L) 11.8 (7.7,18.1) 10.1 (6.5,16.2) 0.215 7.7 (6.1,13.2) 12.5 (8.0,18.8) 0.006
Serum Urea (g/dL) 0.84 (0.59,1.22) 1.07 (0.71,1.40) 0.098 0.84 (0.63,1.32) 0.91 (0.60,1.23) 0.634
Serum Creatinine (mg/dL) 2.12 (1.58,3.28) 3.50 (2.28,4.72) 0.001 2.11 (1.97,3.40) 2.58 (1.59,3.61) 0.670
Acidosis (pH < 7.35) 74 (85.1 %) 21 (72.4 %) 0.126 18 (66.7 %) 77 (86.5 %) 0.042
pH 7.22 (7.08,7.33) 7.30 (7.19,7.37) 0.053 7.32 (7.24,7.39) 7.20 (7.10,7.33) 0.002
HCO3- mmol/L 15.4 (12.7,21.0) 18.8 (15.4,21.5) 0.044 18.6 (14.2,23.8) 15.5 (13.5,20.8) 0.038
Mechanical ventilation 72 (82.8 %) 24 (82.8 %) 1.000 21 (77.8 %) 75 (84.3 %) 0.561
Vasopressor need 76 (87.4 %) 23 (79.3 %) 0.363 22 (81.5 %) 77 (86.5 %) 0.540
Blood pressure MAP (mm Hg) 64 (59,73) 63 (60,74) 0.659 69 (61,76) 63 (58,73) 0.073
Serum Bilirubin (mg/dL) 1.8 (0.9,4.4) 2.60 (1.20,5.13) 0.154 1.57 (0.65,2.13) 2.19 (1.13,5.00) 0.038
OUTCOME
LOS ICU before  
initiation RRT (days)
6.1 (2.8,22.2) 7.0 (3.8,32.6) 0.245 5.7 (2.6,20.1) 6.4 (3.2,24.6) 0.601
LOS hospital before 
initiation RRT (days)
12.3 (4.0,39.2) 10.5 (6.8,38.4) 0.659 11.8 (4.0,31.3) 12.4 (5.1,42.5) 0.353
24 hour Mortality 26 (29.9%) 7 (24.1%) 0.552 7 (27.0%) 30 (33.3%) 0.571
ICU Mortality 71 (81.6%) 26 (89.7%) 0.311 23 (85.2%) 74 (83.1%) 0.802
Hospital Mortality 71 (81.6%) 26 (89.7%) 0.311 23 (85.2%) 74 (83.1%) 0.802
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Table E5.
Impact of modality of renal 
replacement therapy on 
mortality: multivariable 
logistic regression analysis.
Multivariate analysis adjusted for age, gender, 
APACHE II, pH, serum creatinine, serum urea, 
cardiovascular disease. 
 
Model 1 | Hosmer en Lemeshow ‘goodness 
of fit’ Chi2 = 5.811, df = 8, P = 0.661 
Model 2 | Hosmer en Lemeshow ‘goodness 
of fit’ Chi2 = 3.153, df = 8, P = 0.924  
Model 3 | Hosmer en Lemeshow ‘goodness 
of fit’ Chi2 = 3.423, df = 8, P = 0.905 
RRT | Renal Replacement Therapy
OR 95% CI P
MODEL 1 Auc ROC: 0.667 (0.544 – 0.789)
Continuous RRT  
(compared to intermittent RRT)
0.27 0.04 – 1.65 0.156
MODEL 2 Auc ROC : 0.715 (0.597 – 0.833)
Diffusive RRT  
(compared to convective RRT)
0.59 0.12 – 2.93 0.518
MODEL 3 Auc ROC : 0.686 (0.564 – 0.808)
Continuous RRT  
(compared to intermittent RRT)
0.20 0.03 – 1.30 0.092
Diffusive RRT  
(compared to convective RRT)
0.37 0.06 – 2.11 0.262
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BACKGROUND
In ICU patients, acute kidney injury treated 
with renal replacement therapy (AKI-RRT) 
is associated with adverse outcomes. 
The aim of this study was to evaluate 
variables associated with long-term survival 
and kidney outcome and to assess the 
composite endpoint major adverse kidney 
events (MAKE; defined as death, incom-
plete kidney recovery, or development of 
end-stage renal disease treated with RRT) 
in a cohort of ICU patients with AKI-RRT.
METHODS
We conducted a single center prospec-
tive observational study in a 50-bed 
ICU tertiary care hospital. During the 
study period from August 2004 through 
December 2012, all consecutive adult 
patients with AKI-RRT were included. Data 
were prospectively recorded during the 
patients’ hospital stay and were retrieved 
from the hospital databases. Data on 
long-term follow-up were gathered during 
follow-up consultation or, in absence of 
this by consulting the general physician.
RESULTS
AKI-RRT was reported in 1,292 out of 
23,665 first ICU admissions (5.5%). Mortality 
increased from 59.7% at hospital discharge, 
to 72.1% at 3 years. A cox proportional 
hazard model demonstrated association 
of increasing age, severity of illness, and 
continuous RRT with long-term mortality. 
Among hospital survivors with reference 
creatinine measurements, 1-year renal 
recovery was complete in 48.4% and in-
complete in 32.6%. Dialysis dependency 
was reported in 19.0% and associated 
with age, diabetes, CKD and oliguria at 
time of initiation of RRT. MAKE increased 
from 83.1% at hospital discharge to 
93.7% at 3 years. Multivariate regres-
sion analysis showed no association 
of classical determinants of outcome 
(preexisting CKD, timing of iniation of RRT 
and RRT modality with MAKE at 1 year.
CONCLUSION
Our study demonstrates poor long-term 
survival after AKI-RRT that was de-
termined mainly by severity of illness 
and RRT modality at iniation of RRT. 
Renal recovery is limited, especially in 
patients with acute-on-chronic kidney 
disease, making nephrological follow-up 
imperative. MAKE is mainly associated 
with variables determining mortality.
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1. Background
AKI is a frequent finding in ICU patients, 
with a prevalence of approximately 40-57% 
when defined according to the KDIGO 
criteria. AKI treated with renal replacement 
therapy (AKI-RRT) occurs in approximately 
13% of ICU patients [1, 2]. It is associated 
with adverse outcomes such as increased 
length-of-stay, short- and long-term 
mortality and ESRD. In the past, AKI was 
considered a surrogate marker marker for 
severity of illness, and patient mortality 
was considered a consequence of the 
underlying disease [3]. However, there is 
an abundance of epidemiologic data that 
demonstrates that AKI in itself leads to 
adverse outcome. This is so for the most 
severe form of AKI, where patients are 
treated with RRT [4, 5]. In addition, small 
decreases in kidney function are associ-
ated with increased short-term mortality. 
Further, the prevalence of preexisting CKD 
is increasing amongst ICU admissions. CKD 
may lower the threshold for developing 
AKI, and acute-on-chronic kidney disease 
is associated with adverse outcomes [3-7]. 
Further, even mild AKI may predispose 
patients to CKD and so increases the risk 
of subsequent AKI events and finally ESRD 
[8-10]. So, AKI can be considered both the 
cause and consequence of CKD, and AKI 
and CKD therefore are considered intercon-
nected and integrated syndromes [6]. The 
association of CKD with mortality remains 
a matter of debate. One one hand, a recent 
large registry study demonstrated the asso-
ciation with CKD and death [7]. On the other 
hand, critically ill patients with AKI-RRT, 
who had CKD were reported to have lower 
short-term mortality compared to those 
without preexisting CKD [9, 11-14]. Another 
factor that may impact on long-term 
outcomes is modality of RRT. Observational 
studies suggest that CRRT is associated 
with better kidney outcomes, more spe-
cifically less need for chronic dialysis [8, 9]. 
However, prospective randomized studies 
could not demonstrate a survival benefit for 
CRRT compared to intermittent therapies 
[10, 11]. Finally, optimal timing of initiation of 
RRT is unclear. RRT is initiated early in the 
absence of serious complications of AKI 
and may therefore have some advantages. 
 KEY MESSAGE
Long-term survival and 
renal recovery after 
AKI-RRT in critically ill 
patients is poor making 
nephrological follow-up 
imperative. 
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The late and more conservative approach 
takes into account that some patients with 
severe AKI might recover kidney function 
spontaneously without starting RRT, 
avoiding adverse events linked to RRT [12].
Until recently, studies of AKI in ICU patients 
were focused on conventionally accepted 
short-term outcomes such as mortality 
at day 30, or ICU and hospital discharge. 
However, these endpoints may underesti-
mate the true burden of kidney disease. In 
light of the increasing focus on long-term 
outcomes, researchers in several studies 
have investigated the links between AKI, 
CKD and ESRD [13, 14]. By way of analogy to 
major adverse cardiovascular events, this 
led to the introduction of the composite 
endpoint MAKE [15]. MAKE is a composite of 
death, ESRD needing dialysis and incom-
plete kidney recovery, defined as a 25% 
decrease of eGFR, measured at long-term 
endpoints such as 90 days or 1 year.
The aim of the present study was to 
describe long-term patient and kidney 
outcomes in a cohort of AKI-RRT patients 
and to assess possible modifying factors 
of outcome, such as CKD, timing of in-
itiation of RRT and RRT modality .
 
2. Methods
We conducted a single center prospective 
cohort analysis of patients with AKI-RRT 
at the ICU of the Ghent University Hospital 
over an 8-year study period (October 
2004 – October 2012). The Ghent University 
ICU consists of a 22 beds surgical ICU, a 
14 beds medical ICU, an 8 beds cardiac 
surgery ICU, and a 6 beds burn unit.
2.1 STUDY COHORT
The inclusion criteria were ICU patients 
aged ≥ 15 years, who had AKI and were 
treated with RRT and who had follow-up 
data after hospital discharge. During 
the study period, the electronic PDMS 
was gradually introduced. Only patients 
who were registered in the PDMS were 
included in the study [16]. Exclusion criteria 
were extracorporeal blood purification 
techniques for reasons other than AKI, 
patients with CKD receiving chronic 
RRT, RRT initiated before the admission 
to the ICU, and RRT immediately after 
kidney transplant. In cases were a patient 
had several ICU episodes of AKI-RRT 
during the same hospital admission, 
we considered only the first episode.
Indications for RRT, as well as the modality 
chosen (i.e. intermittent hemodialysis (IHD) 
(duration 2 to 4 h per treatment session), 
SLEDD (duration 6 to 12 h per treatment 
session), or continuous renal replacement 
therapy (CRRT) (continuous veno-venous 
hemofiltration or –hemodialysis)), were 
determined by consensus between the 
attending intensivists and nephrologists and 
based on the clinical status of the patient 
(fluid balance, respiratory status, acid-base 
balance). Continuous modalities are pref-
erentially used in patients with severe 
shock, patients who are at risk for cerebral 
oedema (e.g. liver cirrhosis) or patients 
from whom fluid removal is pursued [17].
3. Definitions
Reference serum creatinine was either a 
baseline serum creatinine concentration 
obtained from the laboratory database 
within a 12-month period prior to hospital 
admission or, if unavailable, serum creati-
nine at time of hospital admission. In the 
latter group, some patients already had AKI 
at time of hospital admission. Therefore, 
in the group for which we had to rely on 
hospital admission creatinines, we excluded 
patients who were initiated on RRT within 
2 days after hospital admission, as well as 
patients who had a higher serum creatinine 
concentration at the time of admission 
than at to hospital discharge. We did not 
apply back-calculation of baseline serum 
creatinine with the MDRD eGFR formula 
as suggested by the KDIGO AKI guidelines, 
because this would have led to underes-
timation of the number of patients with 
preexisting CKD stage 3 or higher [18]. 
Timing of initiation of RRT was defined using 
the KDIGO staging criteria. Initiation of RRT 
at KDIGO stage 1 or 2 was defined as “early”, 
and initiation of RRT at stage 3 was defined 
as “late”. Oliguria was defined as a diuresis 
of less than 500 mL over 24h preceding the 
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initiation of RRT. Fluid balance comprising 
the 24h episode before initiaton of RRT was 
calculated by the PDMS. Recovery of kidney 
function was assessed only in patients with 
reference creatinine. Recovery of kidney 
function was classified as complete when 
eGFR was within 25% from reference eGFR 
(based on reference serum creatinine). 
Incomplete kidney recovery comprised 
patients who had a 25% or greater decline of 
reference eGFR and who were not treated 
with dialysis. Absent kidney recovery was 
defined as the permanent need for RRT for 
more than 3 months. Since long-term serum 
creatinine data were available at the exact 
follow up times (e.g. 90days) we allowed the 
following intervals: day 90 ± 7 days, 1 year ± 
60 days, 2 year ± 60 days, 3 years ± 60 days.
CKD was defined according to eGFR cat-
egories per the KDIGO criteria [19]: Stage 
1 CKD is an eGFR > 90 ml/min/1.73 m2, 
stage 2 is 60 – 90 ml/min/1.73 m2, stage 3 
is 30-60 ml/min/1.73 m2, stage 4 is 15 – 30 
ml/min/1.73 m2, and stage 5 is <15 ml/
min/1.73 m2 or chronic RRT (hemodialysis 
or peritoneal dialysis). Patients with CKD 
stage 3 or worse were classified for the 
purposes of this study as patients with 
CKD and compared with patients who 
had CKD stage 2 or less (no CKD) [15]. Late 
initiation of RRT was defined as initia-
tion of RRT at KDIGO stage 3. The MAKE 
composite endpoint was assessed in the 
patient cohort with reference creatinine, 
and it was defined as the presence of 
one or more of the following: death, 
incomplete kidney recovery, or devel-
opment of ESRD treated with RRT [15].
4. Study outcomes
The primary outcome measure of the study 
was mortality 1 year after initiation of RRT. 
The secondary outcomes were long-term 
patient survival and long-term kidney 
function measured as kidney recovery and 
dialysis dependency in hospital survivors. 
In addition, we reported and evaluated 
the composite outcome measure MAKE. 
We eventually assessed the classical de-
terminants of long-term outome of AKI 
treated with RRT: preexisting CKD, timing 
of initiation of RRT, and RRT modality. 
4.1 DATA COLLECTION
Data were prospectively recorded during 
hospital stay. Baseline demographic pa-
rameters were retrieved from the hospital’s 
electronic database and the ICU’s electronic 
PDMS. Data on comorbidity and diagnostic 
categories were retrieved from the elec-
tronic hospital administration’s International 
Classification of Diseases, Ninth Revision, 
coding system. The severity of illness as 
determined by the (SAPS II score (based 
on data recorded during the first 24-hours 
of ICU admission) was recorded at the 
time of ICU admission [20, 21]. At the time 
of initiation of RRT, severity of illness was 
assessed on the basis of parameters of 
organ dysfunction and SOFA score [22]. 
Kidney laboratory data were recorded at 
hospital admission; ICU admission; initi-
ation of RRT; hospital discharge; and 30 
and 90 days and 1, 2 and 3 years. Data on 
long-term follow-up were gathered from 
the patients’ electronic medical records 
(e.g. during follow-up consultation, or in 
cases of absence of such a consultation, 
by contacting the primary care physician 
of the patient by e-mail or telephone). 
4.2 STATISTICAL ANALYSIS
The data are expressed as number (pro-
portion), median (interquartile range), or OR 
(95% CI). Univariate analysis of long-term 
mortality and MAKE were performed with 
the Mann-Whitney U test, Fisher’s exact 
test, Friedman’s two-way analysis of 
variance by ranks test, Wilcoxon rank-sum 
test, Kruskall Wallis test and chi-square 
test, as appropriate. The predictors thus 
obtained were subsequently tested in a 
multivariable logistic regression model. 
Variables selected for inclusion in the re-
gression model were those with plausible 
rationale, with a P value ≤0.25 in bivariate 
analysis. Significant covariates for MAKE 
were identified after constructing a model 
in which all covariates were entered si-
multaneously (enter method). We analyzed 
for colinearity by assessing correlations 
between covariates; in addition, interaction 
was explored. Goodness of fit was assessed 
according the method described by Hosmer 
and Lemeshow. Statistical significance was 
accepted when the P value was <0.05.
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Fig. 1.
Study flowchart 
PDMS | patient data management system, 
AKI | acute kidney injury, ICU | intensive care 
unit, RRT | renal replacement therapy
Fig. 2.
Kaplan-Meier survival curve 
IHD | Intermittent Hemodialysis, SLEDD | Slow Extended Daily 
Dialysis, CRRT | Continuous Renal Replacement Therapy
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a. Kaplan-Meier survival curve over time for the whole cohort. 
c. Kaplan-Meier survival curve stratified for 
RRT modality (log rank P<0.001).
b. Kaplan-Meier survival curve over time in hospital survivors.
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The event-free survival rate was estimated 
using the Kaplan-Meier method, and 
significance was evaluated with the 
log-rank test. A Cox proportional hazards 
model was developed to address the 
predictors for long-term survival. These 
analyses were performed with use 
of IBM SPSS Statistics for Windows, 
version 23.0.0 (IBM, Armonk, NY, USA). 
5. Results
During the 8-year study period, 23,665 
first ICU admissions were registered. A 
total of 1,292 patients (5.5%) had AKI-RRT, 
and 959 patients were included in the 
final analyses (Fig. 1). Of these, 609 patients 
(63.4%) had a reference creatinine level 
documented. Demographic data of the 
study cohort are shown in Table 1. 
5.1 PATIENT OUTCOME AND 
 LONG-TERM SURVIVAL
ICU mortality was 54.6%. Mortality increased 
from 59.7% at time of hospital discharge, 
to 64.5% at 1 year, 67.9% at 2 years and 
72.1% at 3 years (Fig. 2a). Among hospital 
survivors, 11.9% later died at 1 year, 19.3% 
at 2 years and 27.2% at 3 years (Fig. 2b).
One-year nonsurvivors were significantly 
older than survivors but had less CKD. A 
greater proportion of nonsurvivors were 
female and had been admitted to the 
medical ICU. At ICU admission, nonsur-
vivors’ severity of illness based on their 
SAPS II scores were higher than those of 
survivors. At initiation of RRT, nonsurvivors 
had higher SOFA scores than survivors. 
Their hemodynamic status was more 
unstable as a greater proportion of patients 
was treated with vasoactive agents, had a 
positive fluid balance, were more acidotic, 
and had higher serum lactate and more 
negative base excess. Nonsurvivors were 
less often treated with diuretics, and a 
greater proportion were mechanically 
ventilated and treated with CRRT as the 
initial RRT modality (Table 1). Patients treated 
with CRRT as initial RRT modality had 
worse survival than patients treated with 
IHD (P<0.001 by log-rank test) (Fig. 2c).
We found that, after adjustment for 
confounders in a Cox proportional hazards 
model, CRRT as initial RRT modality was 
associated with long-term mortality (HR 
1.570; 95% CI 1.202,2.050; P=0.001). Baseline 
kidney function and timing of RRT were not 
associated with survival in this model. Other 
confounders associated with survival were 
older age, and increased severity of illness 
(full model provided in Additional file 1: Table S1). 
5.2 KIDNEY OUTCOMES
Nephrology consultation after hospital 
discharge was reported in only 34.0% of 
hospital survivors. Nephrology follow-up 
was more frequent in CKD stage ≥3 
patients compared with CKD stage <3 
patients (51.0% versus 31.8%, P=0.003). 
Among hospital survivors dialysis de-
pendency rates were 8.6% at hospital 
discharge, 9.0% at 90 days, 14.1% at 1 year, 
14.0% at 2 year and 16.9% at 3 year.
In order to assess kidney outcomes with 
focus on (in)complete renal recovery, the 
cohort of hospital survivors who had a 
reference creatinine was studied (Table 2). 
In these patients we found that after 1-y 
follow up 48.4% had complete recovery 
of kidney function, 32.6% had incomplete 
recovery, and 19.0% had ESRD and were 
treated with chronic dialysis. Patients 
who had incomplete recovery had better 
kidney function and less often diabetes 
before AKI. Patients receiving chronic 
dialysis more often had diabetes, CKD, 
and oliguria at time of initiation of RRT. 
The evolution of kidney outcome over 
time is summarized in Figure 3. Complete 
renal recovery peaked at 90 days (56.7%) 
and further decreased over time. Dialysis 
dependency increased over time with 13.8% 
at hospital discharge up to 28.1% at 3 years. 
Patients who had prior CKD had more ESRD 
treated with dialysis compared to patients 
without CKD, but less incomplete renal 
recovery (without need for RRT) (Table 3).
5.3 MAJOR ADVERSE  
 KIDNEY EVENTS (MAKE) 
Over time, MAKE increased in the total 
cohort; it was present in 83.1% of the 
patients at hospital discharge, 86.0% at 
90 days, 87.5% at one year and 92.4% 
and 93.7% at two and three years 
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TOTAL 
COHORT
1 YEAR 
SURVIVORS
1 YEAR NON 
-SURVIVORS
P MAKE 1 YR 
ABSENT
MAKE 1 YR 
PRESENT
P
N 959 340 619 102 752
DEMOGRAPHIC DATA
Age (year) 65 (55,75) 64 (52,74) 65 (55,75) 0.030 66 (57,74) 65 (55,75) 0.802
Gender (male, %) 65.4 70.0 62.8 0.026 64.6 64.0 0.892
Black (%) 0.2 0 0.3 0.294 0 0.3 0.593
COMORBID CONDITIONS
Diabetes mellitus (%) 27.5 27.4 27.6 0.928 29.4 28.6 0.864
CKD stage baseline ≥ 3 (%) 39.6 44.2 37.0 0.084 51.6 37.3 0.010
eGFR baseline  
(mL/min/1.73 m2)
69.0 (47.0,91.1) 63.4 (44.4,82.9) 74.1 (49.2,93.8) 0.004 57.3 (42.8,76.5) 72.9 (49.2,93.4) 0.001
Serum Creatinine baseline (mg/dL) 1.07 (0.82,1.41) 1.15 (0.92,1.48) 1.00 (0.79,1.31) <0.001 1.21 (0.96,1.58) 1.03 (0.80,1.34) <0.001
CHARACTERISTICS  
ON ICU ADMISSION  
TYPE OF ICU
Medical (%) 45.8 36.4 51.1
<0.001
32.0 49.6
0.001
Surgical (%) 54.2 63.6 48.9 68.0 50.4
TIMING OF SURGERY
Urgent (%) 61.0 60.2 61.8
0.729
60.2 61.8
0.012
Elective (%) 39.0 39.8 38.2 39.8 38.2
SEVERITY OF ILLNESS 
SAPS II 63 (45,78) 52 (39,69) 70 (54,83) <0.001 49 (34,69) 68 (49,82) <0.001
CHARACTERISTICS  
AT INITIATION OF RRT  
SEVERITY OF ILLNESS
SOFA total 10 (6,14) 9 (5,12) 12 (8,15) <0.001 5 (1,9) 11 (7,14) <0.001
SOFA non-renal 7 (3,11) 6 (2,9) 8 (5,12) <0.001 8 (5,12) 8 (4,11) <0.001
Mechanical ventilation (%) 88.6 82.4 92.0 <0.001 80.8 90.1 0.006
Vasoactive medication (%) 66.2 52.0 74.0 <0.001 48.0 70.4 <0.001
RENAL CHARACTERISTICS 
Oliguria (%) 48.9 45.8 50.8 0.171 36.6 50.9 0.010
Fluid balance (ml) 2163 (1180,3578) 2021 (1019,3220) 2200 (1268,4000) 0.049 1919 (1003,2996) 2229 (1311,4000) 0.054
Urine output (ml) 561 (178,1080) 621 (246,1230) 529 (157,1020) 0.055 792 (297,1483) 529 (152,1055) 0.007
Diuretics (%) 49.3 56.7 45.2 0.001 61.3 45.9 <0.001
ICU to RRT  
length-of-stay (days)
2 (1,7) 2 (1,5) 2 (1,8) 0.050 2 (1,6) 3 (1,8) 0.144
Serum creatinine (mg/dL) 3.57 (2.62,4.69) 4.23 (3.26,5.58) 3.26 (2.38,4.25) <0.001 4.18 (3.11,5.14) 3.38 (2.47,4.44) <0.001
LABORATORY PARAMETERS  
Serum Hemoglobin (g/dL) 9.3 (8.3,10.3) 9.5 (8.6,10.5) 9.2 (8.2,10.2) 0.001 9.4 (8.6,10.4) 9.2 (8.2,10.2) 0.001
Platelets (x 10³/mm³) 115 (67,184) 146 (89,219) 100 (55,158) <0.001 144 (89,202) 104 (60,177) <0.001
Serum Sodium (mmol/L) 139 (135,144) 138 (134,142) 140 (136,145) <0.001 137 (133,142) 140 (136,144) <0.001
Serum Potassium (mmol/L) 4.6 (4.1,5.3) 4.8 (4.2,5.4) 4.6 (4.1,5.2) 0.012 4.9 (4.2,5.4) 4.6 (4.1,5.2) 0.007
Serum Chloride (mmol/L) 102 (98,107) 101 (97,106) 103 (98,108) 0.051 101 (97,106) 103 (98,108) 0.005
Serum Bilirubin (mg/dL) 1.6 (0.7,4.2) 1.3 (0.6,3.3) 1.7 (0.7,4.8) 0.004 1.35 (0.60,2.90) 1.27 (0.86,1.82) 0.001
Serum Urea (g/dL) 1.28 (0.90,1.83) 1.33 (0.99,1.83) 1.26 (0.85,1.87) 0.062 1.36 (1.00,1.85) 1.27 (0.86,1.82) 0.173
Serum Albumin (g/dL) 2.2 (1.8,2.6) 2.3 (2.0,2.8) 2.1 (1.8,2.5) <0.001 2.3 (2.0,2.6) 2.2 (1.8,2.6) 0.003
Lactate (mg/dL) 24 (12,82) 15 (10,36) 34 (15,100) <0.001 14 (9,29) 29 (14,94) <0.001
pH 7.30 (7.24,7.37) 7.34 (7.27,7.39) 7.29 (7.21,7.36) <0.001 7.33 (7.27,7.38) 7.29 (7.22,7.36) <0.001
Base Excess -5.2 (-8.3,-2.2) -4.2 (-6.4,-1.6) -6.0 (-9.4,-2.5) <0.001 -4.5 (-7.1,-1.8) -5.5 (-9.1,-2.5) 0.001
RRT MODALITY 
IHD (%) 54.0 67.6 46.4
<0.001
72.5 49.5
<0.001SLEDD (%) 15.8 16.2 15.6 14.7 15.5
CRRT (%) 30.2 16.2 38.0 12.7 35.0
TIMING OF INITIATION OF RRT
Late (KDIGO stage≥ 3) (%) 54.1 58.9 51.6 0.087 61.1 58.8 0.735
Table 1.
Patient demographics and comparisons. 
Statistically significan tdata (P<0.05) are presented in bold.
CKD | Chronic Kidney Disease, CRRT | Continuous Renal Replacement Therapy, eGFR | 
estimated glomerular filtration ratio, ICU | intensive care unit, IHD | intermittent hemodialysis, 
KDIGO | Kidney Disease: Improving Global Outcomes, MAKE | major adverse kidney events, 
RRT | renal replacement therapy, SAPS II | Simplified Acute Physiology Score II, SLEDD 
| Slow Extended Daily Dialysis, SOFA | Sepsis-related Organ failure Assessment score. 
Data are presented as median (interquartile range) unless otherwise indicated.
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respectively. MAKE was mainly deter-
mined by mortality (Fig. 4). MAKE was 
more frequent in patients with prior 
CKD stage <3 compared to patients 
with preexisting CKD stage ≥3 (Table 3). 
5.4 VARIABLES ASSOCIATED  
 WITH MAKE AT 1 YEAR 
In univariate analysis, variables associated 
with MAKE at 1 year were the absence of 
preexisting CKD, severity of illness on ICU 
admission and at initiation of RRT (based 
on SAPS II and SOFA scores, mechanical 
ventilation, hemodynamic instability with 
need for vasoactive medication, anemia, 
low platelet count, acidosis and hyper-
lactatemia), oliguria, serum creatinine and 
continuous RRT modality at initiation of 
RRT (Table 1). On the basis of this univariate 
analysis we analyzed associations in a 
multivariate logistic regression model. After 
adjustment for confounding covariates, we 
found that preexisting kidney disease, initial 
RRT modality and timing of initiation of RRT 
were not associated with MAKE at 1 year 
(full model provided in Additional file 1: Table S2).
6. Discussion
We conducted a 8-year analysis in more 
than 23,000 first ICU admissions and found 
that AKI-RRT occurred in 5.5% of patients 
admitted to the ICU. Mortality rates were 
high with almost 60% of the patients dying 
during hospital stay and approximately 
an additional 10% per year of the hospital 
survivors in the years following discharge. 
Apart from advancing age and increased 
severity of illness, CRRT as initial RRT 
modality was associated with long-term 
mortality. As for kidney outcomes, almost 
one fifth of the AKI-RRT hospital survivors 
had ESRD at 1 year. Kidney recovery in 
hospital survivors after AKI-RRT was deter-
mined by preexisting renal comorbidity and 
diabetes mellitus. Finally, after adjustment 
for covariates, the occurrence of MAKE 
was not associated with preexisting CKD, 
timing of iniation of RRT, or RRT modality. 
The occurrence rate and mortality of our 
cohort are concordant with data reported 
by units in other developed countries [2, 23, 
24]. Similarly to others and not surprisingly, 
long-term mortality was was associat-
ed not only with advanced age but also 
varibles depicting severity of illness and 
accompanying haemodynamic instability: 
use of mechanical ventilation, vasoactive 
agents, and a positive fluid balance. The 
association of CRRT as initial modality of 
RRT with long-term mortality fits in this 
concept. In our unit, all modalities are 
used, and CRRT is used as initial modality 
in patients who are in severe shock, or for 
whom slow fluid removal is warranted. 
When patient’s condition improves, the 
modality is switched to SLEDD or IHD. In 
other words, choice of the initial modality 
may serve as a surrogate for severity of 
illness. Our findings are similar to those in a 
recent study where RRT modality was also 
chosen on basis of the hemodynamic status 
of the patient, but they are in contrast to 
those in other cohort studies [8, 10, 25, 26, 27]. 
The recently published studies on timing of 
RRT by Wald et al as well as the ELAIN and 
Artificial Kidney Initiation in Kidney Injury 
(AKIKI) studies, also illustrate the complex-
ity of the impact of timing on outcomes. 
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Renal recovery was defined as complete, when estimated 
glomerular filtration rate (eGFR) was within 25% from baseline 
eGFR. Incomplete kidney recovery was defined as those 
patients patients with an eGFR decrease of 25% or more from 
baseline eGFR without need for dialysis. Dialysis dependency 
was defined as end-stage renal disease and the permanent 
need for renal replacement therapy for > 3 months.
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COMPLETE 
RENAL 
RECOVERY 
INCOMPLETE 
RENAL 
RECOVERY
DIALYSIS 
DEPENDENCY
P
N (%) 89 (48.4) 60 (32.6) 35 (19.0)
DEMOGRAPHIC DATA
Age (year) 67 (57,75) 64 (53,75) 66 (55.75) 0.682
Gender (male, %) 64.0 80.0 57.1 0.039
Black (%) 0 0 0 NA
COMORBID CONDITIONS
Diabetes mellitus (%) 32.6 21.7 57.1 0.002
eGFR (mL/min/1.73m2) 60.6 (43.0,77.2) 73.6 (56.0,95.4) 44.6 (27.1,67.4) <0.001
CKD baseline stage≥3 (%) 49.4 28.3 69.6 0.013
Serum creatinine baseline (mg/dL) 1.17 (0.94,1.56) 1.05 (0.83,1.29) 1.41 (1.11,2.42) 0.001
CHARACTERISTICS  
ON ICU ADMISSION  
TYPE OF ICU
Medical (%) 32.2 35.0 48.5
0.246
Surgical (%) 67.8 65.0 51.5
TIMING OF SURGERY
Urgent (%) 55.4 64.1 70.6
0.459
Elective (%) 44.6 35.9 29.4
SEVERITY OF ILLNESS 
APACHE II 25 (19,35) 24 (21.27) 27 (19.31) 0.948
SAPS II 50 (35,69) 55 (43,69) 53 (44,71) 0.871
CHARACTERISTICS  
AT INITIATION OF RRT  
SEVERITY OF ILLNESS
SOFA 8 (5,12) 9 (5,12) 5 (5,11) 0.736
SOFA non-renal 5 (2,9) 7 (2,9) 2 (1,7) 0.727
Mechanical ventilation (%) 78.2 85.0 64.5 0.082
Vasoactive medication (%) 43.7 55.0 35.5 0.172
RENAL CHARACTERISTICS 
Oliguria (%) 39.5 41.5 69.0 0.019
Fluid balance (ml) 1774 (997,3016) 2546 (1364,3551) 2713 (2103,4534) 0.059
Urine output (ml) 768 (253,1496) 665 (351,1225) 219 (98,1080) 0.052
Diuretics (%) 63.2 58.6 40.0 0.084
ICU to RRT  
length-of-stay (days)
3 (1,4) 3 (2,9) 2 (0,4) 0.606
LABORATORY PARAMETERS 
AT INITIATION OF RRT 
Serum Hemoglobin (g/dL) 9.8 (8.9,10.8) 9.3 (8.3,10.5) 9.6 (8.3,10.6) 0.241
Platelets (x 10³/mm³) 143 (80,195) 164 (87,272) 198 (90,265) 0.214
Serum Sodium (mmol/L) 136 (132,140) 140 (136,142) 139 (133,142) 0.011
Serum Potassium (mmol/L) 5.0 (4.4,5.5) 4.9 (4.2,5.3) 4.7 (4.2,5.1) 0.264
Serum Chloride (mmol/L) 100 (96,105) 102 (97,108) 101 (97,108) 0.081
Serum Urea (g/dL) 1.32 (1.09,1.715) 1.27 (0.92,1.78) 1.34 (1.03,1.97) 0.664
Serum Creatinine (mg/dL) 4.23 (3.27,5.05) 3.95 (3.07,5.08) 4.73 (3.37,6.54) 0.194
Serum Albumin (g/dL) 2.3 (2.0,2.8) 2.3 (1.9,2.6) 2.8 (2.2,3.3) 0.074
Lactate (mg/dL) 17 (11,33) 16 (11,83) 11 (7,94) 0.259
pH 7.34 (7.29,7.39) 7.33 (7.25,7.39) 7.33 (7.24,7.38) 0.481
Base Excess -4.0 (-6.6,-1.6) -4.6 (-6.5,-2.9) -4.5 (-7.3,-3.3) 0.628
RRT MODALITY 
IHD (%) 73.0 68.3 74.3
0.799SLEDD (%) 14.6 16.7 8.6
CRRT (%) 12.4 15.0 17.1
TIMING OF INITIATION OF RRT
Early (%) 46.1 35.0 50.0
0.309
Late (%) 53.9 65.0 50.0
Table 2.
Renal recovery (complete and incomplete) versus dialysis dependency 
at 1 year in patients with reference serum creatinine values. 
Statistically significant data (P<0.05) are presented in bold.
Evaluation II, CKD | Chronic Kidney Disease, CRRT | Continuous Renal Replacement Therapy, 
eGFR | estimated glomerular filtration ratio, ICU | intensive care unit, IHD | intermittent 
hemodialysis, IQR | interquartile range, KDIGO | Kidney Disease: Improving Global Outcomes, 
RRT | renal replacement therapy, SAPS II | Simplified Acute Physiology Score II, SLEDD 
| Slow Extended Daily Dialysis, SOFA | Sepsis-related Organ failure Assessment score, a 
Early (KDIGO stage <3 at initiation RRT), Late (KDIGO stage ≥3 at initiation of RRT). 
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While two of these studies could demon-
strate no effect of timing at all, the ELAIN 
study showed a marked survival benefit 
for early initiation. Differences between 
these studies were the definition of early 
and late initiation, as well as the patient’s 
characteristics (surgical versus general 
ICU), modalities used (CRRT in ELAIN versus 
all modalities in the other studies), and 
single center observation (ELAIN) versus 
multicenter studies (Wald and AKIKI) [28-30].
We found that, among 1-y survivors with 
known reference serum creatinine, only 
50% had complete recovery of kidney 
function. With a dialysis dependency rate 
of 9.0% in survivors at day 90, our findings 
were lower to those reported in the Finnish 
Acute Kidney Injury (FINNAKI) study (18.9% 
at 90 days), and higher than in the RENAL 
study (5.6% at 90 days) and the IVOIRE 
study (1.4%) [2, 23, 31]. The FINNAKI, RENAL 
and IVOIRE trial used CRRT only, while we 
started CRRT in only one fifth of patients.
Interestingly, as dialysis dependency was 
predominantly associated with comorbid-
ities such as diabetes and CKD, patients 
with acute-on-chronic kidney disease 
face a significant risk of developing ESRD. 
This is similar to findings in other cohort 
studies and meta-analyses [7, 25, 32, 33]. 
As many as one third of patients in our 
cohort had incomplete renal recovery. 
Follow up of patients in the RENAL study 
also revealed that a large proportion of 
AKI-RRT survivors had albuminuria and 
decreased eGFR [34]. Close follow-up 
and interventions aimed at preserving 
kidney function may positively impact 
on long-term outcomes. Similar to data 
reported in the USA [35], only 34.0% of 
AKI-RRT survivors in our cohort had follow 
up of kidney function by a nephrologist. 
In our hospital, follow-up by a nephrol-
ogist is not protocol-driven but depends 
on the clinical and renal status of the 
patient. So, how this possibly impacted 
kidney outcome and survival is not clear. 
Especially in patients with acute-on- 
chronic disease, more standardized 
kidney follow-up by a general practitioner 
or nephrologist may be appropriate. 
After adjustment for covariates, MAKE 
was not associated with the classic deter-
minants of outcome such as preexisting 
CKD, timing of RRT or modality of RRT. Our 
results demonstrate the benefits and limi-
tations of the use of MAKE as a composite 
endpoint in AKI studies. MAKE is a clearly 
defined and a clinically important endpoint. 
Compared with single outcome endpoints, 
it captures a greater proportion of patients 
with poor long-term outcomes turning 
MAKE into a relevant endpoint. However, 
detailed evaluation of this outcome 
parameter necessitates the presentation of 
the individual components [15, 36-39]. 
In this study, MAKE was mainly determined 
by variables associated with its biggest 
individual component, mortality. Not sur-
prisingly, variables associated with mortality 
in univariate analysis were also associated 
with MAKE: increased severity of illness 
scores and mechanical ventilation but also 
the presence of haemodynamic instability 
at initiation of RRT, depicted by the use of 
vasoactive medication, hyperlactatemia, 
acidosis and a positive fluid balance. 
Fig. 4.
The composite endpoint major adverse kidney events (MAKE) 
comprised of the components death, dialysis dependency 
and incomplete renal recovery. Renal recovery was defined as 
incomplete, when estimated glomerular filtration rate (eGFR) 
decreased 25% or more from baseline eGFR, without need 
for dialysis. Dialysis dependency was defined as end-stage 
renal disease and permanent need for renal replacement 
therapy for > 3 months; CKD chronic kidney disease.
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TOTAL PREEXISTING 
CKD STAGE <3
PREEXISTING 
CKD STAGE ≥3
P
KIDNEY OUTCOME
HOSPITAL DISCHARGE
Complete renal recovery (%) 47.8 47.2 51.3
0.055Incomplete renal recovery (%) 38.4 45.7 32.3
Dialysis dependency (%) 13.8 7.1 14.6
90 DAY 
Complete renal recovery (%) 56.7 55.8 65.2
0.010Incomplete renal recovery (%) 28.1 34.6 15.2
Dialysis dependency (%) 15.2 9.6 19.7
1 YEAR 
Complete renal recovery (%) 48.4 47.4 57.1
0.001Incomplete renal recovery (%) 32.6 45.3 22.1
Dialysis dependency (%) 19.0 7.4 20.8
2 YEAR 
Complete renal recovery (%) 41.5 34.7 57.1
<0.001Incomplete renal recovery (%) 39.5 61.1 22.2
Dialysis dependency (%) 19.0 4.2 20.6
3 YEAR 
Complete renal recovery (%) 39.8 39.1 51.0
<0.001Incomplete renal recovery (%) 32.0 51.6 15.7
Dialysis dependency (%) 28.1 9.4 33.3
MAKE
Hospital discharge (%) 83.1 87.3 51.0 <0.001
90 days (%) 86.0 81.9 78.2 0.280
1 year (%) 87.5 87.4 79.4 0.010
2 years (%) 92.4 92.4 84.2 0.002
3 years (%) 93.7 92.4 88.5 0.124
Table 3.
Renal recovery and development of end-stage renal disease in 
patients with acute- on-chronic kidney disease versus patients without 
preexisting CKD (subgroup analysis in patients with known reference 
baseline serum creatinine concentration).  
Statistically significant data (P<0.05) are presented in bold.
CKD | chronic kidney disease, KDIGO | Kidney Disease: Improving Global Outcomes,  
MAKE | major adverse kidney events 
 
Renal recovery was defined as complete when estimated glomerular filtration rate (eGFR) was 
within 25% from baseline eGFR. Incomplete kidney recovery was defined as patients with an 
eGFR decrease of 25% or more from baseline eGFR without need for dialysis. Dialysis dependency 
was defined as end-stage kidney disease and permanent need for RRT for > 3 months; 
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This study has several strengths. First, 
it describes an up to 8-year follow-up 
period in a large cohort of patients with a 
heavy burden of disease. Secondly, apart 
from the classical mortality rates, we also 
report detailed information concerning 
possible determinants of outcome in ICU 
patients with AKI treated with RRT such 
as preexisting CKD, timing of initiation of 
RRT and initial modality of RRT. Further, 
(in)complete renal recovery and dialysis 
dependency are extensively described. 
By emphasizing the risk of development 
of ESRD not only in patients with a single 
AKI-RRT episode but also in patients with 
acute-on-chronic kidney disease, this 
study provides a key role for nephrological 
follow-up in such a cohort of patients. 
Finally, this study is one of the first to 
report on the recently proposed composite 
endpoint MAKE. The composite endpoint 
MAKE was addressed in detail, not only 
revealing its benefits but also highlight-
ing its limitations in this setting. As the 
study is monocentric, the conclusions 
cannot automatically be extended to other 
ICU’s. Therefore, generalization of these 
findings must be done with caution. 
This cohort study has limitations. First, 
owing to its observational design, we cannot 
exclude that there were unmeasured 
confounders. Second, the data reflect the 
practice at a single tertiary care center 
and may therefore lack external validity. 
However, the reported prevalence of 5.5% 
of AKI-RRT and the hospital mortality 
rate in this study cohort are in line with 
data reported by units in other developed 
countries [2, 27]. Third, we could include only 
all consecutive AKI-RRT patients present in 
the electronic PDMS, owing to its gradual 
introduction. Similarly, patients who, 
because of therapeutic restrictions were 
not started on RRT were not included in this 
analysis. Fourth, we only had a reference 
creatinine in 63.4% of patients. Therefore, 
renal recovery and MAKE was assessed 
in only a subgroup of patients. Because 
patients with absent documentation of a 
baseline serum creatinine more likely have 
normal kidney function, this analysis was 
done in a patient cohort with presuma-
bly a higher-than-normal proportion of 
patients with preexisting CKD. This may 
have impacted on our findings. To correct 
for possible bias, we performed a sensitivity 
analysis excluding baseline kidney function 
from the cox regression and multivariate 
analyses. This intervention did not change 
the HRs and ORs of the covariates included 
in the model. Therefore, we may conclude 
that the possibility of bias induced by 
this subgroup analysis may be limited. 
7. Conclusions
We demonstrated a poor long-term survival 
after AKI-RRT associated with advancing 
age and clinical status at initiation of 
RRT. Initiation with CRRT, a surrogate for 
severity of illness, was associated with 
adverse outcome. Renal recovery was 
limited and associated with CKD and 
diabetes. Patients with acute-on-chronic 
disease frequently developed ESRD, making 
nephrological follow-up imperative. The 
majority of patients were classified as 
MAKE at 1 year. MAKE was determined 
mainly by its biggest component, mortality. 
CKD as well as timing and modality of 
RRT were not associated with MAKE.
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Table S1.
Cox proportional hazard model.
GFR | Glomerular Filtration Rate,  
MICU | Medical ICU, RRT | Renal Replacement 
Therapy, CRRT | Continuous Renal 
Replacement Therapy 
 
* at initiation of RRT 
** KDIGO stage ≥3
MORTALITY
VARIABLES HAZARD 
RATIO
95% 
CONFIDENCE 
INTERVAL
P
AGE 1.021 1.011, 1.030 <0.001
GENDER 1.016 0.819, 1.261 0.885
GFR BASELINE 0.998 0.992, 1.005 0.573
ADMISSION TO MICU 1.520 1.232, 1.875 <0.001
VENTILATION* 0.928 0.646, 1.334 0.687
VASOPRESSOR USE* 1.351 1.065, 1.713 0.013
SERUM CREATININE* 0.789 0.712, 0.875 <0.001
SERUM UREA* 0.993 0.962, 1.024 0.650
SERUM HEMOGLOBIN 1.002 1.000,1.004 0.112
BLOOD PLATELETS* 0.998 0.997,0.999 <0.001
SERUM SODIUM* 1.036 1.016,1.057 <0.001
SERUM POTASSIUM* 1.003 0.999,1.008 0.158
SERUM CHLORIDE* 0.992 0.981,1.002 0.129
BASE EXCESS* 0.977 0.957,0.997 0.022
CRRT AS INITIAL RRT MODALITY 1.570 1.202,2.050 0.001
LATE INITIATION OF RRT** 1.279 0.943,1.734 0.114
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Table S2.
Multivariate regression 
analysis: MAKE at 1 year.
GFR | Glomerular Filtration Rate,  
MICU | Medical ICU, RRT | Renal Replacement 
Therapy, CRRT | Continuous Renal 
Replacement Therapy 
 
Model MAKE 1 year: Goodness of fit (Hosmer 
and Lemeshow) Chi2 = 4.347, df=8, P= 0.825. 
Overall percentage correctly predicted = 
83.3%. 
 
* at initiation of RRT 
** KDIGO stage ≥3
MAKE 1 YEAR
VARIABLES ODDS RATIO 95% 
CONFIDENCE 
INTERVAL
P
AGE 1.029 1.003,1.056 0.027
GENDER 1.205 0.679,2.136 0.524
GFR BASELINE 1.005 0.987, 1.024 0.568
ADMISSION TO MICU 1.987 1.056,3.737 0.033
VENTILATION* 0.526 0.253,1.096 0.860
VASOPRESSOR USE* 1.087 0.599,1.974 0.783
OLIGURIA* 0.958 0.537,1.708 0.884
DIURETICS* 1.274 0.713,2.277 0.414
SERUM CREATININE* 0.923 0.751, 1.133 0.444
SERUM UREA* 0.919 0.641,1.318 0.647
SERUM HEMOGLOBIN 1.045 0.881,1.240 0.612
BLOOD PLATELETS* 1.000 0.997,1.002 0.687
SERUM SODIUM* 1.020 0.967,1.077 0.464
SERUM POTASSIUM* 0.962 0.698,1.325 0.812
SERUM CHLORIDE* 1.003 0.974,1.033 0.825
PH* 1.000 0.994,1.006 0.965
LACTATE* 1.000 1.000,1.000 0.198
BASE EXCESS* 1.016 0.958,1.078 0.593
CRRT AS INITIAL RRT MODALITY* 0.829 0.303,2.264 0.714
LATE INITIATION OF RRT** 0.763 0.348,1.674 0.500
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INTRODUCTION
AKI is a common complication in ICU 
patients and associated with increased 
morbidity and mortality. We compared 
long-term outcome and quality of life 
(QOL) in ICU patients with AKI treated with 
RRT with matched non AKI-RRT patients.
METHODS
During 1 year adult ICU patients consec-
utively were included in a prospective 
cohort study. AKI-RRT patients alive at 
1 year and 4 years were matched with 
non AKI-RRT survivors from the same 
cohort in a 1:2 (1 year) and 1:1 (4 years) 
ratio on gender, age, APACHE II score, and 
admission category. QOL was assessed by 
the EuroQoL-5D and the Short Form-36 
survey before ICU admission and at 3 
months, 1 and 4 years after ICU discharge.
RESULTS
Of 1953 patients, 121 (6.2%) had AKI-RRT. 
AKI-RRT hospital survivors (44.6%; N=54) 
had a 1-year and 4-year survival rate 
of 87.0% (N=47) and 64.8% (N=35) re-
spectively. Forty-seven 1-year AKI-RRT 
patients were matched with 94 1-year non 
AKI-RRT patients.  Of 35 4-years survivors 
3 refused further cooperation, 3 were 
lost-to-follow-up, and 1 had no control. 
Finally, 28 4-years AKI-RRT patients were 
matched with 28 non AKI-RRT patients. 
During ICU stay, 1-year and 4-years AKI-RRT 
patients had more organ dysfunction 
compared to their respective matches 
(SOFA scores 7 vs. 5, P<0.001; 7 vs. 4, 
P<0.001). Long-term QOL was, however, 
comparable between both groups but 
lower than in the general population. QOL 
decreased at 3 months, improved after 1 
and 4 years but remained under baseline 
level. Respectively 1 and 4 years after ICU 
discharge, 19.1% and 28.6% of AKI-RRT 
survivors remained RRT dependent, and 
81.8% and 71% of them were willing to 
undergo ICU admission again if needed.
CONCLUSION
In long-term critically ill AKI-RRT survivors, 
QOL was comparable to matched long-term 
critically ill non AKI-RRT survivors, but 
lower than in the general population. The 
majority of AKI-RRT patients wanted to 
be readmitted to the ICU when needed, 
despite a higher severity of illness 
compared to matched non AKI-RRT 
patients, and despite the fact that one 
quarter had persistent dialysis dependency. 
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1. Introduction
Acute kidney injury treated with renal 
replacement therapy (AKI-RRT) affects 
approximately 5-10% of ICU patients [1]. 
These patients are amongst the most 
severely ill patients in the ICU, as may be 
illustrated by the 50% in-hospital mortality 
[2,4]. AKI-RRT patients who survive may 
develop chronic kidney disease, including 
end stage renal disease, and experi-
ence decreased long-term survival [4-8]. 
Therefore, to fully appreciate outcomes 
of critically ill AKI-RRT survivors, indices 
regarding long-term morbidity and QOL 
should also be taken into account [9,10].
Major reductions in long-term QOL in crit-
ically ill patients are seen in severe acute 
respiratory distress syndrome, prolonged 
mechanical ventilation, severe sepsis, and 
after major trauma, all conditions frequently 
associated with AKI-RRT [11]. Data regarding 
QOL in AKI-RRT patients show that these 
patients have a decreased QOL compared 
to the general population but perceive 
QOL as good [12, 13]. However, these studies 
were either retrospective [14-17], evaluated 
QOL after a short term [12-15, 17-21], lacked 
baseline QOL assessment [12-15, 18,22], or 
dated back more than a decade [14-16, 18,23]. 
It is also unclear whether impairment 
in long-term QOL is the consequences 
of critical illness, AKI-RRT, pre-existing 
co-morbidities, or a combination of these.
The aim of the present study was to 
assess long-term outcomes and QOL of 
critically ill AKI-RRT patients at baseline, 
and at 3 months, 1 year and 4 years after 
ICU discharge and to compare QOL with a 
cohort of matched non AKI-RRT patients [24]. 
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Long-term critically ill 
AKI-RRT survivors have 
comparable quality of  
life to matched long-term 
critically ill survivors 
without RRT. In case of 
deterioration, majority 
of the patients prefer to 
be readmitted to the ICU 
department. 
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2. Methods
2.1 DESIGN, PATIENTS,  
 AND SETTING
The cohort described in this study is a 
subgroup of a prospective observational 
cohort. During one year (March 2008 to 
March 2009), all consecutively admitted 
adult patients at the 14-bed medical (MICU), 
the 22-bed surgical ICU (SICU), and the 
6-bed burn unit of the Ghent University 
Hospital, Belgium, were screened to study 
QOL and cost-effectiveness of intensive 
care [25]. Exclusion criteria were age < 16 
y and admission to the ICU after cardiac 
surgery. In case of multiple ICU admis-
sions, only the first was considered.
In this study, only AKI-RRT patients of 
the larger cohort were included. Chronic 
hemodialysis patients were excluded. 
The attending critical care physician 
and consulting nephrologist assessed 
indication for RRT and modality.
To study the impact of RRT on long-term 
outcome and QOL, we performed a 
matched cohort study, according to the 
STROBE guidelines [26]. Included AKI-RRT 
patients alive at 1 year after hospital 
discharge were defined as exposed patients 
and individually matched with 1-year non 
AKI-RRT survivors (defined as non-exposed 
patients) from the same cohort. Being a 
patient in the non AKI-RRT group did not 
imply normal kidney function: it implied 
no treatment with RRT. To correct for 
possible bias, we excluded patients who 
needed RRT but who did not receive RRT 
due to therapeutic restrictions. Equally, 
AKI-RRT patients alive at time of this 
study (average 4 years later) were individ-
ually matched with 4-years non AKI-RRT 
survivors. The exposed to nonexposed 
ratio was aimed at 1:2 to reduce risk of 
selection bias. When there were more than 
2 nonexposed patients for an exposed 
patient, only the nonexposed patient with 
the best overall match was selected. If an 
exposed patient could only be properly 
matched to 1 nonexposed patient, we 
accepted matching in a 1:1 ratio for the 
respective cohort in order to avoid an 
imbalance of characteristics and to retain 
the best possible matching. Matching was 
based on gender, age (±5 years), APACHE 
II score (± 5), and admission category.
2.2 DATA COLLECTION  
 AND DEFINITIONS
Variables collected within the first 24 hours 
of ICU admission included age, gender, body 
mass index, personal, proxy, and family 
practitioner contact data, living situation, 
activity of daily living, co-morbidity as 
measured by the Charlson co-morbid-
ity index [27], hospitalization in the last 
6 months, main reason for ICU admission, 
APACHE II score [28], SOFA score [29], need 
for mechanical ventilation, use of any vaso-
pressors, and need for RRT. During ICU stay 
SOFA scores, need for mechanical ventila-
tion, vasopressors, RRT, and do-not-resus-
citate codes were collected on a daily base. 
ICU length of stay (LOS), hospital LOS, vital 
status at ICU and hospital discharge, and at 
3 months, 1 year and 4 years following ICU 
discharge were collected for each patient.
Values of serum creatinine of AKI-RRT 
patients were extracted from the STARRT 
database, which includes all relevant 
renal and RRT data of ICU patients with 
AKI–RRT treated in our hospital, and 
from laboratory data in control patients. 
The eGFR was calculated using the 
Chronic Kidney Disease Epidemiology 
Collaboration formula [30]. Renal recovery 
was defined as independence from RRT.
The study was approved by the local ethical 
committee (B67020072805), and conducted 
in accordance with the declaration of 
Helsinki. A signed informed consent was 
obtained from every included patient.
2.3 QUALITY OF LIFE
QOL was assessed by means of the 
Medical Outcomes Study 36-item Short 
Form Health Survey (SF-36v2®) and the 
EuroQoL-5D (EQ-5D). The SF-36 ques-
tionnaire contains 36 items measuring 8 
health domains: physical- (PF), and social 
functioning (SF), role limitations due to 
physical- (RP), or emotional problems 
(RE), mental health (MH), vitality (VT), 
bodily pain (BP), and general perception 
of health (GH) [31]. Two component scores, 
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a physical (PCS) and a mental (MCS), are 
calculated summary scores where re-
spectively the physical domains (PF, RP, 
BP, GH) or the mental domains (VT, SF, 
RE, MH) will account more in the score. 
We assessed SF-36 as norm-based scores 
to be able to compare them directly with 
the general healthy population, with a 
group-level range of 47-53 considered as 
average or normal [31]. Group scores less 
than 47 indicate impaired functioning within 
that health domain; group scores greater 
than or equal to 53 should be considered 
average or above the normative sample.
The 36th item, health transition, provides 
information about perceived changes 
in health status. The validity and relia-
bility of the SF-36 has been confirmed 
in critically ill patients, and its use is 
validated in face-to-face interviews, 
interview by phone or by sending the 
questionnaire by regular mail [32].
The EQ-5D is a generic QOL questionnaire 
that measures health in five dimensions: 
mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression [33]. Each 
dimension has three levels: no problems, 
moderate problems or severe problems. 
On a visual analogue scale (VAS), patients 
can rate their perceived overall health 
between 0 and 100. The EQ-5D is suitable 
for measuring QOL in critical care [34, 35].
QOL was assessed at different time points: 
baseline QOL and at strictly 3 months 
and 1 year after ICU discharge. QOL was 
also assessed in August 2013, a median of 
4.1 years (3.9 years – 4.3 years) after ICU 
discharge. Following ICU admission and 
study inclusion, a face-to-face interview 
to assess baseline QOL (defined as QOL 2 
weeks before ICU admission) was done as 
soon as possible. This interview was prefer-
ably taken from the patient, or when impos-
sible, from the proxy. Three months, 1 year, 
and 4 years after ICU discharge, patients 
were sent the EQ-5D and SF-36 surveys 
by regular mail; at 1 and 4 years, questions 
concerning living situation, memories, 
sleep quality, and willingness to be read-
mitted to an ICU department, were added. 
If the questionnaires were not returned 
within one month, patients or relatives 
were contacted by phone to assess QOL 
after 1 year and after 4 years. Eventually, 
the family practitioner was contacted.
2.4 STATISTICAL ANALYSIS
Data are expressed as median (interquartile 
range) (IQR) for continuous variables and as 
number (%) for categorical variables. QOL 
at the different time points and character-
istics between both groups (AKI-RRT versus 
non AKI-RRT patients) were compared 
by the Mann-Whitney U test for continu-
ous variables and by the Chi-square test 
for categorical variables. For long-term 
analysis of QOL, differences between QOL 
at baseline (only hospital survivors), at 3 
months, at 1 and 4 years after ICU discharge 
were assessed by Chi-square (EQ-5D) 
or Friedman test (SF-36). P-values were 
two-sided and statistical significance was 
set at 0.05. All statistical analyses were 
done using IBM SPSS Statistics software 
version 21 (IBM, Armonk, New york, USA).. 
3. Results
3.1 CHARACTERISTICS OF  
 THE STUDY POPULATION
During the 1-year study period 1953 patients 
were included (Fig. 1.). One hundred for-
ty-seven patients (7.5%) developed AKI with 
need for RRT. Of these, 121 patients (6.2%) 
received RRT. ICU (46.3%), hospital (55.4%), 
3 months (57.9%), 1-year (61.1%) and 4-years 
(71.1%) mortality rates in these patients were 
high. Twenty-six AKI patients (1.3%) did not 
receive RRT due to therapeutic restrictions 
and were excluded for further analysis.
AKI-RRT hospital survivors (44.6%) had a 
1-year and 4-years survival rate of 87.0% 
and 64.8% respectively. Forty-seven 1-year 
AKI-RRT survivors were individually matched 
with 94 1-year non AKI-RRT survivors (two 
matches for all AKI-RRT patients). Of 35 
4-years survivors 3 refused further cooper-
ation, 3 were lost-to-follow-up, and 1 had 
a double match. In 13 of the 28 included 
4-years AKI-RRT survivors only one good 
match could be withhold, so matching 
occurred in a 1:1 ratio. Finally, 28 4-years 
AKI-RRT survivors were individually matched 
with 28 non AKI-RRT patients. AKI-RRT and 
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AKI patients 
with need 
for RRT 
N=147 (7.5%)
Patients 
screened
N=1953
ICU survivors
N=65 (53.7%)
Hospital 
survivors
N=54 (44.6%)
3-month 
survivors
N=51 (42.1%)
4-years 
AKI-RRT 
survivors
N=35 (28.9%)
ICU survivors
N=5 (19.2%)
Hospital 
survivors
N=2 (7.7%)
1- year survivors
without need 
for RRT
N=1347
4-years survivors
without need 
for RRT  
N=1125
AKI patients  
not receiving 
RRT due to 
therapeutic  
restrictions
N=26
Patients 
without
need for RRT
N=1806 (92.5%)
AKI 
patients 
receiving 
RRT
N=121
1-year 
AKI-RRT 
PATIENTS
N=47 (38.8%)
4-years 
AKI-RRT 
PATIENTS
N=28 (23.1%)
1-year 
matched 
non AKI-RRT 
patients 
N=94
4-years 
matched 
non AKI-RRT 
patients
N=28
77 died
14 died
5 died
4 died
12 died
3 lost  
to follow-up
3 refusal
1 no control
Fig. 1.
Patient cohort.
N | number, AKI | acute  
kidney injury, RRT | renal  
replacement therapy,  
ICU | intensive care unit
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non AKI-RRT patients had similar gender, 
age, APACHE II score, and admission 
category at 1 year and 4 years (Table 1).
During ICU stay, 1-year and 4-years 
AKI-RRT patients had higher SOFA scores 
compared to their respective matches, 
and more needed mechanical ventilation 
or vasopressors for a longer time (Table 1).
3.2 RENAL CHARACTERISTICS  
 AND RENAL OUTCOMES 
One year AKI-RRT patients had higher 
baseline serum creatinine concentra-
tions and lower eGFR compared to their 
matches. These measurements did not 
significantly differ between 4-years 
AKI-RRT and non AKI-RRT patients (Table 1).
Respectively 12 1-year (25.5%) and 10 
4-years AKI-RRT patients (35.7%) were 
RRT dependent at hospital discharge. 
Nine (19.1%) of the 1-year and 8 (28.6%) 
of the 4-years AKI-RRT patients 
remained RRT dependent over time.
3.3 QUALITY OF LIFE
An overview of the persons who rated 
QOL, how QOL was assessed and the 
number of completed QOL surveys is given 
in Table 2. Most patients rated their own 
QOL at the different time points, except 
at baseline in 1-year AKI-RRT patients.
Significant differences in QOL between 
AKI-RRT and non AKI-RRT survivors at each 
different time point were small. Figure 2 
and Figure 3 show that the 1-year AKI-RRT 
versus (vs) 1-year non AKI-RRT patients 
had comparable baseline QOL. The 1-year 
AKI-RRT patients were poorer emotionally 
at 3-months (RE 28.7 vs 38.4; P=0.035), 
but had a better mental score (MCS 53.3 
vs 47.8; P=0.039) and less bodily pain (BP 
46.5 vs 41.6; P=0.041) at 1 year (Fig. 3). Figure 
4 and 5 show that the 4-years AKI-RRT vs 
4-years non AKI-RRT patients were emo-
tionally better at baseline (RE 55.9 vs 40.3; 
P=0.030) (Fig. 5.), but had more problems 
with usual activities (81.0% vs 47.8%; 
P=0.023), pain (71.4% vs 26.1%; P=0.003) 
and anxiety (61.9% vs 17.4%; P=0.002) at 
3 months (Fig. 4.). QOL after 1 and 4 years 
showed no differences (Fig. 4. and Fig. 5.).
Comparing QOL within each group between 
the different time points revealed that QOL 
particularly decreased after 3 months.
3.4 EVOLUTION IN QOL OVER  
 TIME: 1 YEAR-COHORT 
All 1-year AKI-RRT patients reported more 
problems on the EQ-5D after 3 months 
compared to baseline. After 1 year, they 
experienced fewer problems but still more 
than before ICU admission. The EQ-5D 
showed the same evolution for 1-year non 
AKI-RRT patients (Supplemental File (AF)-Fig. 1A/1B).
The SF-36 showed significant evolutions in 
QOL over time for 1-year AKI-RRT patients in 
nearly all dimensions. QOL decreased after 
3 months, improved after 1 year but without 
return to the baseline level. QOL also 
remained under the level of the average 
population. The same pattern, although 
less pronounced, was seen in 1-year non 
AKI-RRT patients (Supplemental File-Fig. 2A/2B).
For 1-year AKI-RRT patients median VAS 
scores ranged from 70 (baseline), to 60 
(3 months) and 70 (1 year) (P=0.048). 
In non AKI-RRT patients the VAS 
remained the same, respectively 68, 
65 and 65 at baseline, 3 months and 1 
year after ICU discharge (P=0.917).
3.5 EVOLUTION IN QOL OVER 
 TIME: 4 YEARS-COHORT
Changes in QOL over time assessed by 
the EQ-5D were significant in AKI-RRT 
patients for mobility (P=0.040), usual 
activities (P<0.001), and anxiety (P=0.040) 
(Supplemental File-Fig. 1C) and in 4-years non 
AKI-RRT patients for mobility (P=0.017), 
and usual activities (P=0.014) with 
most problems at 3 months after ICU 
discharge followed by an improvement 
in QOL after 1 year (Supplemental File-Fig. 1D). 
QOL never returned to baseline level.
The SF-36 showed that in both groups, 
QOL decreased after 3 months compared 
to baseline (Supplemental File-Fig. 2C/2D). For 
the 4-years AKI-RRT patients, QOL 
improved after 1 year, especially in the 
mental domains. At 4 years, QOL sig-
nificantly decreased mainly physically 
but improved or remained the same in 
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1-YEAR  
AKI-RRT PAT. 
(N=47)
1-YEAR NON 
AKI-RRT PAT. 
(N=94)
P 4-YEAR  
AKI-RRT PAT. 
(N=28)
4-YEAR NON 
AKI-RRT PAT. 
(N=28)
P
AGE, YRS (median, IQR) 57 (45-69) 57 (48-70) 0.897 54 (45-66) 53 (45-68) 0.718
MALE GENDER, N (%) 31 (66.0) 62 (66.0) 0.999 16 (57.1) 16 (57.1) 0.999
BMI, KG/M2 (median, IQR) 26.2 (22.8-29.7) 25.9 (22.0-29.4) 0.444 27.3 (22.9-31.6) 24.5 (22.9-27.8) 0.092
SERUM CREATININE 
BASELINE (mg/dL, median, IQR)*
1.14 (0.94-1.51) 0.82 (0.66-1.04) 0.001 0.97 (0.80-1.26) 0.78 (0.65-1.11) 0.062
EGFR BASELINE  
(mL/min per 1.73 m², median, IQR)*
86 (71-100) 100 (83-116) 0.007 99 (85-109) 102 (87-116) 0.629
LIVES AT HOME BEFORE 
ADMISSION, N (%)
45 (95.7) 90 (95.75) 0.999  26 (92.9) 27 (96.4) 0.553
ADL, N (%)
No limitations 25 (53.2) 47 (50.0) 0.721 18 (63.4) 21 (75.0) 0.383
Moderate limitations 19 (40.4) 42 (44.7) 0.631 7 (25.0) 7 (25.0) 0.999
Chair-bound 0 (0) 3 (3.2) 0.216 0 (0) 0 (0) NA
Bedridden 3 (6.4) 2 (2.1) 0.198 3 (10.7) 0 (0) <0.001
HOSPITALIZATION IN LAST  
6 MONTHS BEFORE ICU, N (%)
20 (42.6) 46 (48.9) 0.474 10 (35.7) 14 (50.0) 0.280
CHARLSON COMORBIDITY 
INDEX (median, IQR)
1 (0-3) 2 (0-3) 0.115 0 (0-2) 2 (0-3) 0.110
TYPE OF ADMISSION, N (%)
MEDICAL 32 (68.1) 67 (71.3) 0.696 18 (64.3) 18 (64.3) 0.999
SCHEDULED SURGERY 1 (2.1) 4 (4.3) 0.519 0 (0) 4 (14.3) 0.038
EMERGENCY SURGERY 10 (21.3) 18 (19.1) 0.765 7 (25.0) 3 (10.7) 0.163
TRAUMA 3 (6.4) 4 (4.3) 0.376 2 (7.1) 2 (7.1) 0.999
BURNS 1 (2.1) 1 (1.1) 0.614 1 (3.6) 1 (3.6) 0.999
SEVERITY OF ILLNESS AT ICU ADMISSION (FIRST 24 HOURS)
APACHE II SCORE (median, IQR) 26 (21-31) 24 (20-30) 0.251 23 (20-28) 22 (18-25) 0.362
SOFA SCORE (median, IQR) 9 (5-11) 7 (5-10) 0.047 7 (4-12) 6 (4-9) 0.139
MECHANICAL VENTILATION, N (%) 29 (61.7) 49 (52.1) 0.281 21 (75.0) 13 (46.4) 0.029
VASOPRESSORS, N (%) 21 (44.7) 37 (39.4) 0.545 11 (39.3) 9 (32.1) 0.577
RRT, N (%) 11 (23.4) 0 (0) <0.001 6 (21.4) 0 (0) 0.010
ORGAN FAILURE DURING ICU STAY
MECHANICAL VENTILATION, N (%) 39 (83.0) 50 (53.2) <0.001 24 (85.7) 13 (46.4) 0.002
LENGTH OF MECHANICAL 
VENTILATION, DAYS 
(median, IQR)
16 (3-27) 1 (0-3) <0.001 18 (4-31) 0 (0-7) <0.001
VASOPRESSORS, N (%) 36 (76.6) 42 (44.7) <0.001 21 (75.0) 10 (35.7) 0.003
LENGTH OF VASOPRESSOR 
THERAPY, DAYS (median, IQR)
5 (1-8) 0 (0-3) <0.001 3 (0-10) 0 (0-3) 0.002
RRT, N (%) 47 (100) 0 (0) <0.001 28 (100.0) 0 (0) <0.001
MEAN SOFA SCORE (median, IQR) 7 (6-9) 5 (4-7) <0.001 7 (5-10) 4 (4-7) <0.001
Table 1.
Patient characteristics at ICU admission, organ 
failure during ICU admission, and outcomes.
AKI | acute kidney injury, RRT | renal replacement therapy, yrs | years, IQR 
| interquartile range (25%-75%), N | number, BMI | body mass index, eGFR | 
estimated glomerular filtration rate, ICU | intensive care unit, ADL | activity 
of daily living, NA | not applicable, ICU | intensive care unit, APACHE | Acute 
Physiology and Chronic Health Evaluation, SOFA | Sequential Organ Failure 
Assessment, LOS | length of stay, DNR | do-not-resuscitate, NA | not applicable 
 
* Serum creatinine at baseline was defined as serum creatinine 6 months 
before ICU admission. Values were missing in 27 of the 1-year AKI-
RRT patients, in 14 of the 94 1-year non AKI-RRT patients, in 21 of the 
4-years AKI-RRT patients, and in 4 the 4-years non AKI-RRT patients
1-YEAR  
AKI-RRT PAT. 
(N=47)
1-YEAR NON 
AKI-RRT PAT. 
(N=94)
P 4-YEAR  
AKI-RRT PAT. 
(N=28)
4-YEAR NON 
AKI-RRT PAT. 
(N=28)
P
OUTCOMES
ICU LOS, DAYS (median, IQR) 22 (11-42) 5 (3-9) <0.001 24 (13-49) 7 (3-10) <0.001
READMISSIONS, N (%) 8 (17.0) 12 (12.8) 0.495 3 (10.7) 4 (14.3) 0.686
HOSPITAL LOS, DAYS (median, IQR) 70 (30-100) 21 (13-44) <0.001 62 (20-130) 19 (10-46) 0.003
DNR DECISIONS, N (%) 4 (8.5) 3 (3.2) 0.170 2 (7.1) 1 (3.6) 0.312
LONG-TERM MORTALITY, N (%) 12 (25.5) 20 (21.3) 0.570 NA NA NA
NEED FOR RRT AT HOSPITAL 
DISCHARGE, N (%)
12 (25.5) NA NA 10 (35.7) NA NA
NEED FOR RRT  
AT 3 MONTHS, N (%)
9 (19.1) NA NA 8 (28.6) NA NA
NEED FOR RRT  
AT 1 YEAR, N (%)
9 (19.1) NA NA 8 (28.6) NA NA
NEED FOR RRT  
AT 4 YEARS, N (%)
NA NA NA 8 (28.6) NA NA
LIVING SITUATION 
AFTER 1 YEAR, N (%) 46 answers 93 answers 27 answers 26 answers
Independent without 
additional help
25 (54.3) 47 (50.5) 0.672 16 (59.3) 14 (53.8) 0.691
Independent with some help 12 (26.1) 22 (23.7) 0.754 6 (22.2) 6 (23.1) 0.941
Together with relatives 
(others than spouse)
6 (13.0) 14 (15.1) 0.751 3 (11.1) 4 (15.4) 0.646
Special care facility 3 (6.5) 5 (5.4) 0.786 2 (7.4) 1 (3.8) 0.575
Other 0 (0) 5 (5.4) 0.109 0 (0) 1 (3.8) 0.304
LIVING SITUATION 
AFTER 4 YEARS, N (%) NA NA NA 27 answers 26 answers
Independent without 
additional help
NA NA NA 18 (66.7) 14 (53.8) 0.340
Independent with some help NA NA NA 5 (18.5) 6 (23.1) 0.682
Together with relatives 
(others than spouse)
NA NA NA 2 (7.4) 5 (19.2) 0.204
Special care facility NA NA NA 2 (7.4) 1 (3.8) 0.575
Other NA NA NA 0 (0) 0 (0) 0.999
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Fig. 2.
EQ-5D assessments in the 1-year cohort: Percentages 
of patients with some or severe problems per 
dimension at the 3 different time points. 
The X-axis represents the different dimensions of the EQ-5D. 
The Y-axis represents the percentages (%) of patients with 
some or severe problems in a respective dimension. 
Only significant P-values (Chi-Square test) are 
shown above the respective dimensions.
QOL | quality of life, AKI | acute kidney injury, RRT | renal replacement therapy
Fig. 3.
SF-36 assessments in the 1-year cohort: Norm-based  
median scores per domain at the 3 different time points. 
The X-axis represents the different domains of the SF-36. The Y-axis represents the 
norm-based median scores in a respective domain of the SF-36. A norm-based median 
score between 47-53 in a group of patients is considered as normal or average. Norm-
based median scores below 47 indicate impaired functioning or below average; norm-
based median scores above 53 indicate better functioning or above average. 
Only significant P-values (Mann-Whitney U analysis) are shown above the respective domains. 
QOL | quality of life, AKI | acute kidney injury, RRT | renal replacement therapy,  
PCS | physical component score, MCS | mental component score, PF | physical  
functioning, RP | role physical, BP | bodily pain, GH | general health, VT | vitality, 
SF | social functioning, RE | role emotional, MH | mental health
    47 1-year AKI-RRT patients
    94 1-year non AKI-RRT patients
    47 1-year AKI-RRT patients
    94 1-year non AKI-RRT patients
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Fig. 4.
EQ-5D assessments in the 4-years cohort: Percentages 
of patients with some or severe problems per 
dimension at the 4 different time points.
The X-axis represents the different dimensions of the EQ-5D. 
The Y-axis represents the percentages (%) of patients with 
some or severe problems in a respective dimension. 
Only significant P-values (Chi Square test) are 
shown above the respective dimensions.
QOL | quality of life, AKI | acute kidney injury, RRT | renal replacement therapy
Fig. 5.
SF-36 assessments in the 4-years cohort: Norm-based 
median scores per domain at the 4 different time points.
The Y-axis represents the norm-based median scores in a respective domain 
of the SF-36. A norm-based median score between 47-53 in a group of 
patients is considered as normal or average. Norm-based median scores 
below 47 indicate impaired functioning or below average; norm-based 
median scores above 53 indicate better functioning or above average. 
Only significant P-values (Mann-Whitney U analysis) 
are shown above the respective domains. 
QOL | quality of life, AKI | acute kidney injury, RRT | renal replacement therapy,  
PCS | physical component score, MCS | mental component score, PF | physical  
functioning, RP | role physical, BP | bodily pain, GH | general health, VT | 
vitality, SF | social functioning, RE | role emotional, MH | mental health
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Table 2.
Persons who rated QOL, assessment of 
QOL, number of completed QOL surveys.
QOL | quality of life, N | number, AKI | acute kidney injury,  
RRT | renal replacement therapy  
 
* All QOL surveys completed by face-to-face interviews 
** All QOL surveys completed by regular mail 
*** 46 QOL surveys completed; 32 by regular mail (69.6%)  
 and 14 by phone interview (30.4%) 
**** 94 QOL surveys completed; 67 by regular mail (71.3%)  
 and 27 by phone interview (28.7%)  
a 27 QOL surveys completed; 18 by regular mail (66.7%)  
 and 9 by phone interview (33.3% 
b 26 QOL surveys completed; 19 by regular mail (73.1%)  
 and 7 by phone interview (26.9%) 
c 28 QOL surveys completed; 14 by regular mail (50.0%)  
 and 14 by phone interview (50.0%) 
d 28 QOL surveys completed; 20 by regular mail (71.4%)  
 and 8 by phone interview (28.6%)
AKI-
RRT
NON 
AKI-
RRT
P AKI-
RRT
NON 
AKI-
RRT
P AKI-
RRT
NON 
AKI-
RRT
P AKI-
RRT
NON 
AKI-
RRT
P
1-YEAR SURVIVORS BASELINE 3 MONTHS 1 YEAR
N=47 * N=94 * N=34 ** N=71 ** N=46 *** N=94 ****
PATIENT, N (%) 14 (29.8) 57 (60.6) 0.001 25 (73.5) 57 (80.3) 0.434 33 (71.7) 65 (69.1) 0.753
PARTNER, N (%) 15 (31.9) 17 (18.1) 0.065 2 (5.9) 7 (9.9) 0.496 7 (15.2) 13 (13.8) 0.826
SON/DAUGHTER, N (%) 8 (17.0) 9 (9.6) 0.200 3 (8.8) 4 (5.6) 0.540 1  (2.2) 8 (8.5) 0.151
OTHER FAMILY, N (%) 4 (8.5) 5 (5.3) 0.465 0 (0) 0 (0) 0.999 1  (2.2) 2 (2.1) 0.986
OTHERS, N (%) 6 (12.8) 6 (6.4) 0.200 4 (11.8) 4 (11.8) 0.268 4 (8.7) 6 (6.4) 0.618
4-YEARS SURVIVORS BASELINE 3 MONTHS 1 YEAR 4 YEARS
N=28 * N=27 * N=21 ** N=23 ** N=27 a N=26 b N=28 c N=28 d
PATIENT, N (%) 8 (28.6) 18 (66.7) 0.005 17 (81.0) 17 (73.9) 0.578 22 (81.5) 22 (84.6) 0.761 24 (85.7) 21 (77.8) 0.313
PARTNER, N (%) 7 (25.0) 4 (14.8) 0.345 1 (4.8) 3 (13.0) 0.340 3 (11.1) 3 (11.5) 0.961 1 (3.6) 2 (7.4) 0.553
SON/DAUGHTER, N (%) 6 (21.4) 2 (7.4) 0.140 2 (9.5) 1 (4.3) 0.496 1 (3.7) 0 (0) 0.322 0 (0) 2 (7.4) 0.150
OTHER FAMILY, N (%) 3 (10.7) 3 (11.1) 0.962 0 (0) 1 (4.3) 0.334 0 (0) 0 (0) 0.999 0 (0) 2 (7.4) 0.150
OTHERS, N (%) 4 (14.3) 0 (0) 0.041 1 (4.8) 1 (4.3) 0.947 1 (3.7) 1 (3.4) 0.978 3 (10.7) 1 (3.7) 0.299
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the mental components (Additional File-Fig. 
2C). Changes in long-term QOL in the 
4-years non AKI-RRT patients were less 
pronounced (Supplemental File-Fig. 2D).
The 4-years AKI-RRT patients showed a 
decrease in VAS after 3 months (63), and 
improvements after 1 (70) and 4 years 
(68) but without regain of the baseline 
level (70) (P=0.044). The 4-years non 
AKI-RRT patients had the same evolution 
but without significance (P=0.327).
Supplemental file 3 and additional files 
4 illustrate in more detail the variabil-
ity in EQ-5D and SF-36 over time.
Overall, long-term QOL remained 
under the baseline level for AKI-RRT 
and non AKI-RRT patients, and under 
the QOL of the average population.
3.6 ADDITIONAL QUESTIONS  
 AFTER 1 YEAR AND 4 YEARS
One and 4 years after ICU discharge, most 
survivors lived independently, and only a 
minority stayed in a special care facility 
(Table 1). There were no major sleeping 
problems. One year and 4 years after ICU 
discharge, AKI-RRT patients had more bad 
memories than non AKI-RRT patients (17.4% 
vs 4.3%, P=0.010; 21.4% vs 3.8%, P=0.055). 
81.8% of the 1-year AKI-RRT patients 
preferred to be readmitted to an ICU de-
partment in case of deterioration versus 
83.0% of their 1-year matches (P=0.867). 
This number decreased to 71.4% for the 
4-years AKI-RRT patients versus 84.6% for 
the 4-years non AKI-RRT patients (P=0.244). 
4. Discussion
In this prospective single center matched 
cohort study concerning long-term 
outcomes and QOL of AKI-RRT patients, we 
found high mortality rates and lower QOL 
levels compared to the general population.
Similar to others, we found high hospital 
mortality (55%) in this cohort of crit-
ically ill AKI-RRT patients, with only 
moderate increase of mortality at longer 
follow-up (58% at 3 months, 61% at 1 
year, 71% at 4 years) [4, 14, 15, 20, 36].
At hospital discharge and at long-term, 
a quarter of AKI-RRT hospital survivors 
were RRT dependent. These findings are 
similar to those reported in literature [37].
Long-term survival data would be meaning-
less without considering QOL. Remarkably, 
there was no difference in QOL at different 
time points between AKI-RRT patients and 
matched non AKI-RRT patients, although 
changes in QOL over time were less pro-
nounced in the latter group. QOL decreased 
3 months after ICU discharge compared to 
baseline, improved after 1 year, and stayed 
the same or improved slightly after 4 years, 
but still remained under baseline level.
The fact that long-term QOL had the 
same evolution over time in AKI-RRT and 
non AKI-RRT patients was quite surprising 
suggesting that the AKI-RRT component 
during critical illness did not have an 
important impact on long-term QOL. 
Others reported very similar findings, 
however, these studies reported only on 
QOL after 6 months, and in 1 study not 
all AKI patients received RRT, and some 
patients received RRT without AKI [20, 21].
The fact that AKI-RRT patients were more 
severely ill during their ICU stay compared 
to matched patients had no influence on 
QOL over the years. This is in accordance 
with the findings of Orwelius et al [38]. 
In a multicenter study they found that 
6 months after ICU discharge, perceived 
QOL in sepsis patients did not differ from 
ICU survivors with other diagnoses, even 
though these sepsis patients were more 
severely ill, and had a longer ICU stay. 
Another study by Orwelius suggested that 
long-term QOL was mainly affected by 
co-morbidity [39]. In our study AKI-RRT and 
non AKI-RRT patients had a very compara-
ble co-morbidity and medical history, which 
may explain the comparable long-term 
QOL between groups in our study.
QOL was perceived as acceptable and both 
AKI-RRT and non AKI-RRT patients reported 
low dependence in daily life later on. The 
number of AKI-RRT and non AKI-RRT patients 
who agreed to undergo life-sustaining in-
terventions again in case of deterioration 
remained high. However, QOL was lower 
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N=47 * N=94 * N=34 ** N=71 ** N=46 *** N=94 ****
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N=28 * N=27 * N=21 ** N=23 ** N=27 a N=26 b N=28 c N=28 d
PATIENT, N (%) 8 (28.6) 18 (66.7) 0.005 17 (81.0) 17 (73.9) 0.578 22 (81.5) 22 (84.6) 0.761 24 (85.7) 21 (77.8) 0.313
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compared to that of the average popula-
tion in both groups specifically in the more 
physical domains. This is in accordance 
with the findings of others [12-16, 20, 21].
Our study has several strengths. First, the 
matched cohort design demonstrates the real 
impact of AKI-RRT upon long-term QOL. This 
has not been evaluated thus far. Second, QOL 
was assessed with validated questionnaires 
at baseline, which allows for the only reliable 
evaluation of QOL over time without recall 
or selection bias [11, 40]. Third, the additional 
questions and VAS score allowed evalua-
tion of the patients’ perception of the ICU 
admission and the consequences of severe 
illness. Finally, most studies report QOL in 
AKI survivors as a short-term endpoint, while 
this study provides also data for a longer 
follow-up period. Strict time intervals of 3 
months and 1 year after ICU discharge were 
respected in all patients. For long-term 
assessment of QOL, an arbitrary time point 
was chosen (August 2013) which was between 
47-52 months after ICU discharge for all 
patients. Response rate was very high and 
only 3 patients were lost to-follow-up.
Some limitations should also be mentioned. 
First, single center data from a university 
hospital may not reflect general practice 
and may limit external validity of the data. 
Second, although 1-year and 4-years AKI-RRT 
patients were matched to non AKI-RRT 
patients based on 4 criteria, we cannot 
exclude that matched patients had a different 
profile compared to AKI-RRT patients. Third, 
the study cohort is relatively small and may 
lack of statistical power to detect differ-
ences among the QOL domains in our study 
patients. Fourth, medical decisions leading to 
ICU referral may have selected for patients 
with better prospects. Fifth, long-term QOL 
may also be modified by events happening 
to the patient after hospital discharge. These 
were not recorded in the present study. 
5. Conclusions
We found high mortality rates in AKI-RRT 
patients. However, in long-term critically 
ill AKI-RRT survivors, QOL was comparable 
to matched long-term critically ill survivors 
without AKI-RRT, but lower than in the 
general population. The majority of AKI-RRT 
patients wanted to be readmitted to the ICU 
when needed, despite a higher severity of 
illness compared to matched non AKI-RRT 
patients, and despite the fact that one 
quarter had persistent dialysis dependency.
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Table E1.
Variability of the EQ-5D at 
the different time points: 
Percentages and 95% 
confidence intervals* of patients 
with some or severe problems 
on the respective dimensions.
AKI | acute kidney injury, RRT | renal 
replacement therapy, CI | confidence interval 
 
* The confidence interval was calculated 
 according to DG Altman, D Machin, 
 TN Bryant, M Gardner (2000). Statistics 
 with confidence: Confidence intervals 
 and statistical guidelines. BMJ Books
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BASELINE 3 MONTHS 1 YEAR 4 YEARS P
47 1-YEAR AKI-RRT PATIENTS
% (95% CI)
MOBILITY 39.1 (26.4-53.5) 63.6 (46.6-77.8) 60.9 (46.5-73.6) 0.045
SELF-CARE 23.9 (13.9-37.9) 42.4 (27.2-59.2) 37.0 (24.5-51.4) 0.190
USUSAL ACTIVITIES 37.0 (24.5-51.4) 81.8 (65.6-91.4) 60.9 (46.5-73.6) <0.001
PAIN/DISCOMFORT 45.7 (32.2-59.8) 75.8 (59.0-87.2) 54.3 (40.2-67.8) 0.013
ANXIETY/DEPRESSION 30.4 (19.1-44.8) 60.6 (43.7-75.3) 30.4 (19.1-44.8) 0 (0)
94 1-YEAR NON AKI-RRT PATIENTS
% (95% CI)
MOBILITY 37.2 (28.1-47.3) 54.9 (43.4-66.0) 55.4 (45.3-65.2) 0.021
SELF-CARE 24.5 (16.9-34.0) 40.8 (30.2-52.5) 38.0 (28.8-48.3) 0.050
USUSAL ACTIVITIES 46.8 (37.0-56.8) 81.7 (71.2-89.0) 66.3 (56.2-75.1) <0.001
PAIN/DISCOMFORT 51.1 (41.1-60.9) 70.4 (59.0-79.8) 63.0 (52.8-72.2) 0.035
ANXIETY/DEPRESSION 40.4 (31.1-50.5) 39.4 (28.9-51.1) 41.3 (31.8-51.5) 0.971
28 4-YEARS AKI-RRT PATIENTS
% (95% CI)
MOBILITY 25.9 (13.2-44.7) 61.9 (40.9-79.2) 59.3 (40.7-75.5) 50.0 (32.6-67.4) 0.040
SELF-CARE 14.8 (5.9-32.5) 47.6 (28.3-67.6) 33.3 (18.6-52.2) 25.9 (13.2-44.7) 0.090
USUSAL ACTIVITIES 25.9 (13.2-44.7) 81.0 (60.0-92.3) 55.6 (37.3-72.4) 70.4 (51.5-84.1) <0.001
PAIN/DISCOMFORT 48.1 (30.7-66.0) 71.4 (50.0-86.2) 59.3 (40.7-75.5) 55.6 (37.3-72.4) 0.439
ANXIETY/DEPRESSION 29.6 (15.9-48.5) 61.9 (40.9-79.2) 25.9 (13.2-44.7) 29.6 (15.9-48.5) 0.040
28 4-YEARS NON AKI-RRT PATIENTS
% (95% CI)
MOBILITY 18.5 (8.2-36.7) 39.1 (22.2-59.2) 41.7 (24.5-61.2) 60.7 (42.4-76.4) 0.017
SELF-CARE 11.1 (3.9-28.1) 21.7 (9.7-41.9) 25.0 (12.0-44.9) 28.6 (15.3-47.1) 0.436
USUSAL ACTIVITIES 29.6 (15.9-48.5) 47.8 (29.2-67.0) 70.8 (50.8-85.1) 64.3 (45.8-79.3) 0.014
PAIN/DISCOMFORT 37.0 (21.5-55.8) 26.1 (12.5-46.5) 45.8 (27.9-64.9) 53.6 (35.8-70.5) 0.227
ANXIETY/DEPRESSION 51.9 (34.0-69.3) 17.4 (7.0-37.1) 25.0 (12.0-44.9) 32.1 (17.9-50.7) 0.054
127126
Table E2.
Variability of the SF-36 norm-based scores at the 
different time points: median and interquartile ranges.
AKI | acute kidney injury, RRT | renal replacement therapy, IQR | interquartile range 
(25%-75%), PCS | physical component score, MCS | mental component score
BASELINE 3 MONTHS 1 YEAR 4 YEARS P
47 1-YEAR AKI-RRT PATIENTS
MEDIAN (IQR)
PCS 41.7 (28.5-54.2) 30.7 (25.1-40.4) 38.3 (27.7-47.4) 0.003
MCS 53.8 (38.9-61.6) 39.5 (29.3-47.2) 53.3 (39.2-58.6) 0.014
PHYSICAL FUNCTIONING 44.4 (29.1-53.4) 27.6 (19.2-39.1) 40.2 (26.5-46.5) <0.001
ROLE PHYSICAL 34.8 (22.6-56.9) 27.5 (17.7-29.9) 34.8 (25.0-45.8) <0.001
BODILY PAIN 62.1 (37.2-62.1) 39.7 (29.2-50.9) 46.5 (37.2-62.1) 0.015
GENERAL HEALTH 40.1 (30.5-48.2) 36.3 (31.1-41.0) 41.0 (30.5-50.6) 0.078
VITALITY 55.2 (42.7-61.5) 45.8 (39.6-50.5) 50.5 (41.9-59.1) 0.041
SOCIAL FUNCTIONING 51.4 (35.0-56.8) 35.0 (24.1-40.5) 45.9 (29.6-56.8) 0.005
ROLE EMOTIONAL 55.9 (40.3-55.9) 28.7 (20.9-38.4) 48.1 (32.6-55.9) <0.001
MENTAL HEALTH 50.0 (33.1-61.3) 41.6 (30.3-50.0) 50.0 (40.2-58.4) 0.022
94 1-YEAR NON AKI-RRT PATIENTS
MEDIAN (IQR)
PCS 39.4 (29.1-49.6) 31.3 (26.3-43.2) 36.6 (26.0-46.4) 0.007
MCS 48.0 (37.5-55.7) 47.3 (31.6-54.9) 47.8 (34.8-54.0) 0.759
PHYSICAL FUNCTIONING 40.2 (23.4-53.4) 31.8 (21.3-44.4) 33.9 (22.3-48.6) 0.001
ROLE PHYSICAL 34.8 (22.6-56.9) 27.5 (17.7-37.3) 32.4 (23.2-42.2) 0.059
BODILY PAIN 46.5 (33.3-62.1) 39.5 (29.2-50.5) 41.6 (29.2-55.4) 0.008
GENERAL HEALTH 37.7 (30.5-50.6) 40.1 (31.1-45.8) 37.7 (30.5-45.8) 0.871
VITALITY 49.0 (36.5-58.3) 49.0 (39.6-55.2) 49.0 (36.5-58.3) 0.896
SOCIAL FUNCTIONING 48.7 (35.0-56.8) 35.0 (24.1-45.9) 35.0 (24.1-51.4) <0.001
ROLE EMOTIONAL 55.9 (31.6-55.9) 38.4 (20.9-55.9) 44.2 (24.8-55.9) 0.410
MENTAL HEALTH 47.2 (33.1-58.4) 50.0 (34.5-55.7) 47.2 (34.5-55.6) 0.562
28 4-YEARS AKI-RRT PATIENTS
MEDIAN (IQR)
PCS 46.1 (38.7-53.7) 33.2 (26.0-40.4) 39.8 (31.6-46.7) 38.1 (31.6-47.1) 0.007
MCS 57.6 (42.8-62.3) 39.5 (29.3-47.1) 53.5 (40.9-61.6) 53.9 (42.4-60.3) 0.010
PHYSICAL FUNCTIONING 48.6 (36.5-57.0) 27.6 (18.1-43.4) 42.3 (29.7-48.6) 33.9 (29.7-40.2) <0.001
ROLE PHYSICAL 42.2 (27.5-56.9) 27.5 (17.7-31.8) 34.8 (27.5-47.1) 45.9 (27.5-56.9) <0.001
BODILY PAIN 51.1 (38.2-62.1) 41.8 (30.1-50.9) 51.1 (41.8-62.1) 50.7 (34.4-62.1) 0.178
GENERAL HEALTH 42.9 (30.3-47.9) 36.3 (32.9-42.9) 43.4 (36.3-50.6) 38.2 (32.9-48.0) 0.093
VITALITY 55.2 (43.5-64.6) 45.8 (42.7-50.5) 52.1 (45.8-61.5) 49.0 (45.8-58.3) 0.037
SOCIAL FUNCTIONING 56.8 (40.5-56.8) 35.0 (26.9-40.5) 51.4 (35.0-56.8) 45.9 (35.0-56.8) 0.101
ROLE EMOTIONAL 55.9 (50.0-55.9) 24.8 (9.2-38.4) 48.1 (32.6-55.9) 55.9 (20.9-55.9) 0.001
MENTAL HEALTH 55.6 (33.1-64.1) 41.6 (33.1-51.4) 50.0 (41.6-61.3) 52.8 (41.6-58.5) 0.188
28 4-YEARS NON AKI-RRT PATIENTS
MEDIAN (IQR)
PCS 48.4 (36.3-57.0) 37.1 (26.1-45.5) 40.8 (27.9-46.5) 41.0 (32.1-52.6) 0.358
MCS 48.6 (34.3-57.6) 48.9 (37.2-54.8) 49.7 (40.6-54.7) 47.0 (37.4-55.5) 0.913
PHYSICAL FUNCTIONING 52.8 (40.2-54.9) 39.1 (19.2-44.4) 38.1 (22.3-48.6) 38.1 (25.5-48.6) <0.001
ROLE PHYSICAL 52.0 (17.7-56.9) 27.5 (25.0-39.7) 32.4 (25.0-39.7) 39.7 (25.0-47.1) 0.158
BODILY PAIN 50.3 (41.2-62.1) 46.1 (37.2-55.4) 46.1 (36.1-62.1) 46.1 (37.2-62.1) 0.489
GENERAL HEALTH 41.0 (35.3-55.3) 40.1 (29.8-49.4) 41.0 (35.3-48.8) 41.0 (34.7-53.5) 0.577
VITALITY 52.1 (42.7-58.3) 49.0 (39.6-58.3) 52.1 (39.6-58.3) 49.0 (42.7-55.2) 0.403
SOCIAL FUNCTIONING 56.8 (35.0-56.8) 40.5 (24.1-51.4) 35.0 (22.8-52.8) 45.9 (24.1-56.8) 0.058
ROLE EMOTIONAL 40.3 (20.9-55.9) 40.3 (28.7-55.9) 40.3 (24.8-55.9) 44.2 (24.8-55.9) 0.071
MENTAL HEALTH 52.8 (35.9-58.4) 50.0 (37.3-58.5) 50.0 (37.3-58.5) 50.0 (41.6-52.8) 0.962
127
CHAPTER 6    Quality of life
Fig. E1.
EQ-5D assessments over time: Percentages of patients 
with some or severe problems per dimension.
The X-axis represents the different dimensions of the EQ-5D. 
The Y-axis represents the percentages (%) of patients with 
some or severe problems in a respective dimension. 
Only significant P-values (Chi Square test) are 
shown above the respective dimensions.
QOL | quality of life, AKI | acute kidney injury, RRT | renal replacement therapy
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Fig. E2.
SF-36 assessments over time: 
Norm-based median scores per domain.
The X-axis represents the different domains of the SF-36.  
The Y-axis represents the norm-based median scores in a respective 
domain of the SF-36. A norm-based median score between 47-53 in a group 
of patients is considered as normal or average. Norm-based median scores 
below 47 indicate impaired functioning or below average; norm-based 
median scores above 53 indicate better functioning or above average. 
Only significant P-values (Friedman test) are 
shown above the respective domains. 
QOL | quality of life, AKI | acute kidney injury, RRT | renal 
replacement therapy, PCS | physical component score, MCS | 
mental component score, PF | physical functioning, RP | role 
physical, BP | bodily pain, GH | general health, VT | vitality, SF | 
social functioning, RE | role emotional, MH | mental health
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1. Major findings
The overall aim of this doctoral thesis 
was to: 1) describe the epidemiology of 
critically ill patients with AKI-RRT, 2) to 
explore timing of initiation of RRT in these 
patients by studying some “conventional” 
indications of initiation of RRT and evalu-
ating their possible impact on outcome, 3) 
assess short- and long-term patient and 
kidney outcomes in this specific cohort 
of patients and 4) investigate long-term 
quality of life in these patients. These ob-
jectives were addressed by four studies. 
The first objective was to describe the 
epidemiology of critically ill patients with 
AKI-RRT. As an epidemiological research 
project this objective was addressed in all 
four presented studies each highlighting 
specific endpoints and outcome measures. 
In study I and II mortality was the main 
clinical outcome measure. We found that 
almost 60% of the patients died during 
hospital stay. In patients with SLA, these 
mortality rates further increased (>80% 
ICU mortality). In study III we further fo-
cused on long-term patient and kidney 
outcome and highlighted the concept of 
composite endpoints. An additional mor-
tality rate of 10% per year was reported in 
patients discharged from the hospital.
The second objective was to investigate 
some “classical” indications of ini-
tiation of RRT in ICU patients with 
AKI-RRT and to evaluate possible as-
sociations with outcome. This was 
addressed by a retrospective study: 
Study I investigated whether serum urea 
cut-off concentrations for initiation of RRT 
had a possible predictive value for short-
term mortality. On a Vancouver meeting, 
members of the Acute Kidney Injury 
Network formulated indications to initiate 
RRT. Regarding serum urea concentration 
cut-offs they recommended a BUN>76 mg/
dl as a relative and a BUN>100 mg/dl an ab-
solute indication to initiate RRT [1]. Further, 
the 2012 KDIGO guidelines on AKI depicted 
solute control (BUN) as a potential appli-
cation for initiation of RRT but only when 
considering the broader clinical context, the 
presence of conditions that can be modified 
with RRT and trends of laboratory tests [2].
We found that serum urea concentration 
cut-offs at time of initiation of RRT, as they 
have been used from the early days of acute 
RRT have no predicted value for hospital 
mortality in severely ill patients with AKI.
The third objective was to assess the short 
and long-term patient and kidney outcomes 
and their determinants in ICU patients with 
AKI-RRT. This topic was addressed by a 
retrospective study (study II) and an ob-
servational prospective study (Study III):  
Study II extensively focused on a second 
well-known classical indication for initia-
tion of RRT in critically ill patients with AKI: 
severe lactic acidosis. First we described 
the epidemiology of this condition. Second, 
we investigated possible factors that may 
have influenced short-term outcome. SLA 
was present in about one third of AKI-
RRT patients and was associated with an 
ICU mortality rate of more than 80%. We 
demonstrated that the administration of 
RRT –irrespective from RRT modality– was 
associated with an increase in serum pH 
and a decrease of serum lactate concen-
tration in most patients. In addition, serum 
lactate concentration at initiation of RRT 
was not able to discriminate between 
survivors and non-survivors. This study 
suggests that initiation of RRT in these pa-
tients may act as a bridge that buys time to 
treat the underlying cause of the acidosis. 
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Study III evaluated long-term patient and 
kidney outcomes in AKI-RRT patients. We 
also evaluated possible determinants of 
outcome in these patients. Long-term sur-
vival after AKI-RRT was poor and associated 
with age and clinical status at initiation of 
RRT. Renal recovery was limited and de-
ficient recovery was associated with CKD 
and diabetes. Evolution towards ESKD 
was more frequently seen in patients with 
acute on chronic disease. The majority of 
patients classified positive for MAKE. 
The fourth objective was to evaluate  
long-term quality of life in AKI-RRT patients  
after discharge from ICU. This topic was  
addressed by a prospective matched cohort study: 
Study IV described the long-term qual-
ity of life in AKI-RRT patients. The cohort 
described in this study is a subgroup of 
a prospective observational cohort [3]. 
Long-term quality of life was impaired 
compared to the general population but 
was not different from that of ICU survivors 
without AKI. Impaired QOL was predom-
inantly driven by impairment in physical 
domains rather than mental domains.
2. Interpretation  
 of the findings
2.1 OBJECTIVE 1  
 EPIDEMIOLOGY OF CRITICALLY  
 ILL PATIENTS WITH AKI-RRT
Our 8-year analysis of more than 23,000 
first ICU admissions demonstrated that 
AKI-RRT occurred in 5.5% of patients ad-
mitted to the ICU. This incidence is in 
line with the BEST kidney trial reporting 
an AKI-RRT incidence of 4.2% but lower 
than the AKI-EPI study and the study by 
Nisula (13.5% and 10.2%, respectively) [4-6]. 
Differences in baseline characteristics of 
the patients with increased occurrence of 
AKI and differences in timing of initiation 
of RRT may explain these differences [7]. 
In our study cohort, median age was 65 
years, two-third of the patients were male. 
Almost one third of the patients had di-
abetes and almost 40% of the patients 
had a baseline CKD stage ≥3. Patients with 
AKI-RRT were very severely ill as depicted 
by the median SAPS II score of 63. ICU 
mortality was 54.6% and increased to 72.1% 
at three years. Older age and increased 
severity of illness during ICU stay were 
associated with long-term mortality.
2.2  OBJECTIVE 2 
  TIMING OF INITIATION OF RRT  
  IN CRITICALLY ILL PATIENTS 
  WITH AKI-RRT
2.2.1. How to define timing?   Whether timing 
of initiation of RRT influences outcome 
in AKI-RRT patients remains a matter of 
debate [8]. Timing of initiation of RRT is 
puzzling, mainly because of the lack of a 
uniform definition of “early” versus “late”. As 
a consequence, clinical outcomes related 
to timing of initiation of RRT are influenced 
by how timing is defined. Starting dialysis 
in AKI patients may be based on traditional 
indications such as acidosis, electrolyte 
disorders like hyperkalemia, uremic com-
plications (nowadays rarely seen uremic 
encephalopathy or uremic pericarditis) but 
clinical parameters such as UO and fluid 
overload, AKI severity stage or time from 
ICU admission. The present work evaluated 
several of these criteria of initiation of RRT. 
2.2.2. Timing of initiation of RRT: definition 
based on biomarkers   For years dialysis was 
reserved as a treatment for uremic symp-
toms in patients with AKI. In 1953 Teschan 
introduced the concept of “prophylactic 
dialysis” meaning RRT applied before the 
appearance for uremic symptoms [9]. Until 
recently the discussion was about which 
serum urea threshold should be used to op-
timize outcome after AKI. As a consequence 
timing was defined as “early” versus “late” 
with respect to a serum urea threshold 
concentration. Study I extensively focused 
on the possible association between differ-
ent serum urea cut-offs and mortality. We 
demonstrated that serum urea concentra-
tion and serum urea cut-offs for initiation of 
RRT as described in literature had no predic-
tive value for short-term hospital mortality 
in critically ill patients with AKI-RRT. Our 
findings were more recently confirmed 
by a systematic review by Ostermann et 
al [10]. They concluded that serum urea 
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concentration could not adequately define 
the optimal indication and time of initiation 
of RRT. More recently a prospective multi-
center observational study confirmed these 
findings [11]. Consequently, the concept of 
“early” versus “late” timing of initiation of 
RRT based on historical serum urea cut-off 
concentrations does not make sense. This 
is mainly because the use of such a sur-
rogate marker of kidney function is highly 
problematic due to the fact that it is not 
renal specific. The biological rationale that 
urea is a good biomarker for assessing the 
severity and duration of AKI is weak. Serum 
urea is determined by many other variables 
that have no relation to kidney function. It is 
formed by the hepatic metabolism of amino 
acids and excreted primarily by glomerular 
filtration. Serum concentrations may vary as 
a result of changes in urea production and 
tubular urea reabsorption without changes 
in GFR. Both increased metabolism (i.e. in 
the context of gastrointestinal bleeding, 
enhanced tissue breakdown or high protein 
diet) and increased tubular reabsorption 
during hypovolemic states can lead to in-
creased serum urea levels without changes 
in renal function [10-12]. We want to highlight 
the fact that we used the RIFLE classifi-
cation in Study I. RRT was not included in 
that score (see Table 2 p. 82). The more recent 
KDIGO classification for AKI classifies the 
administration of RRT as AKI stage 3. The 
different classification systems for AKI are 
presented in Table 1 (CHAPTER 1 Introduction).
2.2.3. Timing of initiation of RRT: defini-
tion based on life-threatening indications   
According to the KDIGO guidelines, another 
– more decisive – indication for initiation of 
RRT is the condition of severe and therefore 
possibly life-threatening acidosis. Intuitively 
this seems a plausible indication for initia-
tion of RRT. However, evidence supporting 
this advice is scarce. Study II wanted to 
update the literature concerning this topic. 
We found that SLA was a frequent finding 
in critically ill patients associated with high 
mortality. However, in patients with SLA, 
serum lactate concentration at initiation of 
RRT could not discriminate between survi-
vors and non-survivors. We can formulate 
several explanations for this finding. First, 
RRT does not treat the underlying disease. It 
only can provide restoration of homeostatic 
equilibrium [13]. Second, whether lactate 
clearance during RRT could sufficiently 
impact serum lactate remains a matter of 
debate [14, 15]. A decrease in serum lactate 
can be the result of the natural (beneficial) 
course of the underlying disease, rather 
than an increased clearance due to RRT. 
In conclusion, timing of initiation of RRT 
based on serum lactate concentration in 
patients with SLA is not associated with 
outcome. In conclusion timing of initiation 
of RRT based on serum lactate concentra-
tion in patients with SLA is not associated 
with outcome. As such, we suggest not 
to withhold RRT in these very severely ill 
patients as this intervention may create 
a window of opportunity for correcting 
acidosis and restoring homeostasis en-
abling specific therapeutic measures to 
treat the underlying disease. However, 
this hypothesis needs further research.
2.2.4. Timing of initiation of RRT: temporal 
definition   Another used definition of timing 
of initiation of RRT is based on a tempo-
ral approach indicating several arbitrarily 
chosen time intervals: time from hospital 
or ICU admission to initiation of RRT. The 
BEST Kidney investigators performed a pro-
spective multinational observational study 
on 1238 patients evaluating the timing of 
RRT stratified into “early” and “late” by bio-
chemical parameters and temporal criteria 
[16]. Patients were stratified into early RRT 
(defined by start within 2 days), delayed RRT 
(defined by start between 2 and 5 days) and 
late RRT (defined by start after 5 days from 
ICU admission). Late RRT was associated 
with a significantly higher crude mortality as 
compared with delayed or early RRT (72.8% 
versus 62.1%, versus 58.9%;P<0.001). After 
adjustment for covariates late RRT remained 
independently associated with hospital 
mortality and was also associated with an 
increased duration of RRT At hospital dis-
charge, there was no difference in dialysis 
dependency. Despite the better outcome 
in favor of early RRT, a major drawback of 
a temporal definition is that it indicates an 
arbitrarily chosen time interval. It finds origin 
in the initiation of RRT in CKD patients inev-
itably evolving towards RRT, but cannot be 
very easily managed in AKI patients in which 
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dialysis may be avoided [17]. For example, it 
is difficult to discriminate those patients in 
the “late” group who might have had criteria 
for RRT early in a timely fashion. In conclu-
sion, whatever temporal criteria are used to 
define early versus late RRT, it is apparent 
that what may be early for one patient could 
be late for another patient depending on the 
patient’s comorbidity and clinical course [18].
2.2.5. Timing of initiation of RRT: definition 
based on AKI stage   Timing of initiation of 
RRT defined on quantitative data defining 
severity of AKI, rather than on a temporal 
definition has major potential advantages. 
The definition is based on the actual patho-
physiologic course of the disease, rather 
than driven by a surrogate marker or an 
arbitrary temporal definition. Therefore, 
when investigating the concept of timing 
of initiation of RRT we defined in study III 
“early” versus “late” initiation of RRT based 
on AKI stage. AKI stage 1 and 2 were defined 
as “early”, stage 3 was defined as “late”. 
However, in study III we found no associa-
tion between timing of initiation of RRT and 
outcome. Our findings were confirmed by 
the recently published multicenter AKIKI 
trial by Gaudry et al [19]. Early was defined 
as initiation of RRT within 6 hours after 
documentation of AKI stage 3 of KDIGO clas-
sification. Similarly, all RRT modalities were 
used (IHD, CRRT, SLEDD). However, patients 
with life-threatening complications were 
excluded in the AKIKI trial making “late” 
initiation of RRT less risky. The monocen-
tric ELAIN study by Zarbock et al showed 
a survival benefit for early initiation based 
on KDIGO stage (“early” means AKI KDIGO 
stage II, “late” means AKI KDIGO stage III) 
[20]. Early was defined as initiation of RRT at 
stage 2 of the KDIGO classification within 
8 hours. CRRT was the only modality used. 
These studies illustrate how complex the 
impact of timing on outcome is. Differences 
between these studies were the definition of 
early and late initiation, but also modalities 
used (CRRT in ELAIN versus all modalities in 
the other studies) and study design (single 
center observation (ELAIN) versus multi-
center studies). Some shortcomings inherent 
to AKI staging classifications need to be 
made. First, AKI staging is mainly based on 
evolution in serum creatinine concentrations 
and/or UO. Registration of these data may 
be problematic. Baseline sCr is often lack-
ing or does not reflect 'true baseline sCr". 
Furthermore, sCr levels depend on renal 
function but also on nonrenal factors like 
age, muscle percentage of body weight and 
volume of distribution [21]. Fluid adminis-
tration is common in the management of 
of critically ill patients. However, it may 
lead to fluid accumulation and result in an 
increase in total body weight of 10 -15% [22]. 
This may result in an increase in the volume 
of distribution of sCr. As a consequence, 
the severity of AKI may be underestimated 
in critically ill patients with a positive fluid 
balance. In addition, the diagnosis of AKI, 
based on sCr concentration may be delayed. 
Macedo et al developed a formula to correct 
for fluid balance. Serum creatinine values 
were adjusted using a correction factor 
based on the hospital admission weight 
and the daily fluid balance [21]. However 
this approach remains controversial as it 
lacks a clear physiological basis and fails 
to account for the actual kinetics of cre-
atinine excretion [23]. Further, significant 
decreases in GFR are not always reflected 
by a major increase in serum creatinine 
levels hampering adequate AKI staging. 
Significant decreases in GFR are not always 
reflected by a major increase in serum 
creatinine levels hampering adequate AKI 
staging [21]. In addition laboratory techniques 
may also have an influence on the actual 
serum creatinine [23]. Finally, the RIFLE and 
AKIN classifications are scoring systems 
which were developed to grade prognosis 
of AKI but they were never intended to 
predict the need for RRT. For example, by 
definition AKI stage 3 implies RRT [2, 24]. 
2.2.6. Timing of initiation of RRT: definition 
based on clinical parameters   Decision-
making for initiation of RRT is also often 
based on clinical parameters like urine 
output and fluid overload. The usefulness 
of urine criteria for the definition of AKI has 
been debated widely but there is an increas-
ing evidence that a UO of <500-600 mL/24h 
should be viewed as an ominous sign [25, 26]. 
In addition, oliguria is closely correlated with 
fluid accumulation. Recent data suggest that 
fluid overload of >10% of body weight is an 
independent risk factor for mortality in AKI 
135
[27]. Consequently, it may be appropriate to 
consider starting RRT prior to fluid accumu-
lation. Several studies found an association 
between decreased UO and mortality. In a 
retrospective study of critically ill patients 
with AKI, Ostermann found that oligoanuria 
(UO <400ml/24 h) was associated with ICU 
mortality [28]. In addition two small nonran-
domized studies in cardiac surgery patients 
conducted by Demirkilic et al and Elahi et al 
demonstrated a survival benefit in case of 
early initiation of RRT based on UO criteria 
[29, 30]. Further, Sugahara et al conducted a 
small and monocentric RCT in 28 cardiac 
surgery patients [31]. Initiation of RRT was 
based on UO. Early was defined as a UO 
of <30 ml/h for three consecutive hours or 
daily UO of ≤ 750ml. Early initiation of RRT 
was associated with better 14-day survival in 
this specific cohort of patients. Interestingly, 
sCr levels at initiation of RRT did not sig-
nificantly differ between both groups. In a 
recent prospective multicenter observa-
tional study Bagshaw et al demonstrated 
a significant association between mortality 
and UO prior to initiation of RRT [11]. Study 
III showed an inverse association between 
oliguria and renal recovery in univariate 
analysis. However, in multivariate analysis, 
no association could be demonstrated. 
In conclusion, the timing of initiation of RRT 
remains controversial. Two meta-analyses 
showed that early initiation of RRT was 
associated with better outcome. Seabra 
et al concluded that early initiation of RRT 
was associated with a 28% mortality risk 
reduction. However this finding was largely 
based on data from retrospective trials [32]. 
Similarly, Karvellas et al reported an im-
provement in 28-day mortality with early 
RRT. However, a subgroup analysis of the 
included RCTs could not confirm this sur-
vival benefit [33]. These findings were not 
confirmed in two recent meta-analyses. A 
systematic review performed by Wierstra 
et al could not demonstrate an associa-
tion between early initiation of RRT and 
outcome [34]. A systematic review and me-
ta-analysis by Xu et al concluded that “early” 
RRT in one study might be considered as 
“late” in another study [35]. They included 
6 RCTs and reported an equal number of 
definitions of “early” and “late” timing. So no 
firm statements could be made concerning 
the concept of timing of initiation of RRT.
Up to date it is practically impossible to 
predict which patient will benefit from 
RRT, and which patient will spontaneously 
recover from AKI without need of RRT [6]. 
Whether timing of initiation of RRT should 
be measured from ICU admission, from the 
moment of diagnosis of severe AKI, or using 
arbitrary thresholds of traditional or new 
biomarkers remains unclear. Intuitively early 
initiation of RRT seems attractive because 
of potential benefits attributable to more 
rapid metabolic and uremic control, better 
management of fluid overload and the pre-
vention of organ injury following acidemia 
[36]. Pending further clarification, the decision 
to start RRT should be based on trends in 
the general severity of illness, presence of 
oliguria and fluid overload, the number and 
types of failed non-renal organs and the 
risk of further organ failure whether the 
patient is recovering of deteriorating [8]. 
2.3 OBJECTIVE 3 
 PATIENT AND KIDNEY  
 OUTCOMES AND THEIR 
 DETERMINANTS  
 IN AKI-RRT PATIENTS
2.3.1. Short- and long-term mortality    
We found that AKI-RRT was associated 
with adverse outcomes. Mortality rates 
in our cohort were high, with almost 60% 
of the patients dying during their hospital 
stay. These rates were comparable to the 
data presented by Ostermann et al (56.8%) 
and Uchino et al (60.0%), but higher than in 
studies by Nisula et al (25.6%), and Mehta et 
al (37.0%) [4, 6, 10, 37]. In a multicenter study 
on more than 15,000 patients Srisawat et 
al reported an overall hospital mortality of 
27.0% [38]. Recently Ympa et al performed 
a systematic review exploring short-term 
mortality rates in critically ill patients with 
AKI [39]. They included publications between 
1956 and 2003. Crude mortality rates were 
about 50%. The authors reported a wide 
variation in the mortality rates among 
included studies, but could not demon-
strate an improved outcome over time. 
Possible explanations are differences in 
definitions of AKI or in case-mix (medical 
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versus surgical ICUs, increasing age of the 
patients over time). Inclusion criteria and 
patient group characteristics may differ 
among studies. For example, in patients 
with SLA we reported an ICU mortality of 
83.6%. Further, differences in management 
among centers and over time may play a 
role. Similarly, Srisawat et al found a wide 
variety in hospital mortality rates across. 
Illness in ICU patients focused on conven-
tionally accepted short-term outcomes such 
as mortality at day 30, or ICU and hospital 
discharge. However, over the years the 
insight grew that these endpoints may un-
derestimate the true burden of disease. So 
in modern-day ICU care, we should aim for 
more relevant endpoints such as long-term 
mortality (90 days, 6 months, one-year). The 
current project extensively addresses these 
long-term outcome measures. Next to the 
high hospital mortality rate, an additional 
mortality rate of 10% per year of the hospital 
survivors was reported in the years following 
discharge. This finding reflects the impact 
of AKI-RRT on long-term survival after ICU 
discharge. Again, these data are in line with 
current evidence in literature. The RENAL 
study reported a 44.7% mortality rate three 
months after initiation of RRT [40]. To avoid 
the selection bias inherent to hospital-based 
studies Bagshaw and co-workers set up a 
population-based study describing long-
term outcomes in patients with AKI-RRT. 
They reported a 1-year mortality of 63.8% 
[41]. Korkeila et al reported 65.0% mortality 
at 5 years in a mixed surgical and medical 
Finnish ICU population with AKI without 
pre-existing renal failure [42]. Ahlström et 
al confirmed these findings in a cross-sec-
tional cohort study on patients from a 
medical-surgical ICU and acute dialysis 
unit with a 5 years mortality of 70% [43].
We could identify several determinants 
of long-term outcome. Advanced age and 
conditions depicting the severity of illness 
during ICU stay: hemodynamic instability, 
administration of vasoactive medication, 
need for mechanical ventilation and a pos-
itive fluid balance were associated with 
long-term mortality. These findings confirm 
previous research [6, 44]. Interestingly, our 
research highlights the fact that an ICU 
admission complicated with an AKI-RRT 
episode is independently associated with 
mortality and has a long-lasting impact 
in these patients. These findings support 
the recently emerged paradigm shift that 
patients actually die of AKI instead of with 
AKI. In the past, the statement that patients 
died with AKI and not from AKI was widely 
accepted. AKI, and by extension AKI-RRT, 
was often considered a surrogate marker 
for severity of illness. In critically ill pa-
tients, AKI often developed in the course 
of another disease, e.g. sepsis or trauma. 
Patient mortality was considered a con-
sequence of this underlying disease [45].
In study III, CRRT as initial RRT modality 
was associated with adverse long-term 
patient outcome. This finding must be in-
terpreted with caution as the study was 
not designed to investigate differences in 
outcomes based on RRT modality. In addi-
tion, our institution tends to initiate CRRT 
in patients with hemodynamic instability. 
When a patient’s condition improves, the 
modality is switched to SLEDD or IHD. So, 
in our cohort of patients, RRT modality acts 
a surrogate marker for severity of illness 
and may therefore have biased our findings. 
Either way, the optimal RRT modality re-
mains a controversial issue. A recent study 
by Truche et al concluded that RRT mo-
dality had limited influence on patient and 
kidney outcome at 30 days and 6 months. 
CRRT was beneficial in patients with a 
positive fluid balance but was associated 
with adverse outcome in patients with 
stable hemodynamics [46]. A meta-analy-
sis performed by Bagshaw et al could not 
demonstrate an association between RRT 
modality and mortality or renal recovery [41]. 
2.3.2. Renal recovery and dialysis depend-
ency   Until recently, it was widely accepted 
that kidney function of most patients 
surviving AKI fully recovers [47]. However, 
several studies have demonstrated the 
link between AKI, CKD and ESKD [48]. 
Despite the lack of a standard definition, 
the term “renal recovery” is widely used 
and is usually interpreted as independency 
of RRT [49]. However, renal recovery en-
compasses a varying range from full renal 
recovery to incomplete renal recovery 
close to the limit of dialysis dependency. 
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Study III extensively focuses on the concept 
of renal recovery. We further classified renal 
recovery into “complete renal recovery” 
(eGFR within 25% of the baseline eGFR), 
“incomplete renal recovery” (25% of more 
decline of reference eGFR) and “absent renal 
recovery” (permanent need for RRT for more 
than three months). Estimated GFR was 
based on known baseline serum creatinine 
levels. We reported a 90-day dialysis de-
pendency rate of 9.0%. This was lower than 
the dialysis dependency rate reported in the 
FINNAKI trial (18.9% at 90 days) and higher 
than in the RENAL trial (5.6% at 90 days) [6, 
40]. It needs to be mentioned that in both 
these studies, CRRT was the RRT modality 
of choice. As mentioned above, literature on 
the association of RRT modality with kidney 
outcome remains conflicting. A meta-anal-
ysis by Schneider et al suggested that CRRT 
as initial modality may be associated with 
better kidney outcome. However, this was 
mainly based on observational data which 
precluded to make firm conclusions [50]. 
In study III renal recovery was 56.7% at 
90 days (56.7%), and 48.4% at 1-year. At 
the same one year time point, 32.6% of 
the patients had incomplete renal re-
covery and 19.0% had ESKD treated with 
RRT. Dialysis dependency increased over 
time to 28.1% at three years. Patients with 
ESKD more often had diabetes, CKD and 
oliguria at time of initiation of RRT. This is 
similar to findings in other cohort studies 
and meta-analyses [51-54]. Several studies 
demonstrated the long-lasting effects of 
an AKI(-RRT) episode on renal function. In 
a 10-year follow-up study of AKI survivors, 
Ponte et al found that over 50% of the 
patients failed to fully recover kidney func-
tion [55]. In addition, Gammelager et al found 
an increased five-year risk of developing 
ESKD after an AKI-RRT episode [56]. Finally, 
a large Swedish cohort study including 
more than 97,000 patients demonstrated 
that AKI is independently associated with 
increased risk of CKD and ESKD [57]. 
Our findings depict that one third of the 
patients of the study cohort had incom-
plete recovery at 1 year and is therefore 
actually at risk for developing ESKD. With 
only 34% of all AKI-RRT survivors seen by 
a nephrologist after hospital discharge, 
follow-up can be considered inadequate. 
Moreover, this proportion also includes 
patients with ESKD; hence, we can assume 
that the majority of patients with incom-
plete renal recovery lack adequate follow-up 
after their AKI-RRT episode. Although 
data concerning this topic are scarce, this 
patchy follow-up cannot be considered 
a local and therefore isolated problem. A 
sub-study of the RENAL trial demonstrated 
that the prevalence of proteinuria amongst 
survivors was almost 50%, stressing the 
increased long-term risk of death associ-
ated with AKI-RRT [44]. A more recent study 
in patients surviving ICU after an AKI-RRT 
episode reported a specialist nephrology 
follow-up in only 12% of the patients [58].
With regard to these data and taking 
into account the social and economic 
impact of chronic dialysis, specialized 
follow-up of survivors of severe AKI-
RRT by a nephrologist may be justified. 
Follow-up strategies must focus on 
chronic proteinuria reduction strategies 
and the timely diagnosis of CKD [47].
2.3.3. MAKE   In study III we reported the 
composite endpoint MAKE. Compared with 
single-outcome endpoints, this aggregate 
endpoint has a higher incidence than each 
of the component endpoints. As a conse-
quence, it captures a greater proportion of 
patients with poor long-term outcomes [59].
However, in the present work, there was no 
association between MAKE and preexisting 
CKD, timing of RRT and modality of RRT. 
According to recent guidelines we reported 
the individual components of MAKE [60]. 
Consequently we found that MAKE was 
mainly determined by its biggest individual 
component, mortality. Ideally only com-
ponents of similar clinical importance are 
combined [61]. The reported high mortality 
rates in study III may therefore have led to 
the predominance of the mortality compo-
nent in MAKE impairing its interpretation.
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2.4 OBJECTIVE 4
 HEALTH RELATED 
 QUALITY OF LIFE 
Naturally, mortality and dialysis depend-
ency are decisive endpoints. Recently, 
patient-reported outcomes such as HrQOL 
have gained interest as they gather infor-
mation provided by the patient himself 
about his/her personal experience of the 
disease, treatment and care. HrQOL is a 
relevant clinical endpoint as it attempts 
to assess the burden of disease when 
surviving an AKI-RRT episode whether di-
alysis dependent or not. Remarkably, our 
research showed that long-term HrQOL 
had the same evolution over time in AKI-
RRT and in non-AKI-RRT patients. A recent 
meta-analysis that also included our study 
confirmed these findings. It was concluded 
that critically ill patients with AKI-RRT had 
impaired QOL compared with the general 
population, but not different from that of 
ICU survivors without AKI. Of the 18 studies 
included in the meta-analysis, our study had 
the second longest follow-up period. When 
implementing the Modified Downs and 
Black Scores for Included Studies, which is 
a quality index, our study protocol scored 
15 out of 19 points. Further, only 6 out of 
18 studies reported pre-AKI baseline data 
and assessed HrQOL using standardized 
and validated PRO instruments (SF-36 and 
EQ-5D) at fixed durations of follow-up [62]. 
The need for RRT in severely ill patients 
significantly increases the burden of dis-
ease. It may be a pivotal moment in the 
decision-making whether or not to withdraw 
life-sustaining therapy. Our findings shed 
a new light on the discussion. Indeed, AKI-
RRT in critically ill patients heavily impacts 
their long-term survival, but patients who 
survive ICU have a HrQOL comparable with 
critically ill patients without an AKI-RRT 
episode during their ICU stay. Even more 
surprisingly, the majority of the AKI-RRT 
patients are willing to undergo similar 
far-reaching treatment in the ICU again 
when necessary. However, some limitations 
have to be noticed. Firstly, studies tend 
to simplify the reality because of statisti-
cal purposes. Their presented evidence is 
population-based but is not able to make 
firm conclusions on the individual level. As 
a consequence medical treatment should 
not exclusively be based on the available 
evidence but should also be guided by eth-
ical decision-making with respect for the 
wishes and values of the patient. Secondly, 
due to therapy restrictions, not all patients 
were referred to the ICU or were dialyzed 
during their ICU stage. When these patients 
survive critical illness, they may experi-
ence a decreased HrQOL after hospital 
discharge. This may adversely impact their 
willingness to undergo a new ICU admission 
with its inherent drawbacks. Of note, the 
ICU stay with its inherent high mortality 
rates in AKI-RRT patients likely reflects the 
concept of “survival of the fittest”. Once 
the ICU has been survived, former AKI-RRT 
patients tend to function as well as non-
AKI RRT patients after hospital discharge. 
Finally, only patients who survived the ICU 
were interviewed. Patients who stayed 
in the ICU for a long time but eventually 
died could not be studied. This limitation 
may bias our results. However, it would be 
interesting to evaluate the burden of dis-
ease in these patients and their relatives. 
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1. Limitations
2.1 LIMITATIONS DUE TO 
 STUDY  DESIGN AND  
 INCLUSION CRITERIA
We acknowledge that this work has a 
number of shortcomings. First, due to 
the recruitment of patients from a single 
tertiary care center, our findings may lack 
external validity. However, the presented 
data are based on a large cohort of pa-
tients. Furthermore, our epidemiological 
data on incidence of AKI-RRT in critically ill 
patients as well as the reported mortality 
rates were similar to other findings in lit-
erature suggesting our study cohort may 
reflect a typical ICU population as seen in 
the Western world. Second, study I and 
II were retrospective studies on a limited 
number of patients and can therefore only 
be hypothesis generating. To correct for 
this observational design we used multi-
variate regression models and included a 
propensity score to adjust possible bias. In 
addition, the findings presented in study I 
were confirmed by a more recent study 
of Ostermann et al [1]. Third, the present 
work exclusively focuses on critically ill 
patients with AKI-RRT. Obviously, this is a 
very specific cohort of patients and results 
may therefore not be valid in other patient 
populations.  
Also, some patients may have quali-
fied for RRT, but actually not have been 
treated with RRT e.g. if it was considered 
futile in their specific setting. Additionally, 
other groups may use other, more or 
less stringent criteria to initiate RRT.
2.2 HANDLING MISSING DATA
As in most epidemiological studies, we 
faced the unavoidable and common 
problem of lacking or “missing” data. A 
methodological survey of the top 5 gen-
eral medical journals found that 87% of 
published trials reported missing data 
for the primary outcome [63]. Importantly, 
missing data may undermine the validity 
of research results. Therefore, dealing 
adequately with missing data is of great 
importance. It requires careful examination 
of the data which can be very challenging. 
The risk of bias due to missing data 
depends on the reasons why data are 
missing. Basically, there are two “patterns 
of missingness”. Data can be “Missing At 
Random” (MAR) meaning that the underlying 
missing data mechanism is independent 
of the unobserved data and therefore 
“ignorable”. Missing data may also be due 
to a “Missing Not At Random” (MNAR) 
mechanism, meaning that the missing-
ness mechanism depends on unobserved 
data and therefore “non-ignorable” [2]. 
Several strategies were proposed to deal 
with missing data. First, a priori plans to 
minimize missing data are imperative. 
Second is to report the reasons for miss-
ingness and the pattern for missingness 
(at random or not). Third, one can opt to 
include only complete cases in the anal-
ysis. This approach seems logical, but 
only gives valid results if the probability of 
being a complete case is independent of 
outcome. Fourth, a widely used statistical 
method for ad hoc handling of MAR data 
is multiple imputation. The technique is 
based on the assumption that the missing 
data are ignorable. It allows individuals 
with missing data to be included in the 
analysis and has therefore the potential 
to improve the validity and power of the 
research findings. Unfortunately it is not 
possible to distinguish between MAR and 
MNAR using observational data. So finally, 
a sensitivity analysis may be necessary 
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to address the problem of missing data. 
Basically a sensitivity analysis gives an idea 
of what would happen if the data are MNAR 
by investigating possible violations of the 
MAR assumption. It assesses the robust-
ness of the main findings under different 
assumptions regarding the outcomes of 
participants with missing data [3,4]. For ex-
ample, when there are missing outcome 
data, a common sensitivity analysis is to 
explore “best” and “worst” case scenarios 
by replacing missing values with good out-
comes in one group and bad outcomes in 
the other group. If the results are reasona-
bly consistent, one can assume that even if 
data are MNAR, they would not compromise 
the findings. However, the MNAR hypothe-
sis is rarely explored, although it has been 
recommended by various guidelines.
We used the above mentioned guidelines 
to handle the missing data in the present 
work. The retrospective design of Study I 
and Study II made a priori planning to min-
imize missing data impossible. Study III and 
IV had a prospective design, so a strategy 
to minimize missing data was set-up more 
easily. Patients were prospectively included, 
which allowed more complete medical files 
and baseline data. In addition, follow-up 
was strict. When necessary, the general 
practitioner (GP) was contacted to complete 
the data. When unavoidable, we reported 
the missing cases by presenting a flow 
chart in all studies and clarified the reasons 
for missing data. Most missing cases were 
MAR as they were due to the gradual intro-
duction of the PDMS. In all studies included 
in this thesis, we only analyzed cases when 
included in the PDMS. However, when con-
fronted with additional missing data (mostly 
laboratory data) in these patients, we used 
a sensitivity analysis as an ad hoc approach 
to test the MNAR hypothesis. This was the 
case in Study I, II and III. No differences in 
outcome could be demonstrated, suggest-
ing that missing data were MAR and could 
therefore only have led to limited bias.
2.  Future  
  perspectives
Our findings and also those of others high-
lighted the urgent need for better evidence 
to guide us on the optimal timing of RRT for 
AKI. As indicated in the discussion above, 3 
prospective studies have addressed early 
initiation of RRT based on KDIGO criteria 
[5-7]. In addition, to these studies, 2 other 
large studies are currently being conducted. 
The Initiation of Dialysis Early Versus de-
Layed in Intensive Care Unit (IDEAL-ICU) 
study is a French multicenter RCT to 
assess whether the timing of initiation of 
RRT has an impact on 90-day mortality 
in critically ill patients with AKI during the 
initial phase of septic shock (clinicaltrials.
gov NCT01682590). In addition the Canadian 
Standard versus Accelerated Initiation of 
RRT in Acute Kidney Injury (STARRT-AKI) 
trial is a prospective multicenter RCT in-
vestigating the impact of timing of initiation 
of RRT on patient and kidney outcome 
(clinicaltrials.gov NCT02568722). Together 
these studies will include more than 3,500 
patients, and will therefore have sufficient 
power to address this issue. However, it 
is uncertain whether a certain AKI stage 
cut-off will be the optimal tool to indicate 
optimal timing of RRT. This may already 
be illustrated by the diverging signals 
generated by the AKIKI, STARRT-AKI, and 
ELAIN studies [5-7]. There is an ongoing 
need for an adequately powered trial 
that is applicable to current practice. 
The present work focused on long-term pa-
tient and kidney outcomes in ICU patients 
with AKI-RRT.  We highlighted the impact 
of such an AKI-RRT episode during ICU stay 
on outcome measures such as mortality, 
renal recovery, and evolution towards ESKD. 
As many as one-third of the patients in our 
cohort had incomplete kidney recovery. 
Somewhat surprisingly only 34% of the pa-
tients had follow-up of the kidney function 
by a nephrologist. This follow-up is not 
protocol driven but based on clinical and 
renal status of the patient at discharge of 
the ICU and/or hospital. However, follow-up 
of patients in the RENAL study revealed 
that a large proportion of AKI-RRT survivors 
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had albuminuria and decreased eGFR [8]. 
Following these findings, we think that a 
prospective long-term outcome study on 
the potential benefit of nephrological fol-
low-up after an AKI-RRT episode in critically 
ill patients seems to be imperative.  Ideally 
such a study includes all adult critically 
ill patients with AKI-RRT, discharged from 
ICU. However, one could also consider 
including patients who had less severe 
AKI. Possible endpoints are the incidence 
of CKD and evolution to ESKD. Possible 
outcome measures are mortality, renal 
recovery, dialysis dependency. Follow-up 
during hospital stay may be provided by 
the nephrologist. However, after hospital 
discharge, the patient may be followed by 
the GP in alternation with the nephrologist 
at defined time intervals, or by the GP with 
telephonic, e-based or other back-up by the 
nephrologist. Another option is the creation 
of specialized post-AKI clinics [9]. It is im-
portant to report every AKI episode in the 
medical history of the patient. Follow-up 
should focus on monitoring kidney function 
(assessing evolution of sCR concentration 
and GFR over time, screening for (micro)al-
buminuria) and the detection and treatment 
of risk factors for the development of CKD. 
Known risk factors are arterial hyperten-
sion, diabetes, cardiac failure and vascular 
disease. In addition, nephrotoxic drugs (e.g. 
NSAIDS) and intravascular contrast media 
should be avoided [10]. The GP should be 
provided criteria for referral of patients 
with deteriorating CKD to the nephrolo-
gist. Obviously, this follow up should be 
continued in patients who developed CKD. 
At present, we lack data on how long this 
follow up should be continued in patients 
with complete recovery of kidney function.
 
In the present work the composite end-
point MAKE falls short of expectations. As 
MAKE was mainly determined by its big-
gest component mortality, this aggregate 
endpoint didn’t add much value compared 
with the classical mortality endpoint. 
However composite endpoints remain of 
interest as they may reduce sample size 
and may increase statistical efficiency [11]. 
Ideally, future research entails the weigh-
ing up of the individual components of 
MAKE to minimalize distortions by these 
individual endpoints.  Only then can the 
correct interpretation of MAKE be made. 
In addition, another opportunity lies in the 
introduction of advanced statistical tech-
niques in the field of AKI. A randomized 
clinical trial is the standard design to 
quantify the causal effect of an interven-
tion. However, in many cases we have 
to rely on observational data. In order to 
estimate this effect from observational 
data it is necessary to adjust not only for 
baseline covariates but also for time-var-
ying confounders such as indicators of 
disease progression. Marginal structural 
models provide a way to overcome the 
drawbacks of standard models by esti-
mating causal effects [12]. To this date this 
approach seems to be lacking in the field of 
AKI. However, standard definitions for AKI 
have only been established very recently.  
It is to be expected that these statistical 
techniques will find their way into the 
field of AKI which is characterized by the 
complex dynamics and interplay between 
severity of illness, the development of AKI 
eventually leading to the administration of 
RRT and outcome. Future understanding 
of this epidemiology will play a vital role 
in diminishing the public health burden of 
AKI. Fortunately, the clinical study of AKI 
has been facilitated in recent years by the 
increasing availability of administrative data  
[13]. According to Bagshaw et al, AKI may 
be an ideal syndrome to focus on. AKI is 
common in hospitalized patients and it is 
associated with an increased risk for ad-
verse outcomes. Further, patients suffering 
from AKI consume great resources and 
have a significant longer ICU and hospital 
stay. Finally, recent data have stressed the 
suboptimal care of patients with AKI [14]. 
Recently, the ADQI convened a panel of ex-
perts to examine how big data can enhance 
scientific progress and improve outcomes 
in AKI. They raised some concerns over 
the quality of the data. Data obtained from 
large, national administrative datasets are 
usually not collected for conducting clinical 
research. Further the current coding struc-
ture of administrative data is hampered  by 
a lack of sensitivity. The reduced awareness 
for AKI and the risk for subjective coding 
limits the understanding of AKI. However, 
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these limitations emphasized opportunities 
to improve the quality of the data [15]. In 
conclusion, the use of big data in healthcare 
holds great promise to drive innovation, 
address knowledge gaps in AKI and improve 
outcomes for patients suffering from AKI.
Finally, we assessed the long-term HrQOL 
in patients after an AKI-RRT episode. Some 
of the interviewed patients and peers 
remembered their ICU stay as harsh and 
disturbing. Others highlighted the lack of 
autonomy and self-determination. These 
experiences can be an incentive to evaluate 
and optimize the “humanization” of the ICU. 
Several problems and mechanisms can 
contribute to dehumanization of the ICU 
[16]. The admission of a critically ill patient 
on the ICU is frequently associated with 
unrealistic expectations of that patient, 
his/her family members or the referring 
physician. Technological advances have 
enabled clinicians to prolong lives of 
critically ill patients even when there is 
no hope for successful treatment of the 
underlying disease. On the contrary, most 
people believe that futile treatments should 
not be provided. However, differences in 
people’s perceptions of futile treatment, 
the burden of disease, severity of illness 
and the “grade of invasiveness” of med-
ical interventions may alter the ICU in a 
hostile and brutal place for all involved. 
Furthermore, the individual’s sense of self, 
cornerstone of contemporary Western 
bioethics, is under threat [17]. The focus 
on self-determination can be difficult to 
apply in the ICU because the patient may 
lack the intact consciousness required to 
exercise that autonomy. The presence of 
altered consciousness, severity of illness 
and the unavoidable uncertainty about life 
and death may induce a kind of inertia and 
even “compassion fatigue” in ICU caregivers 
working in a demanding setting [18]. To cope 
with this uncertainty relatives and caregiv-
ers see patients as belonging in the group of 
non-survivors or survivors. In non-survivors, 
palliative care should be optimized. On the 
contrary, in the survivor group, technological 
imperatives focused on prolonging life pre-
dominate. Unfortunately it is very difficult 
to categorize the critically ill patient. The 
known prognostic scores that adjust for se-
verity of illness are useful tools for hospital 
benchmarking. However, they can’t predict 
individual outcome [19]. As the current 
prognostication is not accurate enough to 
eliminate uncertainty, this further increases 
the risk for “dehumanization” of the ICU.
Several measures can be taken to humanize 
the ICU and improve respect for the patient 
and his/her family. Focusing on the wishes 
and values of the individual is the corner-
stone of patient-centered care.  Advanced 
care planning, a well-known concept in the 
geriatric literature should be introduced in 
the ICU. It is a process by which patients, 
together with their physicians and family 
establish goals and preferences for future 
care. Implementation of ACP improves 
the quality of dying [20]. Ideally, ACP is or-
ganized previous to an ICU admission to 
avoid unintended admissions. ACP may 
increase the awareness that optimal care 
may encompass withdrawing life-sustaining 
therapy as a respectful and valuable alter-
native for life-prolonging interventions in 
terminally-ill patients. Further, engagement 
of the patient, his/her family and the ICU 
team may ease the burden of critical illness 
by decreasing the sense of isolation and 
helplessness [21]. In addition, open visitation 
policies are crucial. They strengthen the 
social networks of the patient and allow 
families to contribute to his/her recov-
ery [22]. Finally, giving honest information 
regarding diagnosis and prognosis is the 
starting point for an optimal communica-
tion. Information tailored to the patient and 
his/her family improves general satisfac-
tion and decreases stress among families 
of critically ill patients near death [23].
Respect and dignity are often used to de-
scribe the opposite of dehumanization. 
Some simple measures may improve 
respect for the patient: knowing his/her 
name, knocking on the door before en-
tering the room, asking permission before 
examining the patient. As a consequence 
these values can be used as outcome 
measures to assess future quality of 
care and humanization of the ICU [24].
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AKI is a frequent finding in ICU patients. 
Despite decades of progress in critical care 
it is associated with adverse outcomes 
such as increased LOS, short and long-
term mortality and ESKD. In its most severe 
form AKI is treated with RRT. AKI-RRT in 
critically ill patients is associated with 
mortality, development of CKD and ESKD.
The overall aim of this doctoral thesis 
was to describe the epidemiology of AKI 
in critically ill patients treated with RRT. 
Special attention was paid to some of 
the conventional indications of initia-
tion of RRT. In addition, the short- and 
long-term patient and kidney outcomes 
and long-term quality of life in critically 
ill patients AKI-RRT were explored.
There is a longstanding consensus to initi-
ate RRT in life-threatening situations such 
as severe acidosis, electrolyte disorders, 
the presence of uremic signs or in case 
of volume overload. However, the precise 
timing of initiation of RRT remains a matter 
of debate. The present work evaluated 
some conventional indications for initia-
tion of RRT. First we investigated whether 
the commonly used serum urea cut-off 
concentrations for initiation of RRT had a 
possible predictive value for mortality. We 
found that they had no predictive value for 
hospital mortality in severely ill patients 
with AKI. Second, we explored another in-
dication for initiation of RRT in critically ill 
patients with AKI: severe lactic acidosis. As 
literature describing this condition is scarce 
we described the epidemiology of SLA and 
determined possible factors influencing 
outcome. We found that severe lactic ac-
idosis was present in about one third of 
critically ill patients with AKI treated with 
RRT. We demonstrated that the adminis-
tration of RRT improved acid-base balance 
in most patients. Further, lactate concen-
tration at initiation of RRT could not be 
used to discriminate between survivors and 
non-survivors. As a consequence, the ad-
ministration of RRT may act as a bridge that 
treats the underlying cause of the acidosis. 
We found that AKI-RRT occurred in 5.5% 
of patients admitted to the ICU. Mortality 
rates were high, with almost 60% of the 
patients dying during their hospital stay 
and approximately an additional 10% per 
year of the hospital survivors in the years 
following discharge. Mortality was associ-
ated with advancing age and clinical status 
at initiation of RRT. Further, renal recovery 
was limited. Almost one-fifth of the AKI-
RRT survivors had ESKD at one year. Renal 
recovery was often incomplete and asso-
ciated with comorbidities such as diabetes 
and CKD. These findings highlight the need 
for long-term nephrological follow-up. 
Finally we described the long-term 
quality of life in this specific cohort of 
patients. These patients are amongst the 
most severely ill patients in the ICU. In 
addition, AKI-RRT patients who survive 
may develop CKD, including ESKD. As 
expected, their HrQOL was lower than 
the general population. However, de-
spite the heavy burden of disease, their 
QOL was comparable to matched sur-
vivors without AKI-RRT. Moreover, the 
majority of the patients wanted to be 
readmitted to the ICU when needed.
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Acuut nierfalen komt frequent voor op 
intensieve zorgen. Ondanks vooruitgang in 
de zorg voor de kritiek zieke patiënt blijft 
acuut nierfalen geassocieerd met een ver-
lengd ziekenhuisverblijf, een hoge sterfte en 
evolutie naar terminaal nierfalen. In geval 
van zeer ernstig nierfalen wordt er nierfunc-
tievervangende therapie of dialyse opgestart. 
Patiënten met ernstig acuut nierfalen behan-
deld met dialyse hebben een verhoogd risico 
op sterfte en de ontwikkeling van chronisch 
en terminaal nierfalen. Het doel van dit doc-
toraatswerk is de epidemiologie van deze 
specifieke cohorte van patiënten te beschrij-
ven. Speciale aandacht wordt besteed aan 
de optimale timing van start van dialyse. 
Verder worden de korte- en langetermijn 
effecten van acuut nierfalen behandeld met 
dialyse op overleving, nierfunctie en kwaliteit 
van leven uitgebreid behandeld. 
Er is een algemene consensus rond het 
opstarten van nierfunctievervangende 
therapie in geval van levensbedreigende 
situaties zoals ernstige acidose, elektro-
lietenstoornissen, de aanwezigheid van 
uremische complicaties of in geval van ern-
stige tekenen van overvulling. Nochtans is er 
geen consensus omtrent de exacte timing 
waarop dialyse dient opgestart te worden. 
Dit proefschrift bespreekt een aantal klas-
sieke indicaties tot opstarten van dialyse. 
Vooreerst werden de klassieke serum ureum 
cut-off concentraties waarop vervolgens 
dialyse wordt gestart uitvoerig bestudeerd. 
We konden besluiten dat er geen verband 
was tussen deze serum ureum waarden bij 
de start door dialyse en ziekenhuissterfte. 
Vervolgens werd de conditie van ernstige 
lactaatacidose grondig bestudeerd. Hoewel 
ernstige lactaatacidose een indicatie voor het 
opstarten van dialyse is, vindt men weinig 
literatuur die deze conditie behandeld. We 
beschreven uitvoerig de epidemiologie van 
ernstige lactaatacidose en poogden deter-
minanten van sterfte te bepalen. We stelden 
vast dat ernstige lactaatacidose tot in 1/3 
van de kritiek zieke patiënten met ernstig 
nierfalen behandeld met dialyse voorkomt. 
Ernstige lactaatacidose geeft aanleiding tot 
een hoge sterfte op intensieve zorgen maar 
de absolute van het serum lactaat bij start 
dialyse is geen hulp bij het onderscheiden 
van patiënten die al dan niet zouden overle-
ven. Nierfunctievervangende therapie zorgde 
wel bij deze patiënten voor een verbeterde 
zuurbase balans. Aldus kan dialyse in deze 
patiënten een tijdskader creëren waarbinnen 
de onderliggende oorzaak van de lactaataci-
dose kan behandeld worden. 
Dit doctoraatswerk toonde aan dat 5.5% 
van de patiënten opgenomen op de afdeling 
intensieve zorgen lijdt aan acuut nierfalen 
behandeld met nierfunctievervangende the-
rapie. De ziekenhuissterfte in deze groep van 
patiënten loopt op tot 60%. Na ontslag uit 
het ziekenhuis noteerden we bij de overle-
venden aan bijkomende sterfte van 10% per 
jaar in de jaren volgend aan het ziekenhuis 
ontslag. Er was een duidelijk verband aan-
toonbaar tussen sterfte en leeftijd en de 
klinische toestand op het ogenblik van start 
van dialyse. Bovendien was het herstel van 
de nierfunctie eerder beperkt. We evalueer-
den de nierfunctie een jaar na ontslag uit het 
ziekenhuis en rapporteerden een terminaal 
nierfalen in 1/5 van de patiënten. Een onvol-
ledig herstel van nierfunctie werd frequent 
gezien wanneer de patiënten gekend waren 
met diabetes en chronisch nierfalen. Deze 
bevindingen bevestigen de noodzaak voor 
een gedegen follow-up van de nierfunctie in 
deze specifieke groep van patiënten. 
Als laatste werd de kwaliteit van leven na 
ontslag uit het ziekenhuis uitvoerig bestu-
deerd. Zoals verwacht was de levenskwaliteit 
lager dan van een verglijkbare populatie die 
niet werd opgenomen op intensieve zorgen. 
Verrassend genoeg was de kwaliteit van 
leven bij patiënten na nierfalen behandeld 
met dialyse vergelijkbaar met kritiek zieke 
patiënten zonder nierfalen behandeld met 
dialyse. Bovendien waren ze bereid dezelfde 
intensieve behandeling opnieuw te onder-
gaan indien nodig.
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